indexNCT04502056重复_由于各措施对应结局,nctid,outcome_description,participate_group_num,outcome_group_num,group_info,outcome,standard_outcome,standard_outcome_id,outcome_id,"checker (Manually add results if checker is empty,Manually filter if the number of checkers is greater than or equal to 2)",Time_Frame
1,NCT04452435,Change From Baseline in C-reactive Protein (CRP) After Treatment With C21 200 mg Daily Dose (100 mg b.i.d.),O1:45|O2:46,O1:0.19|O2:0.22,C21 Treatment|Placebo Treatment,C-reactive Protein (CRP),CRP,indicator_1,outcome_1,"['C-reactive Protein (CRP)', 'C-reactive Protein']",Time Frame: Day 1 through Day 29 
2,NCT04452435,Change From Baseline in Body Temperature,O1:51|O2:54,O1:-0.11|O2:-0.34,C21 Treatment|Placebo Treatment,Body Temperature ,Body Temperature ,indicator_2,outcome_2,['Body Temperature'],Time Frame: Baseline 
3,NCT04452435,Change From Baseline in IL-6,O1:31|O2:34,O1:0.73|O2:0.73,C21 Treatment|Placebo Treatment,IL-6 ,IL-6 ,indicator_3,outcome_3,['IL-6'],"Time Frame: Study period, up to two months from the day the first participant was screened "
4,NCT04452435,Change From Baseline in IL-10,O1:37|O2:39,O1:0.66|O2:0.73,C21 Treatment|Placebo Treatment,IL-10 ,IL-10 ,indicator_4,outcome_4,['IL-10'],"Time Frame: Study period, up to two months from the day the first participant was screened "
5,NCT04452435,Change From Baseline in TNF,O1:46|O2:46,O1:0.91|O2:1.01,C21 Treatment|Placebo Treatment,TNF,TNF,indicator_5,outcome_5,['TNF'],"Time Frame: from date of patient admission to date of patient discharge or date of death, whichever came first, assessed up to 45 days "
6,NCT04452435,Change From Baseline in CA125,O1:46|O2:48,O1:1.16|O2:1.17,C21 Treatment|Placebo Treatment,CA125,CA125,indicator_6,outcome_6,['CA125'],Time Frame: Baseline 
7,NCT04452435,Change From Baseline in Ferritin,O1:46|O2:47,O1:0.75|O2:0.74,C21 Treatment|Placebo Treatment,Ferritin ,Ferritin ,indicator_7,outcome_7,['Ferritin'],"Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 "
8,NCT04452435,Number of Subjects Not in Need of Oxygen Supply,O1:51|O2:55,O1:37|O2:30,C21 Treatment|Placebo Treatment,Need of Oxygen Supply ,Oxygen,indicator_8,outcome_8,"['Oxygen', 'Need of Oxygen Supply']",Time Frame: Up to 28 days 
9,NCT04452435,Number of Subjects Not in Need of Mechanical Invasive or Non-invasive Ventilation,O1:51|O2:55,O1:50|O2:53,C21 Treatment|Placebo Treatment,Need of Mechanical Invasive or Non-invasive Ventilation ,Mechanical Ventilation,indicator_9,outcome_9,['Need of Mechanical Invasive or Non-invasive Ventilation'],Time Frame: Up to 28 days 
10,NCT04452435,Time to Need of Mechanical Invasive or Non-invasive Ventilation,O1:1|O2:2,O1:60.0|O2:77.925,C21 Treatment|Placebo Treatment,Time to Need of Mechanical Invasive or Non-invasive Ventilation ,Mechanical Ventilation,indicator_9,outcome_10,"['Time to Need of Mechanical Invasive or Non-invasive Ventilation', 'Need of Mechanical Invasive or Non-invasive Ventilation']","Time Frame: from date of patient admission to date of patient discharge or date of death, whichever came first, assessed up to 45 days "
11,NCT04452435,Time on Oxygen Supply (for Those Not Needing Mechanical Invasive or Non-invasive Ventilation),O1:51|O2:55,O1:5.0|O2:5.0,C21 Treatment|Placebo Treatment,Time on Oxygen Supply,Oxygen,indicator_8,outcome_11,"['Oxygen', 'Time on Oxygen Supply']",Time Frame: 5 and 14 days 
12,NCT04452435,Adverse Events,O1:51|O2:55,O1:31|O2:37,C21 Treatment|Placebo Treatment,Adverse Events ,Adverse,indicator_10,outcome_12,"['Adverse Events', 'Adverse', 'Adverse Event']",Time Frame: At the first day of the study 
13,NCT04452435,Oxygen Supplementation at Day 14,O1:51|O2:55,O1:1|O2:11,C21 Treatment|Placebo Treatment,Oxygen,Oxygen,indicator_8,outcome_13,['Oxygen'],NA
14,NCT04431908,"Sensitivity, Specificity and Accuracy",O1:1042,O1:889|O1:106|O1:27|O1:20,Outpatients (Drive Thru),"Sensitivity, Specificity and Accuracy ","Sensitivity, Specificity and Accuracy ",indicator_11,outcome_14,"['Sensitivity, Specificity and Accuracy']",Time Frame: Baseline up to 60 days 
15,NCT04431908,Repeatability,O1:0|O2:0,NA,Outpatients (Drive Thru)|High Risk Asymptomatics,Repeatability ,Repeatability ,indicator_12,outcome_15,['Repeatability'],"Time Frame: Baseline, Days 4, 7, 15, 21, and 29 "
16,NCT04431908,"Asymptomatic Sensitivity, Specificity and Accuracy",O1:278,O1:244|O1:31|O1:27|O1:1,High Risk Asymptomatics,"Asymptomatic Sensitivity, Specificity and Accuracy ","Asymptomatic Sensitivity, Specificity and Accuracy ",indicator_13,outcome_16,"['Asymptomatic Sensitivity, Specificity and Accuracy', 'Symptom', 'Sensitivity, Specificity and Accuracy']",Time Frame: At the first 5 days of study 
17,NCT04716426,COVID-19 Contamination Rate.,O1:50|O2:50,O1:2|O2:5,Tetracycline Hydrochloride 3%|Placebo,Contamination Rate,Contamination Rate,indicator_14,outcome_17,['Contamination Rate'],Time Frame: 12 days 
18,NCT04716426,Number of Participants With Adverse Events,O1:50|O2:50,O1:17|O2:23,Tetracycline Hydrochloride 3%|Placebo,Adverse Events ,Adverse,indicator_10,outcome_18,"['Adverse Events', 'Adverse', 'Adverse Event']",Time Frame: At the first day of the study 
19,NCT04716426,Average Number of Adverse Events,O1:50|O2:50,O1:0.65|O2:0.94,Tetracycline Hydrochloride 3%|Placebo,Adverse Events ,Adverse,indicator_10,outcome_19,"['Adverse Events', 'Adverse', 'Adverse Event']",Time Frame: At the first day of the study 
20,NCT04716426,Days Over Which an Adverse Event Was Reported,O1:50|O2:50,O1:0.36|O2:0.28,Tetracycline Hydrochloride 3%|Placebo,Adverse Event,Adverse,indicator_10,outcome_20,"['Adverse', 'Adverse Event']",Time Frame: 24 hours 
21,NCT04716426,Other Virus or Bacteria Contamination Rate.,O1:50|O2:50,O1:0|O2:0,Tetracycline Hydrochloride 3%|Placebo,Virus or Bacteria Contamination Rate,Virus or Bacteria Contamination Rate,indicator_15,outcome_21,"['Virus or Bacteria Contamination Rate', 'Contamination Rate']",Time Frame: 0 to 24 hours post-dose 
22,NCT04392141,Mortality Rate,O1:60|O2:60,O1:6|O2:1,Standard Treatment|Colchicine and Herbal Phenolic Monoterpene Fractions,Mortality Rate ,Death ,indicator_16,outcome_22,"['Mortality Rate', 'Mortality']",Time Frame: Up to and including day 28 
23,NCT04392141,SpO2,O1:60|O2:60,O1:87.39|O2:90.94|O1:92.89|O2:93.49,Standard Treatment|Colchicine and Herbal Phenolic Monoterpene Fractions,SpO2,SpO2,indicator_17,outcome_23,['SpO2'],Time Frame: Days 1 - 29. 
24,NCT04392141,Length of Hospitalization,O1:54|O2:59,O1:6.39|O2:4.17,Standard Treatment|Colchicine and Herbal Phenolic Monoterpene Fractions,Hospitalization ,Hospitalization,indicator_18,outcome_24,"['Hospitalization', 'hospitalization', 'Hospital']",Time Frame: Day 1 through Day 29 
25,NCT04392141,Lymphocyte Count,O1:60|O2:60,O1:1.19|O2:1.31|O1:1.17|O2:1.74,Standard Treatment|Colchicine and Herbal Phenolic Monoterpene Fractions,Lymphocyte Count,Lymphocyte Count,indicator_19,outcome_25,['Lymphocyte Count'],"Time Frame: Baseline, Day 15, Day 29 "
26,NCT04392141,Serum Lactate Dehydrogenase,O1:60|O2:60,O1:664.98|O2:680.27|O1:691.04|O2:542.94,Standard Treatment|Colchicine and Herbal Phenolic Monoterpene Fractions,Serum Lactate Dehydrogenase ,Lactate Dehydrogenase,indicator_20,outcome_26,['Serum Lactate Dehydrogenase'],Time Frame: 28 days 
27,NCT04474496,Personal Preventative Behaviors to Decrease Risk of COVID-19 Exposure,O1:117|O1:117|O1:117|O1:117|O1:117|O1:116|O1:117|O1:117|O1:117|O1:117|O1:117,O1:114|O1:112|O1:114|O1:109|O1:105|O1:113|O1:115|O1:113|O1:99|O1:114,Marshallese Adults in the U.S.|Marshallese Adults in the U.S.|Marshallese Adults in the U.S.|Marshallese Adults in the U.S.|Marshallese Adults in the U.S.|Marshallese Adults in the U.S.|Marshallese Adults in the U.S.|Marshallese Adults in the U.S.|Marshallese Adults in the U.S.|Marshallese Adults in the U.S.|Marshallese Adults in the U.S.,Personal Preventative Behaviors to Decrease Risk of COVID-19 Exposure ,Personal Preventative Behaviors ,indicator_21,outcome_27,['Personal Preventative Behaviors to Decrease Risk of COVID-19 Exposure'],Time Frame: 14 days 
28,NCT04474496,Workplace Preventative Actions to Decrease Risk of COVID-19 Exposure,O1:120,O1:27|O1:23|O1:73|O1:41|O1:58|O1:59|O1:31|O1:61|O1:41|O1:47|O1:5|O1:3,Marshallese Adults in the U.S.,Workplace Preventative Actions to Decrease Risk of COVID-19 Exposure ,Workplace Preventative,indicator_22,outcome_28,['Workplace Preventative Actions to Decrease Risk of COVID-19 Exposure'],Time Frame: 0 to 24 hours post dose 
29,NCT04474496,Effects of COVID-19 on General Health Status,O1:119,O1:20|O1:74|O1:19|O1:6,Marshallese Adults in the U.S.,Effects of COVID-19 on General Health Status ,General Health Status ,indicator_23,outcome_29,"['Effect', 'Effects of COVID-19 on General Health Status']","Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 "
30,NCT04474496,Effects of COVID-19 on Access to Healthcare Services,O1:120,O1:20|O1:14|O1:20|O1:21|O1:53|O1:5,Marshallese Adults in the U.S.,Effects of COVID-19 on Access to Healthcare Services ,Access to Healthcare Services ,indicator_24,outcome_30,"['Effect', 'Effects of COVID-19 on Access to Healthcare Services']",Time Frame: Treatment period of 7 days (Day 1 to Day 8) 
31,NCT04474496,Effects of COVID-19 on Dietary Habits,O1:119,O1:25|O1:41|O1:30|O1:18|O1:5,Marshallese Adults in the U.S.,Effects of COVID-19 on Dietary Habits ,Dietary Habits ,indicator_25,outcome_31,"['Effects of COVID-19 on Dietary Habits', 'Effect']",Time Frame: Day 11 
32,NCT04474496,Effects of COVID-19 on Physical Activity Behaviors (Not Specifically for Exercise),O1:119,O1:27|O1:52|O1:35|O1:5,Marshallese Adults in the U.S.,Effects of COVID-19 on Physical Activity Behaviors (Not Specifically for Exercise) ,Physical Activity Behaviors,indicator_26,outcome_32,"['Effect', 'Effects of COVID-19 on Physical Activity Behaviors (Not Specifically for Exercise)']",Time Frame: 14 days 
33,NCT04474496,Effects of COVID-19 on Physical Activity Behaviors (Specifically for Exercise),O1:119,O1:17|O1:56|O1:37|O1:9,Marshallese Adults in the U.S.,Effects of COVID-19 on Physical Activity Behaviors (Specifically for Exercise) ,Physical Activity Behaviors,indicator_26,outcome_33,"['Effect', 'Effects of COVID-19 on Physical Activity Behaviors (Specifically for Exercise)']","Time Frame: From start of mechanical ventilation until extubation or date of death from any cause, whichever came first, assessed up to 6 months "
34,NCT04474496,Effects of COVID-19 on Weight,O1:119,O1:30|O1:26|O1:34|O1:26|O1:3,Marshallese Adults in the U.S.,Effects of COVID-19 on Weight ,Weight ,indicator_27,outcome_34,"['Effects of COVID-19 on Weight', 'Effect']",Time Frame: 0 to 24 hours post-dose 
35,NCT04474496,Effects of COVID-19 on HbA1c (Glycated Hemoglobin),O1:13,O1:2|O1:5|O1:3|O1:3,Marshallese Adults in the U.S.,HbA1c (Glycated Hemoglobin),HbA1c,indicator_28,outcome_35,"['Effect', 'Hemoglobin', 'HbA1c (Glycated Hemoglobin)']",NA
36,NCT04474496,Barriers to Type 2 Diabetes Management Due to COVID-19,O1:13,O1:2|O1:1|O1:1|O1:3|O1:0|O1:9,Marshallese Adults in the U.S.,Barriers to Type 2 Diabetes Management Due to COVID-19 ,Type 2 Diabetes,indicator_29,outcome_36,['Barriers to Type 2 Diabetes Management Due to COVID-19'],Time Frame: Pre-SSI to 3-month follow-up 
37,NCT04474496,COVID-19 Screening,O1:120,O1:9|O1:7|O1:45|O1:32|O1:27|O1:28|O1:6,Marshallese Adults in the U.S.,COVID-19 Screening ,Screening ,indicator_30,outcome_37,['COVID-19 Screening'],Time Frame: Baseline to Day 28 
38,NCT04474496,COVID-19 Testing,O1:120,O1:20|O1:1|O1:6|O1:54|O1:33|O1:9,Marshallese Adults in the U.S.,COVID-19 Testing ,Testing ,indicator_31,outcome_38,['COVID-19 Testing'],Time Frame: 14 days 
39,NCT04474496,COVID-19 Vaccine Willingness/Hesitancy,O1:113,O1:39|O1:25|O1:8|O1:9|O1:32,Marshallese Adults in the U.S.,COVID-19 Vaccine Willingness/Hesitancy ,Vaccine Willingness/Hesitancy,indicator_32,outcome_39,['COVID-19 Vaccine Willingness/Hesitancy'],"Time Frame: Pre-SSI, Immediately Post-SSI "
40,NCT04474496,Trusted Sources of COVID-19 Information,O1:117,O1:12|O1:15|O1:1|O1:14|O1:4|O1:40|O1:17|O1:7|O1:1|O1:1|O1:1|O1:4,Marshallese Adults in the U.S.,Trusted Sources of COVID-19 Information ,Trusted Sources,indicator_33,outcome_40,['Trusted Sources of COVID-19 Information'],Time Frame: Immediately Post-SSI only 
41,NCT04474496,Effects of COVID-19 on Housing,O1:118,O1:3|O1:12|O1:4|O1:98|O1:1,Marshallese Adults in the U.S.,Effects of COVID-19 on Housing ,Housing ,indicator_34,outcome_41,"['Effect', 'Effects of COVID-19 on Housing']","Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 "
42,NCT04474496,Effects of COVID-19 on Employment,O1:120,O1:12|O1:13|O1:9|O1:27|O1:4|O1:23|O1:4|O1:27|O1:5,Marshallese Adults in the U.S.,Effects of COVID-19 on Employment ,Employment ,indicator_35,outcome_42,"['Effect', 'Effects of COVID-19 on Employment']",Time Frame: Day 1 through Day 29 
43,NCT04474496,Effects of COVID-19 on Income,O1:119,O1:3|O1:66|O1:43|O1:7,Marshallese Adults in the U.S.,Effects of COVID-19 on Income ,Income ,indicator_36,outcome_43,"['Effect', 'Effects of COVID-19 on Income']",Time Frame: Day 12 
44,NCT04474496,Sources of Stress During COVID-19,O1:120,O1:75|O1:90|O1:75|O1:79|O1:61|O1:75|O1:59|O1:24|O1:43|O1:32|O1:27|O1:47|O1:5|O1:1|O1:2,Marshallese Adults in the U.S.,Sources of Stress During COVID-19 ,Sources of Stress,indicator_37,outcome_44,['Sources of Stress During COVID-19'],"Time Frame: Day 1 (Baseline), Day 15 "
45,NCT04646109,Gender Distribution of the Patients,O1:30|O2:30,O1:19|O2:21|O1:11|O2:9,Control Group|Study Group,Gender,Gender,indicator_38,outcome_45,['Gender'],"Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 "
46,NCT04646109,Age Distribution of the Patients,O1:30|O2:30,O1:66.23|O2:58.17,Control Group|Study Group,Age Distribution,Age Distribution,indicator_39,outcome_46,['Age Distribution'],Time Frame: At the first day of the study 
47,NCT04646109,Percentage of Patients With Accompanying Diseases,O1:30|O2:30,O1:10|O2:9|O1:12|O2:15|O1:8|O2:5|O1:1|O2:0|O1:3|O2:6|O1:1|O2:0|O1:1|O2:0,Control Group|Study Group,Accompanying Diseases ,Accompanying Diseases ,indicator_40,outcome_47,['Accompanying Diseases'],Time Frame: Treatment period of 7 days (Day 1 to Day 8) 
48,NCT04646109,Percentage of Patients With Baseline Clinical Symptoms,O1:30|O2:30,O1:13|O2:15|O1:14|O2:16|O1:1|O2:3|O1:19|O2:23|O1:2|O2:5|O1:11|O2:13|O1:7|O2:9|O1:0|O2:1|O1:0|O2:1,Control Group|Study Group,Clinical Symptoms ,Symptoms,indicator_41,outcome_48,"['Symptom', 'Clinical Symptoms']",Time Frame: Baseline 
49,NCT04646109,Body Temperature Means of the Patients,O1:30|O2:30,O1:36.8|O2:36.9,Control Group|Study Group,Body Temperature,Body Temperature,indicator_42,outcome_49,['Body Temperature'],Time Frame: Baseline 
50,NCT04646109,Heart Rate Means of the Patients,O1:30|O2:30,O1:92|O2:88,Control Group|Study Group,Heart Rate,Heart Rate,indicator_43,outcome_50,['Heart Rate'],Time Frame: Day 1 through Day 29 
51,NCT04646109,Respiratory Rate Means of the Patients,O1:30|O2:30,O1:24.7|O2:24,Control Group|Study Group,Respiratory Rate,Respiratory Rate,indicator_44,outcome_51,['Respiratory Rate'],Time Frame: Baseline to Day 29 
52,NCT04646109,Systolic and Diastolic Pressure Means of the Patients,O1:30|O2:30,O1:124.61|O2:124.39|O1:73.43|O2:75.64,Control Group|Study Group,Systolic and Diastolic Pressure,Blood Pressure,indicator_45,outcome_52,['Systolic and Diastolic Pressure'],Time Frame: 14 days 
53,NCT04646109,Number of Participants With Clinical Response,O1:30|O2:30,O1:11|O2:14,Control Group|Study Group,Clinical Response ,Clinical Response,indicator_46,outcome_53,['Clinical Response'],Time Frame: Baseline 
54,NCT04646109,Changes in Oxygen Saturation (SpO2) Values,O1:30|O2:30,O1:89.67|O2:89.93|O1:90.50|O2:92.85|O1:91.90|O2:93.07|O1:93.00|O2:93.52,Control Group|Study Group,Oxygen Saturation (SpO2),SpO2,indicator_17,outcome_54,"['Oxygen', 'SpO2', 'Oxygen Saturation (SpO2)', 'Oxygen Saturation']",Time Frame: 28 days after randomization 
55,NCT04646109,Changes in the Ratio of Partial Pressure of Oxygen (PaO2) to Fraction of Inspired Oxygen (FiO2) (PaO2/FiO2),O1:30|O2:30,O1:197.44|O2:158.83|O1:181.83|O2:147.31|O1:174.77|O2:147.74|O1:180.13|O2:178.94,Control Group|Study Group,PaO2/FiO2,P/F Ratio,indicator_47,outcome_55,"['Oxygen', 'PaO2/FiO2']",Time Frame: 28 days after randomization 
56,NCT04646109,Changes in Serum Lymphocyte Counts,O1:30|O2:30,O1:1010|O2:932|O1:1034|O2:928|O1:977|O2:1021|O1:968|O2:1273,Control Group|Study Group,Serum Lymphocyte Counts,Lymphocyte,indicator_48,outcome_56,"['Serum Lymphocyte Counts', 'Lymphocyte Count']",Time Frame: 28 days 
57,NCT04646109,Changes in the Ratio of Polymorphonuclear Leukocyte Count to Lymphocyte Count (PNL/L),O1:30|O2:30,O1:7.48|O2:8.77|O1:7.74|O2:10.82|O1:9.26|O2:9.02|O1:9.88|O2:7.16,Control Group|Study Group,PNL/L,PNL/L,indicator_49,outcome_57,"['PNL/L', 'Lymphocyte Count']",Time Frame: Anytime during pregnancy or within 6 months after given birth. 
58,NCT04646109,Changes in Serum Ferritin Levels,O1:30|O2:30,O1:747.05|O2:682.75|O1:783.03|O2:834.94|O1:881.17|O2:875.90|O1:1028.24|O2:875.12,Control Group|Study Group,Serum Ferritin Levels ,Ferritin,indicator_50,outcome_58,"['Serum Ferritin Levels', 'Ferritin']",Time Frame: Baseline up to 60 days 
59,NCT04646109,Changes in Serum D-dimer Levels,O1:30|O2:30,O1:1.32|O2:1.25|O1:2.80|O2:1.40|O1:4.14|O2:3.24|O1:3.58|O2:5.85,Control Group|Study Group,Serum D-dimer Levels ,D-dimer,indicator_51,outcome_59,"['Serum D-dimer Levels', 'D-dimer']",Time Frame: Baseline up to 60 days 
60,NCT04646109,Genetic Examination of Haplotypes and Mutations That Cause Function Losing for Ivermectin Metabolism,O1:0|O2:36,O1:0|O2:6|O1:0|O2:30,Control Group|Study Group,Genetic Examination of Haplotypes and Mutations That Cause Function Losing for Ivermectin Metabolism ,Genetic Examination,indicator_52,outcome_60,['Genetic Examination of Haplotypes and Mutations That Cause Function Losing for Ivermectin Metabolism'],Time Frame: Day 1 through Day 29 
61,NCT04646109,Treatment-Related Adverse Events as Assessed by CTCAE v4.0,O1:30|O2:30,O1:2|O2:0|O1:1|O2:0,Control Group|Study Group,Adverse Events,Adverse,indicator_10,outcome_61,"['Adverse Events', 'Adverse', 'Adverse Event']",Time Frame: 48 hours 
62,NCT04646109,Mortality,O1:30|O2:30,O1:9|O2:6,Control Group|Study Group,Mortality ,Death ,indicator_16,outcome_62,['Mortality'],Time Frame: Baseline 
63,NCT04646109,Rate of COVID-19 Polymerase Chain Reaction (PCR) Test Negativity,O1:8|O2:16,O1:3|O2:14,Control Group|Study Group,Polymerase Chain Reaction (PCR),PCR,indicator_53,outcome_63,['Polymerase Chain Reaction (PCR)'],Time Frame: Up to and including day 7 
64,NCT04542694,Rate of Clinical Status Improvement,O1:100|O2:100,O1:27|O2:15,Favipiravir (Areplivir)|Standard of Care,Improvement,Improvement,indicator_54,outcome_64,"['improvement', 'Improvement', 'Clinical Status']",Time Frame: 28 days 
65,NCT04542694,Time to Clinical Improvement,O1:100|O2:100,O1:8|O2:12,Favipiravir (Areplivir)|Standard of Care,Improvement,Improvement,indicator_54,outcome_65,"['improvement', 'Improvement']",Time Frame: 28 days 
66,NCT04542694,Rate of Viral Elimination by Day 10,O1:100|O2:100,O1:98|O2:79,Favipiravir (Areplivir)|Standard of Care,Viral Elimination,Viral Clearance,indicator_55,outcome_66,['Viral Elimination'],Time Frame: Pre-SSI only 
67,NCT04542694,Time Before the End of Fever,O1:100|O2:100,O1:4|O2:5,Favipiravir (Areplivir)|Standard of Care,Fever ,Fever ,indicator_56,outcome_67,['Fever'],"Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 "
68,NCT04542694,Change in the Level of Lung Damage According to CT,O1:100|O2:100,O1:60|O2:40,Favipiravir (Areplivir)|Standard of Care,Lung Damage,Lung Damage,indicator_57,outcome_68,['Lung Damage'],"Time Frame: Baseline, Day 15, Day 29 "
69,NCT04542694,Rate of Transfer to the Intensive Care Unit,O1:100|O2:100,O1:0|O2:0,Favipiravir (Areplivir)|Standard of Care,Intensive Care,Intensive Care,indicator_58,outcome_69,['Intensive Care'],"Time Frame: Baseline, Minutes 5, 10, 15, 30 (15 minutes after treatment ends) "
70,NCT04542694,Rate of the Use of Non-invasive Lung Ventilation,O1:100|O2:100,O1:0|O2:0,Favipiravir (Areplivir)|Standard of Care,Non-invasive Lung Ventilation ,Non-invasive Lung Ventilation ,indicator_59,outcome_70,['Non-invasive Lung Ventilation'],Time Frame: One-month 
71,NCT04542694,Rate of the Use of Mechanical Ventilation,O1:100|O2:100,O1:0|O2:0,Favipiravir (Areplivir)|Standard of Care,Mechanical Ventilation ,Mechanical Ventilation ,indicator_60,outcome_71,"['mechanical Ventilation', 'Mechanical Ventilation']","Time Frame: from date of patient admission to date of patient discharge or date of death, whichever came first, assessed up to 45 days "
72,NCT04542694,Mortality,O1:100|O2:100,O1:0|O2:0,Favipiravir (Areplivir)|Standard of Care,Mortality,Death ,indicator_16,outcome_72,['Mortality'],Time Frame: within 14 days after enrollement 
73,NCT04401579,Time to Recovery,O1:515|O2:518,O1:7.0|O2:8.0,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Recovery,Recovery,indicator_61,outcome_73,"['Recovery', 'Time to Recovery']","Time Frame: Day 14, Chronic Phase "
74,NCT04401579,Change From Baseline in Alanine Transaminase (ALT),O1:491|O2:491|O1:491|O2:491|O1:407|O2:406|O1:268|O2:284|O1:187|O2:201|O1:250|O2:270|O1:256|O2:255,O1:3.3|O2:2.0|O1:16.8|O2:8.8|O1:7.9|O2:7.8|O1:0.0|O2:7.3|O1:5.0|O2:3.9|O1:-5.4|O2:2.3,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Alanine Transaminase (ALT),ALT,indicator_62,outcome_74,['Alanine Transaminase (ALT)'],Time Frame: From starting to the end of ivermectin therapy (0 to the end of 5th day) 
75,NCT04401579,Change From Baseline in Aspartate Transaminase (AST),O1:486|O2:487|O1:486|O2:487|O1:404|O2:403|O1:265|O2:282|O1:185|O2:200|O1:246|O2:266|O1:251|O2:251,O1:3.1|O2:2.4|O1:27.4|O2:2.8|O1:-5.6|O2:-4.3|O1:-10.6|O2:6.4|O1:-6.0|O2:-3.9|O1:-17.1|O2:2.4,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Aspartate Transaminase (AST),AST,indicator_63,outcome_75,['Aspartate Transaminase (AST)'],Time Frame: At the first day of ivermectin therapy (1st day) 
76,NCT04401579,Change From Baseline in Creatinine,O1:494|O2:495|O1:494|O2:495|O1:412|O2:410|O1:270|O2:285|O1:190|O2:202|O1:254|O2:273|O1:260|O2:257,O1:-0.036|O2:-0.019|O1:-0.078|O2:0.001|O1:-0.082|O2:0.129|O1:-0.055|O2:0.194|O1:-0.042|O2:0.094|O1:-0.034|O2:0.033,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Creatinine,Creatinine,indicator_64,outcome_76,['Creatinine'],"Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 "
77,NCT04401579,Change From Baseline in Glucose,O1:493|O2:493|O1:493|O2:493|O1:412|O2:409|O1:270|O2:284|O1:190|O2:203|O1:252|O2:271|O1:257|O2:256,O1:-17.1|O2:-6.0|O1:-15.9|O2:-1.6|O1:-16.8|O2:5.0|O1:-8.1|O2:1.2|O1:-11.1|O2:0.8|O1:-4.6|O2:-2.2,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Glucose,Glucose,indicator_65,outcome_77,['Glucose'],Time Frame: Day 1 through Day 29 
78,NCT04401579,Change From Baseline in Hemoglobin,O1:493|O2:494|O1:493|O2:494|O1:410|O2:409|O1:270|O2:284|O1:189|O2:199|O1:253|O2:267|O1:260|O2:254,O1:-0.46|O2:-0.34|O1:-0.62|O2:-0.64|O1:-0.93|O2:-1.08|O1:-1.29|O2:-1.62|O1:-0.96|O2:-1.12|O1:-0.54|O2:-0.77,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Hemoglobin,Hemoglobin,indicator_66,outcome_78,['Hemoglobin'],Time Frame: Day 1 through Day 29 
79,NCT04401579,Change From Baseline in Platelets,O1:493|O2:494|O1:493|O2:494|O1:410|O2:409|O1:269|O2:284|O1:189|O2:199|O1:252|O2:267|O1:260|O2:254,O1:55.9|O2:52.6|O1:116.6|O2:106.1|O1:197.9|O2:158.9|O1:229.9|O2:145.7|O1:175.9|O2:111.6|O1:16.5|O2:36.9,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Platelets,Platelet,indicator_67,outcome_79,"['Platelets', 'Platelet']",Time Frame: 28 and 90 day evaluation 
80,NCT04401579,Change From Baseline in Prothrombin International Normalized Ratio (INR),O1:447|O2:439|O1:447|O2:439|O1:360|O2:370|O1:244|O2:250|O1:162|O2:175|O1:222|O2:241|O1:232|O2:232,O1:-0.03|O2:0.05|O1:0.02|O2:0.08|O1:0.01|O2:0.08|O1:0.04|O2:0.03|O1:-0.04|O2:-0.08|O1:-0.12|O2:-0.03,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Prothrombin International Normalized Ratio (INR),INR,indicator_68,outcome_80,['Prothrombin International Normalized Ratio (INR)'],Time Frame: 24 hours after a 1000 U intranasal dose of heparin 
81,NCT04401579,Change From Baseline in Total Bilirubin,O1:490|O2:491|O1:490|O2:491|O1:407|O2:405|O1:268|O2:284|O1:187|O2:201|O1:250|O2:270|O1:256|O2:254,O1:-0.06|O2:-0.01|O1:-0.04|O2:0.01|O1:-0.06|O2:0.01|O1:-0.08|O2:0.08|O1:-0.10|O2:0.08|O1:-0.10|O2:0.01,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Total Bilirubin,Total Bilirubin,indicator_69,outcome_81,['Total Bilirubin'],Time Frame: Pre-SSI to Immediately Post-SSI; Pre-SSI to 3-month follow-up 
82,NCT04401579,Change From Baseline in White Blood Cell Count (WBC),O1:493|O2:494|O1:493|O2:494|O1:410|O2:409|O1:270|O2:284|O1:189|O2:199|O1:253|O2:267|O1:260|O2:254,O1:-0.831|O2:-0.037|O1:-0.276|O2:0.392|O1:0.663|O2:1.606|O1:1.869|O2:2.938|O1:0.694|O2:2.162|O1:-0.364|O2:0.712,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,White Blood Cell Count (WBC),WBC,indicator_70,outcome_82,['White Blood Cell Count (WBC)'],Time Frame: 0 to 24 hours post dose 
83,NCT04401579,Change From Baseline in Neutrophils,O1:488|O2:493|O1:488|O2:493|O1:408|O2:404|O1:268|O2:282|O1:186|O2:196|O1:249|O2:267|O1:257|O2:253,O1:-1.925|O2:-0.333|O1:-1.334|O2:-0.204|O1:-0.813|O2:1.139|O1:-0.046|O2:1.847|O1:-1.192|O2:1.414|O1:-1.708|O2:-0.656,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Neutrophils,Neutrophils,indicator_71,outcome_83,['Neutrophils'],Time Frame: Day 28 
84,NCT04401579,Change From Baseline in Lymphocytes,O1:488|O2:493|O1:488|O2:493|O1:408|O2:404|O1:268|O2:282|O1:186|O2:196|O1:249|O2:267|O1:257|O2:253,O1:0.503|O2:0.074|O1:0.620|O2:0.205|O1:0.515|O2:0.304|O1:0.541|O2:0.409|O1:0.687|O2:0.718|O1:0.653|O2:0.927,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Lymphocytes,Lymphocytes,indicator_72,outcome_84,['Lymphocytes'],"Time Frame: Baseline, Day 15, Day 29 "
85,NCT04401579,Change From Baseline in Monocytes,O1:487|O2:493|O1:487|O2:493|O1:408|O2:404|O1:268|O2:282|O1:186|O2:196|O1:249|O2:267|O1:257|O2:253,O1:0.004|O2:0.062|O1:0.094|O2:0.153|O1:0.105|O2:0.279|O1:0.210|O2:0.378|O1:0.256|O2:0.329|O1:0.108|O2:0.212,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Monocytes,Monocytes,indicator_73,outcome_85,['Monocytes'],Time Frame: 14 days 
86,NCT04401579,Change From Baseline in Basophils,O1:483|O2:492|O1:483|O2:492|O1:402|O2:402|O1:265|O2:281|O1:185|O2:195|O1:247|O2:265|O1:257|O2:250,O1:0.000|O2:0.001|O1:0.007|O2:0.006|O1:0.011|O2:0.017|O1:0.014|O2:0.022|O1:0.026|O2:0.037|O1:0.022|O2:0.036,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Basophils,Basophils,indicator_74,outcome_86,['Basophils'],Time Frame: From 6th to the end of 10th day 
87,NCT04401579,Change From Baseline in Eosinophils,O1:484|O2:492|O1:484|O2:492|O1:405|O2:403|O1:265|O2:281|O1:185|O2:195|O1:247|O2:264|O1:257|O2:251,O1:0.050|O2:0.039|O1:0.104|O2:0.075|O1:0.088|O2:0.086|O1:0.078|O2:0.115|O1:0.121|O2:0.109|O1:0.192|O2:0.205,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Eosinophils,Eosinophils,indicator_75,outcome_87,['Eosinophils'],"Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 "
88,NCT04401579,Change in National Early Warning Score (NEWS) From Baseline,O1:515|O2:518,O1:-0.5|O2:-0.1|O1:-0.9|O2:-0.4|O1:-1.5|O2:-0.8|O1:-1.8|O2:-1.1|O1:-2.1|O2:-1.2|O1:-2.0|O2:-1.2|O1:-2.2|O2:-1.4,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,National Early Warning Score (NEWS) ,NEWS,indicator_76,outcome_88,['National Early Warning Score (NEWS)'],Time Frame: Up to 28 days 
89,NCT04401579,Percentage of Participants Reporting Grade 3 and 4 Clinical and/or Laboratory Adverse Events (AEs),O1:507|O2:509,O1:40.8|O2:46.8,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Adverse Events,Adverse,indicator_10,outcome_89,"['Adverse Events', 'Adverse', 'Adverse Event']",Time Frame: 22 days after randomization. 
90,NCT04401579,Percentage of Participants Reporting Serious Adverse Events (SAEs),O1:507|O2:509,O1:16.0|O2:21.0,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Adverse Events,Adverse,indicator_10,outcome_90,"['Adverse Events', 'Adverse', 'Adverse Event']",Time Frame: 22 days after randomization. 
91,NCT04401579,Duration of Hospitalization,O1:515|O2:518|O1:515|O2:518|O1:491|O2:481,O1:8|O2:8|O1:8|O2:8,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Hospitalization,Hospitalization,indicator_18,outcome_91,"['Hospitalization', 'hospitalization', 'Hospital']",Time Frame: Day 11 
92,NCT04401579,Duration of New Non-invasive Ventilation or High Flow Oxygen Use,O1:70|O2:82|O1:70|O2:82|O1:65|O2:72,O1:6|O2:4.5|O1:5|O2:4,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,New Non-invasive Ventilation or High Flow Oxygen Use,Oxygen,indicator_8,outcome_92,"['Oxygen', 'New Non-invasive Ventilation or High Flow Oxygen Use', 'Oxygen Use']",Time Frame: Day 28 
93,NCT04401579,Duration of New Oxygen Use,O1:16|O2:29,O1:3|O2:3|O1:3|O2:3,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,New Oxygen Use,Oxygen,indicator_8,outcome_93,"['Oxygen', 'New Oxygen Use', 'Oxygen Use']","Time Frame: Day 0, Day 3, Day 5, and Day 7 "
94,NCT04401579,Duration of New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use,O1:46|O2:70|O1:46|O2:70|O1:39|O2:52,O1:16|O2:27|O1:13|O2:20,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use,ECMO,indicator_77,outcome_94,"['Oxygen', 'ECMO', 'New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use']",Time Frame: after each inhalation during 10 days 
95,NCT04401579,Duration of Oxygen Use,O1:445|O2:446|O1:445|O2:446|O1:421|O2:409,O1:10|O2:12|O1:9|O2:10,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Oxygen Use,Oxygen,indicator_8,outcome_95,"['Oxygen', 'Oxygen Use']",Time Frame: 28 days after randomization 
96,NCT04401579,Percentage of Participants Discontinued or Temporarily Suspended From Investigational Therapeutics,O1:515|O2:518,O1:55|O2:51|O1:0|O2:1|O1:66|O2:59|O1:0|O2:1|O1:2|O2:2|O1:16|O2:18|O1:23|O2:27|O1:30|O2:34|O1:3|O2:4|O1:4|O2:5,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Discontinued or Temporarily Suspended From Investigational Therapeutics,Discontinued,indicator_78,outcome_96,"['Discontinued or Temporarily Suspended From Investigational Therapeutics', 'Discontinued']",Time Frame: Day 1 through Day 29 
97,NCT04401579,Percentage of Participants Requiring New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use,O1:461|O2:461,O1:10|O2:15,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use,ECMO,indicator_77,outcome_97,"['Oxygen', 'ECMO', 'Participants Requiring New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use', 'New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use']","Time Frame: from first inhalation until discharge from the clinic, up to 30 days "
98,NCT04401579,Percentage of Participants Requiring New Oxygen Use,O1:70|O2:72,O1:23|O2:40,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,New Oxygen Use,Oxygen,indicator_8,outcome_98,"['Oxygen', 'New Oxygen Use', 'Participants Requiring New Oxygen Use', 'Oxygen Use']","Time Frame: Day 0, Day 3, Day 5, and Day 7 "
99,NCT04401579,Mean Change in the Ordinal Scale,O1:515|O2:518,O1:0.1|O2:0.1|O1:0.0|O2:0.0|O1:-0.3|O2:-0.1|O1:-0.4|O2:-0.2|O1:-2.3|O2:-1.9|O1:-2.7|O2:-2.3|O1:-2.9|O2:-2.5,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Ordinal Scale,Ordinal Scale,indicator_79,outcome_99,"['Ordinal Scale', 'Mean Change', 'ordinal scale']","Time Frame: Day 7, Day 14, Day 21 & Day 30 "
100,NCT04401579,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 15,O1:515|O2:518,O1:2|O2:3|O1:9|O2:16|O1:4|O2:4|O1:8|O2:10|O1:6|O2:3|O1:2|O2:1|O1:34|O2:31|O1:34|O2:32,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Ordinal Scale,Ordinal Scale,indicator_79,outcome_100,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']","Time Frame: Day 7, Day 14, Day 21 & Day 30 "
101,NCT04401579,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 1,O1:515|O2:518,O1:0|O2:0|O1:10|O2:11|O1:20|O2:22|O1:56|O2:53|O1:14|O2:14|O1:0|O2:0|O1:0|O2:0|O1:0|O2:0|O1:0|O2:0|O1:0|O2:0|O1:0|O2:0,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Ordinal Scale,Ordinal Scale,indicator_79,outcome_101,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']","Time Frame: day 7, day 14 ,day 21 & day 30 "
102,NCT04401579,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 3,O1:515|O2:518,O1:0.4|O2:0|O1:15|O2:16|O1:22|O2:22|O1:45|O2:44|O1:16|O2:14|O1:0.2|O2:1|O1:0|O2:0|O1:0|O2:0|O1:0|O2:0|O1:0.2|O2:0.4|O1:1|O2:2,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Ordinal Scale,Ordinal Scale,indicator_79,outcome_102,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']",Time Frame: Pre and Post 1st dose; Pre and Post 2nd dose 
103,NCT04401579,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 5,O1:515|O2:518,O1:1|O2:0|O1:15|O2:18|O1:17|O2:18|O1:35|O2:33|O1:19|O2:15|O1:1|O2:1|O1:0.2|O2:0|O1:0.2|O2:0|O1:0|O2:0.2|O1:10|O2:13|O1:2|O2:3,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Ordinal Scale,Ordinal Scale,indicator_79,outcome_103,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']","Time Frame: Baseline, Day 7, Day 14, Day 21 & Day 30 "
104,NCT04401579,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 8,O1:515|O2:518,O1:1|O2:1|O1:13|O2:18|O1:11|O2:12|O1:18|O2:18|O1:12|O2:10|O1:1|O2:1|O1:0.2|O2:0|O1:0.4|O2:0|O1:0|O2:0.4|O1:40|O2:36|O1:3|O2:4,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Ordinal Scale,Ordinal Scale,indicator_79,outcome_104,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']",Time Frame: up to Day 30 
105,NCT04401579,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 11,O1:515|O2:518,O1:1|O2:2|O1:11|O2:16|O1:6|O2:7|O1:12|O2:10|O1:9|O2:7|O1:1|O2:1|O1:0|O2:0|O1:0.2|O2:0.2|O1:0|O2:1|O1:56|O2:52|O1:3|O2:4,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Ordinal Scale,Ordinal Scale,indicator_79,outcome_105,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']",Time Frame: Up to day 14 
106,NCT04401579,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 22,O1:515|O2:518,O1:4|O2:6|O1:6|O2:9|O1:3|O2:1|O1:3|O2:5|O1:2|O2:3|O1:1|O2:0.4|O1:24|O2:25|O1:44|O2:37|O1:0|O2:0|O1:4|O2:3|O1:9|O2:10,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Ordinal Scale,Ordinal Scale,indicator_79,outcome_106,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']",Time Frame: Up to day 28 
107,NCT04401579,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 29,O1:515|O2:518,O1:5|O2:7|O1:3|O2:7|O1:2|O2:1|O1:2|O2:3|O1:3|O2:1|O1:1|O2:0.2|O1:23|O2:23|O1:49|O2:43|O1:0|O2:0|O1:0.4|O2:1|O1:12|O2:13|O1:0.2|O2:0.2,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Ordinal Scale,Ordinal Scale,indicator_79,outcome_107,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']",Time Frame: 14 days 
108,NCT04401579,14-day Participant Mortality,O1:515|O2:518,O1:0.02|O2:0.03,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Mortality,Death ,indicator_16,outcome_108,['Mortality'],Time Frame: 28 days 
109,NCT04401579,28-day Participant Mortality,O1:515|O2:518,O1:0.05|O2:0.08,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Mortality,Death ,indicator_16,outcome_109,['Mortality'],Time Frame: within 14 days after enrollement 
110,NCT04401579,Time to an Improvement of One Category Using an Ordinal Scale,O1:515|O2:518,O1:6.0|O2:8.0,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Improvement,Improvement,indicator_54,outcome_110,"['Ordinal Scale', 'improvement', 'Improvement', 'ordinal scale']",Time Frame: 15 days 
111,NCT04401579,Time to an Improvement of Two Categories Using an Ordinal Scale,O1:515|O2:518,O1:12.0|O2:13.0,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Improvement,Improvement,indicator_54,outcome_111,"['Ordinal Scale', 'improvement', 'Improvement', 'ordinal scale']",Time Frame: 15 days 
112,NCT04401579,"Time to Discharge or to a NEWS of 2 or Less and Maintained for 24 Hours, Whichever Occurs First",O1:361|O2:334,O1:6.0|O2:7.0,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Discharge,Discharge,indicator_80,outcome_112,"['discharge', 'Discharge']",Time Frame: Day 22 
113,NCT04401579,Change From Baseline in C-reactive Protein (CRP),O1:446|O2:455|O1:446|O2:455|O1:368|O2:367|O1:241|O2:250|O1:159|O2:181|O1:221|O2:240|O1:217|O2:219,O1:-23.035|O2:-18.671|O1:-58.935|O2:-30.908|O1:-78.411|O2:-62.038|O1:-103.789|O2:-88.881|O1:-122.339|O2:-112.588|O1:-131.333|O2:-122.342,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,C-reactive Protein (CRP),CRP,indicator_1,outcome_113,"['C-reactive Protein (CRP)', 'C-reactive Protein']","Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 "
114,NCT04401579,Change From Baseline in D-dimer Concentration,O1:436|O2:432|O1:436|O2:432|O1:352|O2:347|O1:227|O2:230|O1:153|O2:160|O1:215|O2:230|O1:223|O2:206,O1:-0.374|O2:0.384|O1:0.053|O2:-0.149|O1:-0.271|O2:0.351|O1:0.622|O2:0.309|O1:-0.988|O2:-0.422|O1:0.774|O2:-0.219,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,D-dimer Concentration,D-dimer,indicator_51,outcome_114,"['D-dimer', 'D-dimer Concentration']","Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 "
115,NCT04280705,Time to Recovery,O1:521|O2:541,O1:15|O2:10,Placebo|Remdesivir,Time to Recovery ,Recovery,indicator_61,outcome_115,"['Recovery', 'Time to Recovery']","Time Frame: from date of patient admission to date of patient discharge or date of death, whichever came first, assessed up to 45 days "
116,NCT04280705,Change From Baseline in Alanine Transaminase (ALT),O1:463|O2:465|O1:463|O2:465|O1:403|O2:398|O1:327|O2:296|O1:257|O2:227|O1:242|O2:257|O1:180|O2:220,O1:14.3|O2:2.9|O1:23.1|O2:10.8|O1:24.2|O2:8.9|O1:27.7|O2:3.4|O1:28.1|O2:1.7|O1:-3.9|O2:-6.8,Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir,Alanine Transaminase (ALT),ALT,indicator_62,outcome_116,['Alanine Transaminase (ALT)'],Time Frame: From starting to the end of ivermectin therapy (0 to the end of 5th day) 
117,NCT04280705,Change From Baseline in Aspartate Transaminase (AST),O1:438|O2:445|O1:438|O2:445|O1:384|O2:380|O1:315|O2:285|O1:247|O2:219|O1:236|O2:248|O1:170|O2:208,O1:13.7|O2:-2.0|O1:12.8|O2:6.0|O1:13.1|O2:1.1|O1:11.5|O2:-0.3|O1:4.2|O2:-2.3|O1:-18.4|O2:-14.0,Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir,Aspartate Transaminase (AST),AST,indicator_63,outcome_117,['Aspartate Transaminase (AST)'],Time Frame: From starting to the end of ivermectin therapy (0 to the end of 5th day) 
118,NCT04280705,Change From Baseline in Creatinine,O1:475|O2:482|O1:475|O2:482|O1:418|O2:411|O1:335|O2:309|O1:269|O2:234|O1:249|O2:262|O1:189|O2:229,O1:0.037|O2:0.038|O1:-0.695|O2:0.075|O1:-0.882|O2:0.158|O1:1.173|O2:0.236|O1:-1.239|O2:0.319|O1:-1.863|O2:0.075,Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir,Creatinine,Creatinine,indicator_64,outcome_118,['Creatinine'],"Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 "
119,NCT04280705,Change From Baseline in Glucose,O1:456|O2:459|O1:456|O2:459|O1:407|O2:395|O1:323|O2:301|O1:260|O2:228|O1:241|O2:250|O1:180|O2:219,O1:-0.2|O2:-3.0|O1:6.3|O2:2.1|O1:2.2|O2:3.2|O1:1.0|O2:-0.1|O1:-2.8|O2:-2.9|O1:-13.5|O2:-11.7,Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir,Glucose,Glucose,indicator_65,outcome_119,['Glucose'],Time Frame: Day 1 through Day 29 
120,NCT04280705,Change From Baseline in Hemoglobin,O1:475|O2:475|O1:475|O2:475|O1:420|O2:406|O1:334|O2:310|O1:269|O2:230|O1:253|O2:260|O1:189|O2:227,O1:-0.52|O2:-0.69|O1:-0.83|O2:-0.99|O1:-1.22|O2:-0.49|O1:-1.66|O2:-1.29|O1:-1.51|O2:-1.02|O1:-1.02|O2:-1.21,Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir,Hemoglobin,Hemoglobin,indicator_66,outcome_120,['Hemoglobin'],Time Frame: Day 1 through Day 29 
121,NCT04280705,Change From Baseline in Platelets,O1:471|O2:474|O1:471|O2:474|O1:419|O2:403|O1:332|O2:308|O1:269|O2:229|O1:252|O2:258|O1:189|O2:224,O1:39.3|O2:46.0|O1:76.5|O2:90.1|O1:111.8|O2:130.8|O1:109.3|O2:101.0|O1:96.5|O2:71.1|O1:32.7|O2:39.6,Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir,Platelets,Platelet,indicator_67,outcome_121,"['Platelets', 'Platelet']","Time Frame: From date of randomization until first positive culture or clinical diagnosis of infection if occurs, assessed up to 3 months "
122,NCT04280705,Change From Baseline in Prothrombin Time (PT),O1:339|O2:352|O1:339|O2:352|O1:296|O2:306|O1:246|O2:234|O1:199|O2:182|O1:176|O2:193|O1:134|O2:163,O1:-0.18|O2:0.44|O1:-0.30|O2:1.15|O1:0.01|O2:1.43|O1:0.86|O2:1.88|O1:0.34|O2:-0.03|O1:-0.28|O2:-0.63,Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir,Prothrombin Time (PT),PT,indicator_82,outcome_122,['Prothrombin Time (PT)'],Time Frame: 24 hours after 2000 U dose intranasal heparin 
123,NCT04280705,Change From Baseline in Total Bilirubin,O1:451|O2:456|O1:451|O2:456|O1:394|O2:389|O1:315|O2:288|O1:247|O2:220|O1:237|O2:254|O1:178|O2:216,O1:0.08|O2:-0.04|O1:0.58|O2:-0.03|O1:0.22|O2:0.01|O1:0.23|O2:0.07|O1:0.00|O2:0.09|O1:-0.17|O2:-0.12,Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir,Total Bilirubin,Total Bilirubin,indicator_69,outcome_123,['Total Bilirubin'],Time Frame: Pre-SSI to Immediately Post-SSI; Pre-SSI to 3-month follow-up 
124,NCT04280705,Change From Baseline in White Blood Cell Count (WBC),O1:474|O2:475|O1:474|O2:475|O1:419|O2:405|O1:333|O2:310|O1:268|O2:230|O1:252|O2:260|O1:189|O2:226,O1:18.691|O2:-18.970|O1:9.886|O2:-28.209|O1:27.223|O2:-45.997|O1:1.967|O2:-34.702|O1:56.311|O2:-70.884|O1:-0.898|O2:0.251,Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir,White Blood Cell Count (WBC),WBC,indicator_70,outcome_124,['White Blood Cell Count (WBC)'],Time Frame: 0 to 24 hours post-dose 
125,NCT04280705,Change From Baseline in Neutrophils,O1:463|O2:459|O1:463|O2:459|O1:406|O2:389|O1:317|O2:298|O1:257|O2:220|O1:241|O2:253|O1:177|O2:218,O1:9.429|O2:-8.093|O1:4.177|O2:-15.067|O1:17.916|O2:-28.179|O1:3.010|O2:-21.773|O1:36.024|O2:-39.988|O1:-1.269|O2:-0.840,Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir,Neutrophils,Neutrophils,indicator_71,outcome_125,['Neutrophils'],Time Frame: Day 14 
126,NCT04280705,Change From Baseline in Lymphocytes,O1:463|O2:459|O1:463|O2:459|O1:406|O2:389|O1:317|O2:299|O1:257|O2:220|O1:241|O2:253|O1:177|O2:218,O1:5.883|O2:-7.847|O1:4.064|O2:-11.723|O1:8.006|O2:-15.455|O1:0.393|O2:-12.016|O1:14.793|O2:-23.836|O1:0.668|O2:0.743,Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir,Lymphocytes,Lymphocytes,indicator_72,outcome_126,['Lymphocytes'],Time Frame: 29 days 
127,NCT04280705,Change From Baseline in Monocytes,O1:463|O2:458|O1:463|O2:458|O1:406|O2:388|O1:316|O2:299|O1:257|O2:220|O1:241|O2:253|O1:177|O2:218,O1:2.448|O2:-2.940|O1:1.498|O2:-2.628|O1:2.324|O2:-3.645|O1:0.383|O2:-2.539|O1:6.475|O2:-8.738|O1:0.125|O2:0.117,Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir,Monocytes,Monocytes,indicator_73,outcome_127,['Monocytes'],Time Frame: 5 days 
128,NCT04280705,Change From Baseline in Basophils,O1:455|O2:452|O1:455|O2:452|O1:394|O2:380|O1:309|O2:293|O1:253|O2:218|O1:235|O2:248|O1:176|O2:216,O1:0.020|O2:0.005|O1:0.038|O2:0.005|O1:0.196|O2:0.005|O1:0.024|O2:0.028|O1:0.158|O2:-0.058|O1:0.040|O2:0.029,Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir,Basophils,Basophils,indicator_74,outcome_128,['Basophils'],Time Frame: From 6th to the end of 10th day 
129,NCT04280705,Change From Baseline in Eosinophils,O1:456|O2:455|O1:456|O2:455|O1:397|O2:387|O1:311|O2:293|O1:254|O2:218|O1:237|O2:251|O1:176|O2:217,O1:0.634|O2:0.016|O1:0.666|O2:-0.066|O1:0.596|O2:-0.221|O1:0.093|O2:-0.088|O1:1.992|O2:-0.420|O1:0.241|O2:0.211,Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir,Eosinophils,Eosinophils,indicator_75,outcome_129,['Eosinophils'],"Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 "
130,NCT04280705,Change in National Early Warning Score (NEWS) From Baseline,O1:499|O2:502|O1:499|O2:502|O1:447|O2:438|O1:348|O2:321|O1:291|O2:254|O1:290|O2:301|O1:151|O2:120|O1:221|O2:251,O1:0.1|O2:-0.3|O1:0.3|O2:-0.4|O1:-0.3|O2:-0.5|O1:-0.3|O2:-0.5|O1:-1.4|O2:-1.7|O1:-1.4|O2:-1.7|O1:-3.2|O2:-3.3,Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir,National Early Warning Score (NEWS),NEWS,indicator_76,outcome_130,['National Early Warning Score (NEWS)'],Time Frame: Up to 28 days 
131,NCT04280705,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 1,O1:521|O2:541,O1:0|O2:0|O1:30|O2:24|O1:19|O2:18|O1:39|O2:43|O1:12|O2:14|O1:0|O2:0|O1:0|O2:0|O1:0|O2:0|O1:0|O2:1|O1:0|O2:0|O1:1|O2:1,Placebo|Remdesivir,Ordinal Scale,Ordinal Scale,indicator_79,outcome_131,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']","Time Frame: Baseline (Day 1), Day 7, Day 14 Day 21 & Day 30 "
132,NCT04280705,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 3,O1:521|O2:541,O1:1|O2:1|O1:36|O2:28|O1:17|O2:16|O1:32|O2:37|O1:12|O2:13|O1:0.4|O2:0.2|O1:0|O2:0|O1:0|O2:0.4|O1:0|O2:0|O1:0.2|O2:2|O1:1|O2:2,Placebo|Remdesivir,Ordinal Scale,Ordinal Scale,indicator_79,outcome_132,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']","Time Frame: Day 7, Day14, Day 21 & Day30 "
133,NCT04280705,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 5,O1:521|O2:541,O1:2|O2:2|O1:37|O2:28|O1:14|O2:12|O1:26|O2:28|O1:11|O2:15|O1:1|O2:1|O1:0|O2:0.2|O1:0.2|O2:0|O1:0|O2:0|O1:7|O2:12|O1:2|O2:3,Placebo|Remdesivir,Ordinal Scale,Ordinal Scale,indicator_79,outcome_133,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']","Time Frame: Day 7, Day14, Day 21 & Day30 "
134,NCT04280705,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 8,O1:521|O2:541,O1:7|O2:3|O1:33|O2:24|O1:9|O2:9|O1:15|O2:17|O1:10|O2:11|O1:1|O2:1|O1:0|O2:0.2|O1:0.2|O2:0|O1:0|O2:0.4|O1:22|O2:30|O1:2|O2:4,Placebo|Remdesivir,Ordinal Scale,Ordinal Scale,indicator_79,outcome_134,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']","Time Frame: Day 7, Day14, Day 21 & Day30 "
135,NCT04280705,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 11,O1:521|O2:541,O1:8|O2:4|O1:28|O2:22|O1:7|O2:6|O1:13|O2:11|O1:6|O2:7|O1:2|O2:2|O1:0.4|O2:0.4|O1:0.2|O2:0|O1:0|O2:0|O1:33|O2:44|O1:2|O2:4,Placebo|Remdesivir,Ordinal Scale,Ordinal Scale,indicator_79,outcome_135,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']","Time Frame: Day7, Day14, Day21 & Day 30 "
136,NCT04280705,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 15,O1:521|O2:541,O1:11|O2:6|O1:22|O2:15|O1:4|O2:4|O1:11|O2:10|O1:6|O2:7|O1:2|O2:3|O1:17|O2:19|O1:22|O2:29|O1:0|O2:0|O1:2|O2:2|O1:3|O2:5,Placebo|Remdesivir,Ordinal Scale,Ordinal Scale,indicator_79,outcome_136,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']","Time Frame: Day7 ,Day 14 ,Day 21, Day 30 "
137,NCT04280705,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 22,O1:521|O2:541,O1:13|O2:9|O1:14|O2:9|O1:2|O2:2|O1:8|O2:5|O1:5|O2:6|O1:1|O2:1|O1:18|O2:19|O1:32|O2:39|O1:0|O2:0|O1:2|O2:3|O1:4|O2:6|O1:0|O2:0.2,Placebo|Remdesivir,Ordinal Scale,Ordinal Scale,indicator_79,outcome_137,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']","Time Frame: Day 7, Day 14, Day 21 & Day 30 "
138,NCT04280705,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 29,O1:521|O2:541,O1:15|O2:11|O1:9|O2:6|O1:2|O2:1|O1:4|O2:4|O1:3|O2:3|O1:1|O2:1|O1:19|O2:20|O1:36|O2:46|O1:0.2|O2:0|O1:3|O2:1|O1:5|O2:7|O1:3|O2:2,Placebo|Remdesivir,Ordinal Scale,Ordinal Scale,indicator_79,outcome_138,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']","Time Frame: Day 7, Day14, Day 21 and Day 30. "
139,NCT04280705,Percentage of Participants Reporting Grade 3 and 4 Clinical and/or Laboratory Adverse Events (AEs),O1:516|O2:532,O1:57|O2:51,Placebo|Remdesivir,Adverse Events,Adverse,indicator_10,outcome_139,"['Adverse Events', 'Adverse', 'Adverse Event']",Time Frame: 22 days after randomization. 
140,NCT04280705,Percentage of Participants Reporting Serious Adverse Events (SAEs),O1:516|O2:532,O1:32|O2:24,Placebo|Remdesivir,Adverse Events,Adverse,indicator_10,outcome_140,"['Adverse Events', 'Adverse', 'Adverse Event']",Time Frame: 22 days after randomization. 
141,NCT04280705,Percentage of Participants Discontinued or Temporarily Suspended From Investigational Therapeutics,O1:521|O2:541,O1:30|O2:41|O1:4|O2:3|O1:2|O2:2|O1:21|O2:16,Placebo|Remdesivir,Discontinued,Discontinued,indicator_78,outcome_141,"['Discontinued or Temporarily Suspended From Investigational Therapeutics', 'Discontinued']",Time Frame: Day 1 through Day 29 
142,NCT04280705,Duration of Hospitalization,O1:521|O2:541|O1:521|O2:541|O1:443|O2:480,O1:17|O2:12|O1:14|O2:10,Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir,Hospitalization,Hospitalization,indicator_18,outcome_142,"['Hospitalization', 'hospitalization', 'Hospital']",Time Frame: Day 8 
143,NCT04280705,Duration of New Non-invasive Ventilation or High Flow Oxygen Use,O1:64|O2:52|O1:64|O2:52|O1:50|O2:43,O1:4|O2:3|O1:3|O2:3,Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir,New Non-invasive Ventilation or High Flow Oxygen Use ,Oxygen,indicator_8,outcome_143,"['Oxygen', 'New Non-invasive Ventilation or High Flow Oxygen Use', 'Oxygen Use']",Time Frame: Up to 28 days 
144,NCT04280705,Duration of New Oxygen Use,O1:28|O2:27|O1:28|O2:27|O1:25|O2:24,O1:5.5|O2:4|O1:3|O2:3.5,Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir,New Oxygen Use ,Oxygen,indicator_8,outcome_144,"['Oxygen', 'New Oxygen Use', 'Oxygen Use']",Time Frame: 30 days after clinic discharge 
145,NCT04280705,Duration of New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use,O1:82|O2:52|O1:82|O2:52|O1:57|O2:39,O1:23|O2:21.5|O1:16|O2:14,Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir,New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use ,ECMO,indicator_77,outcome_145,"['Oxygen', 'ECMO', 'New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use']",Time Frame: 10 days during inhalation 
146,NCT04280705,Percentage of Participants Requiring New Non-invasive Ventilation or High-flow Oxygen Use,O1:266|O2:307,O1:24|O2:17,Placebo|Remdesivir,Participants Requiring New Non-invasive Ventilation or High-flow Oxygen Use,Oxygen,indicator_8,outcome_146,"['Oxygen', 'Participants Requiring New Non-invasive Ventilation or High-flow Oxygen Use', 'Oxygen Use']",Time Frame: 28 days after randomization 
147,NCT04280705,Percentage of Participants Requiring New Oxygen Use,O1:63|O2:75,O1:44|O2:36,Placebo|Remdesivir,Participants Requiring New Oxygen Use,Oxygen,indicator_8,outcome_147,"['Oxygen', 'New Oxygen Use', 'Participants Requiring New Oxygen Use', 'Oxygen Use']",Time Frame: 28 days after randomization 
148,NCT04280705,Percentage of Participants Requiring New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use,O1:364|O2:402,O1:23|O2:13,Placebo|Remdesivir,Participants Requiring New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use,ECMO,indicator_77,outcome_148,"['Oxygen', 'ECMO', 'Participants Requiring New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use', 'New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use']",Time Frame: 28 days after randomization 
149,NCT04280705,Mean Change in the Ordinal Scale,O1:518|O2:533,O1:0.2|O2:0.1|O1:0.1|O2:0.0|O1:0.0|O2:-0.2|O1:-0.1|O2:-0.3|O1:-1.4|O2:-1.9|O1:-1.9|O2:-2.4|O1:-2.3|O2:-2.7,Placebo|Remdesivir,Ordinal Scale ,Ordinal Scale,indicator_79,outcome_149,"['Ordinal Scale', 'Mean Change', 'ordinal scale']",Time Frame: assessed on study day 3 
150,NCT04280705,14-day Participant Mortality,O1:521|O2:541,O1:0.12|O2:0.07,Placebo|Remdesivir,Mortality,Death ,indicator_16,outcome_150,['Mortality'],Time Frame: Day 28 
151,NCT04280705,29-day Participant Mortality,O1:521|O2:541,O1:0.15|O2:0.11,Placebo|Remdesivir,Mortality,Death ,indicator_16,outcome_151,['Mortality'],Time Frame: 28 days 
152,NCT04280705,Time to an Improvement by at Least One Category Using an Ordinal Scale,O1:521|O2:541,O1:9|O2:7,Placebo|Remdesivir,Improvement,Improvement,indicator_54,outcome_152,"['Ordinal Scale', 'improvement', 'Improvement', 'ordinal scale']",Time Frame: 15 days 
153,NCT04280705,Time to an Improvement of at Least Two Categories Using an Ordinal Scale,O1:521|O2:541,O1:14|O2:11,Placebo|Remdesivir,Improvement,Improvement,indicator_54,outcome_153,"['Ordinal Scale', 'improvement', 'Improvement', 'ordinal scale']",Time Frame: 6 days and 10 Days 
154,NCT04280705,"Time to Discharge or to a NEWS of 2 or Less and Maintained for 24 Hours, Whichever Occurs First",O1:521|O2:541,O1:12|O2:8,Placebo|Remdesivir,Discharge,Discharge,indicator_80,outcome_154,"['discharge', 'Discharge']",Time Frame: Day 15 
155,NCT04332081,Mortality,O1:20|O2:60,O1:10|O2:22,Hyperbaric Oxygen Therapy (HBOT)|Standard of Care,Mortality,Death ,indicator_16,outcome_155,['Mortality'],NA
156,NCT04332081,Need for Mechanical Ventilation,O1:20|O2:60,O1:2|O2:18,Hyperbaric Oxygen Therapy (HBOT)|Standard of Care,Mechanical Ventilation,Mechanical Ventilation,indicator_9,outcome_156,"['mechanical Ventilation', 'Mechanical Ventilation']",NA
157,NCT04329923,Time to Release From Quarantine Time,O1:15|O2:13,O1:8|O2:11,Cohort 1 HCQ|Cohort 1 Placebo,Release,Release,indicator_83,outcome_157,[],NA
158,NCT04329923,Time to Hospital Discharge,O1:4|O2:3,O1:5.5|O2:4,Cohort 2 HCQ High Dose|Cohort 2 HCQ Low Dose,discharge,Discharge,indicator_80,outcome_158,"['discharge', 'Discharge', 'Hospital']",NA
159,NCT04329923,Number of Health Care Workers Who Developed SARS-COV-2 Infection,O1:64|O2:61,O1:4|O2:4,Cohort 3 HCQ|Cohort 3 Placebo,Infect,Infect,indicator_84,outcome_159,['Infect'],NA
160,NCT04329923,Rate of Housemate Infection,O1:17|O2:17,O1:2|O2:2,Cohort 1 HCQ|Cohort 1 Placebo,Infect,Infect,indicator_84,outcome_160,['Infect'],NA
161,NCT04329923,Rate of Hospitalization,O1:17|O2:17,O1:1|O2:0,Cohort 1 HCQ|Cohort 1 Placebo,Hospitalization,Hospitalization,indicator_18,outcome_161,"['Hospitalization', 'hospitalization', 'Hospital']",NA
162,NCT04329923,Time to Release From Quarantine Time,NA,NA,NA,Release,Release,indicator_83,outcome_157,[],NA
163,NCT04329923,Time to Hospital Discharge,NA,NA,NA,discharge,Discharge,indicator_80,outcome_158,"['discharge', 'Discharge', 'Hospital']",NA
164,NCT04329923,Number of Health Care Workers Who Developed SARS-COV-2 Infection,NA,NA,NA,Infect,Infect,indicator_84,outcome_159,['Infect'],NA
165,NCT04329923,Rate of Housemate Infection,NA,NA,NA,Infect,Infect,indicator_84,outcome_160,['Infect'],NA
166,NCT04329923,Rate of Hospitalization,NA,NA,NA,Hospitalization,Hospitalization,indicator_18,outcome_161,"['Hospitalization', 'hospitalization', 'Hospital']",NA
167,NCT04329923,Time to Release From Quarantine Time,NA,NA,NA,Release,Release,indicator_83,outcome_157,[],NA
168,NCT04329923,Time to Hospital Discharge,NA,NA,NA,discharge,Discharge,indicator_80,outcome_158,"['discharge', 'Discharge', 'Hospital']",NA
169,NCT04329923,Number of Health Care Workers Who Developed SARS-COV-2 Infection,NA,NA,NA,Infect,Infect,indicator_84,outcome_159,['Infect'],NA
170,NCT04329923,Rate of Housemate Infection,NA,NA,NA,Infect,Infect,indicator_84,outcome_160,['Infect'],NA
171,NCT04329923,Rate of Hospitalization,NA,NA,NA,Hospitalization,Hospitalization,indicator_18,outcome_161,"['Hospitalization', 'hospitalization', 'Hospital']",NA
172,NCT04410159,Number of Participants With Early Viral Clearance,O1:5|O2:5|O3:5|O4:5,O1:5|O2:4|O3:1|O4:0,Povidone-iodine|Essential Oils|Tap Water|Control,Viral Clearance,Viral Clearance,indicator_55,outcome_162,['Viral Clearance'],Time Frame: Pre-SSI 
173,NCT04410159,Number of Participants With Negative RT-PCR Results,O1:5|O2:5|O3:5|O4:5,O1:5|O2:4|O3:2|O4:1,Povidone-iodine|Essential Oils|Tap Water|Control,RT-PCR,RT-PCR,indicator_85,outcome_163,['RT-PCR'],Time Frame: Baseline to Day 29 
174,NCT04410159,Number of Patients That Progress to More Severe Disease,O1:5|O2:5|O3:5|O4:5,O1:0|O2:0|O3:0|O4:0,Povidone-iodine|Essential Oils|Tap Water|Control,More Severe Disease,More Severe Disease,indicator_86,outcome_164,['More Severe Disease'],Time Frame: Day 14 
175,NCT04410159,Number of Patients With Abnormal Radiological Findings,O1:5|O2:5|O3:5|O4:5,O1:0|O2:0|O3:0|O4:0,Povidone-iodine|Essential Oils|Tap Water|Control,Abnormal Radiological,Abnormal Radiological,indicator_87,outcome_165,['Abnormal Radiological'],Time Frame: Treatment period of 7 days ((Day 1 to Day 8) 
176,NCT04410159,Number of Patients With Abnormal Laboratory Findings,O1:5|O2:5|O3:5|O4:5,O1:0|O2:0|O3:0|O4:0,Povidone-iodine|Essential Oils|Tap Water|Control,Abnormal Laboratory Findings,Abnormal Laboratory Findings,indicator_88,outcome_166,['Abnormal Laboratory Findings'],Time Frame: Treatment period of 7 days (Day 1 to Day 8) 
177,NCT04335136,All Cause-death or Invasive Mechanical Ventilation,O1:88|O2:90,O1:9|O2:12,Group A (Active) APN01|Group B (Placebo Control),Death,Death ,indicator_16,outcome_167,"['mechanical Ventilation', 'Mechanical Ventilation', 'Invasive Mechanical Ventilation', 'Death']",NA
178,NCT04335136,Lactate Dehydrogenase (LDH) Level,O1:74|O2:74,O1:5.82|O2:5.80,Group A (Active) APN01|Group B (Placebo Control),LDH,LDH,indicator_89,outcome_168,['LDH'],NA
179,NCT04335136,Mortality,O1:88|O2:90,O1:9|O2:7,Group A (Active) APN01|Group B (Placebo Control),Mortality,Death ,indicator_16,outcome_169,['Mortality'],NA
180,NCT04335136,Ventilator-free Days (VFD),O1:88|O2:90|O1:88|O2:90|O1:88|O2:90|O1:80|O2:84|O1:88|O2:90|O1:88|O2:90|O1:79|O2:83,O1:17.2|O2:16.7|O1:17.4|O2:16.7|O1:18.9|O2:17.9|O1:25.7|O2:25.1|O1:26.3|O2:25.6|O1:28.2|O2:26.9,Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control),Ventilator-free,Ventilator-free,indicator_90,outcome_170,['Ventilator-free'],NA
181,NCT04335136,Time to Death,O1:88|O2:90,NA|NA,Group A (Active) APN01|Group B (Placebo Control),Death,Death ,indicator_16,outcome_171,['Death'],NA
182,NCT04335136,"Number of Responders, Defined as ≥2 Improvement in World Health Organization (WHO)'s 11-Point Score System at Days 7, 10, 14 and 28",O1:88|O2:90|O1:88|O2:88|O1:86|O2:85|O1:83|O2:85|O1:79|O2:83,O1:2|O2:0|O1:17|O2:13|O1:38|O2:32|O1:72|O2:74,Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control),Improvement,Improvement,indicator_54,outcome_172,"['improvement', 'Improvement']",NA
183,NCT04335136,Time to Hospital Discharge,O1:88|O2:90,O1:14|O2:14,Group A (Active) APN01|Group B (Placebo Control),discharge,Discharge,indicator_80,outcome_173,"['discharge', 'Discharge', 'Hospital']",NA
184,NCT04335136,Viral Ribonucleic Acid (RNA).,O1:88|O2:90|O1:59|O2:49|O1:47|O2:58|O1:56|O2:64|O1:65|O2:61|O1:73|O2:73|O1:37|O2:0,O1:27996|O2:3900|O1:20931|O2:13681|O1:9825|O2:11912|O1:5229|O2:2094|O1:9274|O2:53|O1:36,Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control),Viral Ribonucleic Acid (RNA),RNA,indicator_91,outcome_174,[],NA
185,NCT04335136,Time to a 2-point Decrease in WHO's 11-Point Score System,O1:88|O2:90,O1:27|O2:27,Group A (Active) APN01|Group B (Placebo Control),WHO's 11-Point Score,WHO's 11-Point Score,indicator_92,outcome_175,[],NA
186,NCT04335136,Number of Patients With Any Use of Invasive Mechanical Ventilation up to 28 Days or Hospital Discharge,O1:88|O2:90,O1:7|O2:7|O1:86|O2:88,Group A (Active) APN01|Group B (Placebo Control),Invasive Mechanical Ventilation/ Hospital Discharge,Mechanical Ventilation,indicator_9,outcome_176,"['discharge', 'Discharge', 'mechanical Ventilation', 'Mechanical Ventilation', 'Invasive Mechanical Ventilation', 'Hospital']",NA
187,NCT04335136,Time to First Use of Invasive Mechanical Ventilation up to 28 Days or Hospital Discharge,O1:88|O2:90,NA|NA,Group A (Active) APN01|Group B (Placebo Control),Invasive Mechanical Ventilation/ Hospital Discharge,Mechanical Ventilation,indicator_9,outcome_177,"['discharge', 'Discharge', 'mechanical Ventilation', 'Mechanical Ventilation', 'Invasive Mechanical Ventilation', 'Hospital']",NA
188,NCT04335136,PaO2/FiO2 Value,O1:88|O2:90|O1:30|O2:28|O1:19|O2:24|O1:14|O2:13|O1:9|O2:11|O1:1|O2:3,O1:223.07|O2:185.14|O1:218.74|O2:192.21|O1:290.00|O2:186.62|O1:197.00|O2:185.00|O1:261.00|O2:185.00,Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control),PaO2/FiO2,P/F Ratio,indicator_47,outcome_178,['PaO2/FiO2'],NA
189,NCT04335136,"Modified Sequential Organ Failure Assessment Score (mSOFA Score, Total Score)",O1:88|O2:90|O1:80|O2:80|O1:83|O2:77|O1:80|O2:77|O1:79|O2:75|O1:39|O2:38,O1:2.6|O2:2.2|O1:1.8|O2:1.6|O1:1.0|O2:1.0|O1:1.0|O2:0.9|O1:0.2|O2:0.8,Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control),"Modified Sequential Organ Failure Assessment Score (mSOFA Score, Total Score)","Modified Sequential Organ Failure Assessment Score (mSOFA Score, Total Score)",indicator_93,outcome_179,[],NA
190,NCT04335136,Lymphocyte Count,O1:88|O2:90|O1:82|O2:82|O1:85|O2:83|O1:82|O2:80|O1:81|O2:75|O1:77|O2:73|O1:37|O2:37,O1:1.13|O2:1.06|O1:1.25|O2:1.16|O1:1.45|O2:1.62|O1:1.74|O2:1.79|O1:1.70|O2:1.71|O1:2.28|O2:1.72,Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control),Lymphocyte Count,Lymphocyte Count,indicator_19,outcome_180,['Lymphocyte Count'],NA
191,NCT04335136,C-reactive Protein Levels,O1:88|O2:90|O1:77|O2:79|O1:80|O2:74|O1:78|O2:76|O1:74|O2:71|O1:69|O2:73|O1:36|O2:37,O1:56.0|O2:62.8|O1:36.1|O2:43.7|O1:21.7|O2:26.1|O1:13.9|O2:26.3|O1:15.8|O2:38.3|O1:4.9|O2:8.5,Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control),C-reactive Protein,CRP,indicator_1,outcome_181,['C-reactive Protein'],NA
192,NCT04335136,D-Dimer,O1:88|O2:90|O1:71|O2:73|O1:69|O2:74|O1:73|O2:68|O1:70|O2:66|O1:70|O2:66|O1:32|O2:31,O1:1341|O2:1187|O1:1109|O2:881|O1:1208|O2:1139|O1:988|O2:1219|O1:1015|O2:1013|O1:573|O2:685,Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control),D-dimer,D-dimer,indicator_51,outcome_182,['D-dimer'],NA
193,NCT04335136,Log-transformed Levels of LDH,O1:88|O2:90|O1:78|O2:77|O1:76|O2:76|O1:78|O2:74|O1:72|O2:74|O1:69|O2:71|O1:38|O2:38,O1:5.91|O2:5.87|O1:5.86|O2:5.88|O1:5.77|O2:5.75|O1:5.66|O2:5.67|O1:5.55|O2:5.52|O1:5.43|O2:5.50,Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control),LDH,LDH,indicator_89,outcome_183,['LDH'],NA
194,NCT04331366,Oxygen Saturation by Pulse Oximetry,O1:2,O1:92|O1:93.5|O1:94|O1:94|O1:92.5,GO2 PEEP MOUTHPIECE,Oxygen Saturation,SpO2,indicator_17,outcome_184,"['Oxygen', 'Oxygen Saturation']",Time Frame: 28 days after randomization 
195,NCT04331366,Respiratory Rate,O1:2,O1:23.5|O1:20|O1:18|O1:17|O1:18.5,GO2 PEEP MOUTHPIECE,Respiratory Rate,Respiratory Rate,indicator_44,outcome_185,['Respiratory Rate'],Time Frame: Baseline to Day 29 
196,NCT04331366,Heart Rate,O1:2,O1:84.5|O1:87.5|O1:90.5|O1:86.5|O1:86.5,GO2 PEEP MOUTHPIECE,Heart Rate,Heart Rate,indicator_43,outcome_186,['Heart Rate'],Time Frame: Day 1 through Day 29 
197,NCT04331366,Blood Pressure,O1:2,O1:152.5|O1:65|O1:155|O1:72.5|O1:150|O1:70|O1:145|O1:67.5|O1:152.5|O1:65,GO2 PEEP MOUTHPIECE,Blood Pressure,Blood Pressure,indicator_45,outcome_187,['Blood Pressure'],Time Frame: Baseline 
198,NCT04331366,Count of Participants With Subjective Work of Breathing,O1:2|O1:0|O1:2|O1:2|O1:2|O1:0,O1:1|O1:0|O1:0,GO2 PEEP MOUTHPIECE|GO2 PEEP MOUTHPIECE|GO2 PEEP MOUTHPIECE|GO2 PEEP MOUTHPIECE|GO2 PEEP MOUTHPIECE|GO2 PEEP MOUTHPIECE,Subjective Work of Breathing,Breathing,indicator_94,outcome_188,['Subjective Work of Breathing'],Time Frame: Days 1 - 17. 
199,NCT04331899,Duration Until Viral Shedding Cessation,O1:60|O2:60,O1:7|O2:7,Lambda|Placebo,Viral Shedding,Viral Clearance,indicator_55,outcome_189,['Viral Shedding'],Time Frame: 0 to 24 hours post-dose 
200,NCT04331899,Change in Sars-CoV-2 Viral Load,O1:60|O2:60,O1:-4.3|O2:-4.9,Lambda|Placebo,Viral Load,Viral Load,indicator_95,outcome_190,['Viral Load'],Time Frame: Pre-SSI to 3-month follow-up 
201,NCT04331899,Area Under the Curve of SARS-COV-2 Viral Load,O1:60|O2:60,O1:28.5|O2:29.6,Lambda|Placebo,Viral Load,Viral Load,indicator_95,outcome_191,['Viral Load'],Time Frame: Pre-SSI to 3-month follow-up 
202,NCT04331899,Duration Until Resolution of Symptoms,O1:60|O2:60,O1:8|O2:9,Lambda|Placebo,Resolution of Symptoms,Resolution of Symptoms,indicator_96,outcome_192,"['Symptom', 'Resolution of Symptoms']","Time Frame: Baseline, Days 4, 7, 15, 21, and 29 "
203,NCT04331899,Count of Participants Requiring Emergency Department Visits or Hospitalizations Within 28 Days of Initiation of Treatment,O1:60|O2:60,O1:2|O2:2|O1:5|O2:3,Lambda|Placebo,hospitalization,Hospitalization,indicator_18,outcome_193,"['Hospitalization', 'hospitalization', 'Hospital']",Time Frame: Day 22 
204,NCT04292899,Part A: Percentage of Participants in Each Clinical Status Category as Assessed by a 7-Point Ordinal Scale on Day 14,O1:200|O2:197,O1:8.0|O2:10.7|O1:8.5|O2:16.8|O1:4.0|O2:5.1|O1:9.5|O2:7.6|O1:6.0|O2:6.1|O1:4.0|O2:1.5|O1:60.0|O2:52.3,Part A: Remdesivir (RDV) for 5 Days|Part A: Remdesivir for 10 Days,ordinal scale,Ordinal Scale,indicator_79,outcome_194,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']","Time Frame: days 1, 5 and 14 "
205,NCT04292899,Part A: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs),O1:200|O2:197,O1:71.5|O2:75.1,Part A: Remdesivir (RDV) for 5 Days|Part A: Remdesivir for 10 Days,Adverse Events,Adverse,indicator_10,outcome_195,"['Adverse Events', 'Adverse', 'Adverse Event']",Time Frame: Admission to discharge dates (approximately 4-14 days after admission). Discharge variables considered as the last available data before their death for the expired patients. 
206,NCT04292730,Part A: Percentage of Participants in Each Clinical Status Category as Assessed by a 7-Point Ordinal Scale on Day 11,O1:191|O2:193|O3:200,O1:0.0|O2:1.0|O3:2.0|O1:0.0|O2:0.5|O3:2.0|O1:2.6|O2:0.0|O3:3.5|O1:3.7|O2:6.2|O3:5.5|O1:19.9|O2:22.8|O3:23.0|O1:3.7|O2:4.7|O3:4.0|O1:70.2|O2:64.8|O3:60.0,Part A: Remdesivir for 5 Days|Part A: Remdesivir for 10 Days|Part A: SOC Therapy,ordinal scale,Ordinal Scale,indicator_79,outcome_196,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']",Time Frame: 14 days 
207,NCT04292730,Part A: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs),O1:191|O2:193|O3:200,O1:51.3|O2:58.5|O3:46.5,Part A: Remdesivir for 5 Days|Part A: Remdesivir for 10 Days|Part A: SOC Therapy,Adverse Events,Adverse,indicator_10,outcome_197,"['Adverse Events', 'Adverse', 'Adverse Event']","Time Frame: The duration of hospitalization for the patients (admission to discharge dates, approximately 4-14 days after admission). The patients who died were excluded. "
208,NCT04320615,Clinical Status Assessed Using a 7-Category Ordinal Scale at Day 28 (Week 4),O1:294|O2:144,Tocilizumab (TCZ) mITT Arm|Placebo Modified Intent-to-Treat (mITT) Arm,NA,Ordinal Scale,Ordinal Scale,indicator_79,outcome_198,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']",NA
209,NCT04320615,"Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours",O1:294|O2:144,NA,NA,Improvement,Improvement,indicator_54,outcome_199,"['improvement', 'Improvement', 'National Early Warning Score 2']",NA
210,NCT04320615,Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status,O1:294|O2:144,NA,NA,Improvement,Improvement,indicator_54,outcome_200,"['Ordinal Scale', 'improvement', 'Improvement', 'Clinical Status', 'ordinal scale']",NA
211,NCT04320615,"Time to Hospital Discharge or ""Ready for Discharge""",O1:294|O2:144,NA,NA,discharge,Discharge,indicator_80,outcome_201,"['discharge', 'Discharge', 'Hospital']",NA
212,NCT04320615,Incidence of Mechanical Ventilation by Day 28,O1:294|O2:144|O3:183|O4:90,NA,NA,Mechanical Ventilation,Mechanical Ventilation,indicator_9,outcome_202,"['mechanical Ventilation', 'Mechanical Ventilation']",NA
213,NCT04320615,Ventilator-Free Days to Day 28,O1:294|O2:144,NA,NA,Ventilator-free,Ventilator-free,indicator_90,outcome_203,['Ventilator-free'],NA
214,NCT04320615,Incidence of Intensive Care Unit (ICU) Stay by Day 28 (Week 4),O1:294|O2:144|O3:127|O4:64,NA,NA,ICU,ICU,indicator_97,outcome_204,"['Intensive Care', 'ICU']",NA
215,NCT04320615,Duration of ICU Stay to Day 28 (Week 4),O1:294|O2:144,NA,NA,ICU,ICU,indicator_97,outcome_205,['ICU'],NA
216,NCT04320615,Clinical Status Assessed Using a 7-Category Ordinal Scale at Day 14,O1:294|O2:144,NA,NA,Ordinal Scale,Ordinal Scale,indicator_79,outcome_206,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']",NA
217,NCT04320615,Time to Clinical Failure to Day 28 (Week 4),O1:294|O2:144,NA,NA,Time,Time,indicator_98,outcome_207,[],NA
218,NCT04320615,Mortality Rate at Day 28 (Week 4),O1:294|O2:144,NA,NA,Mortality,Death ,indicator_16,outcome_208,"['Mortality Rate', 'Mortality']",NA
219,NCT04320615,Time to Recovery to Day 28 (Week 4),O1:294|O2:144,NA,NA,Recovery,Recovery,indicator_61,outcome_209,"['Recovery', 'Time to Recovery']",NA
220,NCT04320615,Duration of Supplemental Oxygen to Day 28 (Week 4),O1:294|O2:144,NA,NA,Oxygen,Oxygen,indicator_8,outcome_210,['Oxygen'],NA
221,NCT04401202,Percentage of Participants With Clinical Recovery Within 14 Days After Randomization,O1:87|O2:86,O1:54|O2:31,Nigella Sativa Oil|Control,Recovery,Recovery,indicator_61,outcome_211,['Recovery'],"Time Frame: Day 0 through Day 2, acute phase "
222,NCT04401202,The Number of Days to Recovery,O1:87|O2:86,O1:11|O2:14,Nigella Sativa Oil|Control,Recovery,Recovery,indicator_61,outcome_212,['Recovery'],"Time Frame: Day 1 through Day 15, chronic phase "
223,NCT04401202,Duration of Each Symptom,O1:87|O2:86,O1:8.5|O2:10.4|O1:2.5|O2:3.7|O1:3.5|O2:5.5|O1:2.1|O2:4.9,Nigella Sativa Oil|Control,Symptom,Symptom,indicator_99,outcome_213,['Symptom'],Time Frame: 14 days 
224,NCT04401202,Side Effects,O1:87|O2:86,O1:3|O2:0,Nigella Sativa Oil|Control,Effect,Effect,indicator_100,outcome_214,['Effect'],Time Frame: Day 1 through Day 29 
225,NCT04401202,Hospital Admission Due to Disease Complications,O1:87|O2:86,O1:0|O2:4,Nigella Sativa Oil|Control,Complication,Complication,indicator_101,outcome_215,"['Complication', 'Hospital']",Time Frame: 7 days 
226,NCT04435808,SARS-CoV-2 Infection,NA,NA,NA,Infect,Infect,indicator_84,outcome_216,['Infect'],NA
227,NCT04435808,Symptomatic vs. Asymptomatic Infection With SARS-CoV-2,NA,NA,NA,Symptom,Symptom,indicator_99,outcome_217,"['Symptom', 'Infect']",NA
228,NCT04435808,Occupational Health Exposure,NA,NA,NA,Health Exposure,Health Exposure,indicator_102,outcome_218,[],NA
229,NCT04435808,Impact of Hydroxychloroquine Use on Need for Hospitalization With SARS-CoV-2 Infection,NA,NA,NA,Hospitalization,Hospitalization,indicator_18,outcome_219,"['Hospitalization', 'Infect', 'hospitalization', 'Hospital']",NA
230,NCT04435808,Impact of Hydroxychloroquine Use on Need for ICU Care With SARS-CoV-2 Infection,NA,NA,NA,ICU,ICU,indicator_97,outcome_220,"['Infect', 'ICU']",NA
231,NCT04435808,Adverse Effect Profile of Hydroxychloroquine,NA,NA,NA,Adverse,Adverse,indicator_10,outcome_221,"['Effect', 'Adverse']",NA
232,NCT04435808,Seroconversion Following SARS-CoV-2 Infection,NA,NA,NA,Infect,Infect,indicator_84,outcome_222,['Infect'],NA
233,NCT04435808,Metagenomic Next Generation Sequencing of SARS-CoV-2 Isolates,NA,NA,NA,Sequencing,Sequencing,indicator_103,outcome_223,[],NA
234,NCT04338074,Hospitalization,O1:3|O2:2,O1:0|O2:0,Tranexamic Acid Treatment|Placebo Treatment,Hospitalization,Hospitalization,indicator_18,outcome_224,"['Hospitalization', 'hospitalization', 'Hospital']",NA
235,NCT04338074,NA,NA,NA,NA,nan,nan,indicator_104,outcome_225,['nan'],NA
236,NCT04358068,Number of Participants Who Died From Any Cause or Were Hospitalized,O1:7|O2:9,O1:0|O2:1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)|Arm B: Placebo for Hydroxychloroquine and Azithromycin,Died,Death ,indicator_16,outcome_226,['Hospital'],NA
237,NCT04358068,Number of Participants Who Died From Any Cause,O1:7|O2:9,O1:0|O2:0,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)|Arm B: Placebo for Hydroxychloroquine and Azithromycin,Died,Death ,indicator_16,outcome_227,[],NA
238,NCT04358068,"Number of Participants Who Died From Any Cause, or Were Hospitalized, or Had an Urgent Visit to Emergency Room or Clinic",O1:7|O2:9,O1:1|O2:1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)|Arm B: Placebo for Hydroxychloroquine and Azithromycin,Died,Death ,indicator_16,outcome_228,['Hospital'],NA
239,NCT04358068,Number of Participants Who Died From Any Cause or Were Hospitalized Through the End of Follow-up,O1:0|O2:0,NA,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)|Arm B: Placebo for Hydroxychloroquine and Azithromycin,Died,Death ,indicator_16,outcome_229,['Hospital'],NA
240,NCT04358068,Number of Participants Who Prematurely Discontinue Study Treatment Due to an Adverse Event,O1:7|O2:9,O1:0|O2:1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)|Arm B: Placebo for Hydroxychloroquine and Azithromycin,Adverse,Adverse,indicator_10,outcome_230,"['Adverse', 'Adverse Event']",NA
241,NCT04358068,Number of Participants Who Had Any Cardiac Adverse Events,O1:7|O2:9,O1:0|O2:0,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)|Arm B: Placebo for Hydroxychloroquine and Azithromycin,Adverse,Adverse,indicator_10,outcome_231,"['Adverse Events', 'Adverse', 'Adverse Event']",NA
242,NCT04358068,Duration of Fever,O1:7|O2:8,O1:0|O2:0,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)|Arm B: Placebo for Hydroxychloroquine and Azithromycin,Fever ,Fever ,indicator_56,outcome_232,['Fever'],NA
243,NCT04358068,Duration of Symptoms Associated With COVID-19 Disease,O1:7|O2:9,O1:11.0|O2:10.0,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)|Arm B: Placebo for Hydroxychloroquine and Azithromycin,Symptom,Symptom,indicator_99,outcome_233,['Symptom'],NA
244,NCT04358068,Participant-specific Area Under the Curve (AUC) of the Symptom Score Associated With COVID-19 Disease Over Time,O1:7|O2:9,O1:4.0|O2:2.8,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)|Arm B: Placebo for Hydroxychloroquine and Azithromycin,Symptom,Symptom,indicator_99,outcome_234,['Symptom'],NA
245,NCT04358068,Time to Self-reported Return to Usual (Pre-COVID) Health.,O1:7|O2:9,O1:17.0|O2:10.0,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)|Arm B: Placebo for Hydroxychloroquine and Azithromycin,Time,Time,indicator_98,outcome_235,[],NA
246,NCT04358068,SARS-CoV-2 RNA Detection Status From Self-collected Nasal and Site-collected NP Swabs Among Subset,O1:0|O2:0,NA,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)|Arm B: Placebo for Hydroxychloroquine and Azithromycin,Detection,Detection ,indicator_105,outcome_236,['Detection'],NA
247,NCT04358068,SARS-CoV-2 RNA Level (Continuous) From Self-collected Nasal and Site-collected NP Swabs Among Subset,O1:0|O2:0,NA,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)|Arm B: Placebo for Hydroxychloroquine and Azithromycin,RNA,RNA,indicator_91,outcome_237,[],NA
248,NCT04358068,Number of Participants With an Occurrence of Fainting,O1:7|O2:9,O1:1|O2:1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)|Arm B: Placebo for Hydroxychloroquine and Azithromycin,Fainting,Fainting,indicator_106,outcome_238,[],NA
249,NCT04358081,Number of Participants Who Achieved Clinical Response by Day 15,O1:7|O2:7|O3:5,O1:7|O2:7|O3:4,Arm 1: Hydroxychloroquine + Aithromycin Placebo|Arm 2: Hydroxychloroquine + Azithromycin|Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,Clinical Response,Clinical Response,indicator_46,outcome_239,['Clinical Response'],Time Frame: Baseline 
250,NCT04358081,Number of Participants Who Achieved Viral Clearance,O1:7|O2:7|O3:5,O1:2|O2:3|O3:3|O1:2|O2:3|O3:3,Arm 1: Hydroxychloroquine + Aithromycin Placebo|Arm 2: Hydroxychloroquine + Azithromycin|Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,Viral Clearance,Viral Clearance,indicator_55,outcome_240,['Viral Clearance'],Time Frame: Pre-SSI 
251,NCT04358081,Number of Participants Discharged or Ready for Discharge,O1:7|O2:7|O3:5,O1:7|O2:7|O3:4,Arm 1: Hydroxychloroquine + Aithromycin Placebo|Arm 2: Hydroxychloroquine + Azithromycin|Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,Discharge ,Discharge,indicator_80,outcome_241,"['discharge', 'Discharge']",Time Frame: Day 1 through Day 29 
252,NCT04358081,Time to Return to Pre-morbid Supplemental Oxygen Requirement in Participants Receiving Hydrochloroquine or Hydrochloroquine Plus Azithromycin Relative to Placebo,O1:7|O2:7|O3:5,O1:7|O2:6|O3:4,Arm 1: Hydroxychloroquine + Aithromycin Placebo|Arm 2: Hydroxychloroquine + Azithromycin|Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,Oxygen,Oxygen,indicator_8,outcome_242,['Oxygen'],Time Frame: Enrollment to Day 28 
253,NCT04523831,Number of Patients With Early Clinical Improvement,O1:183|O2:180,O1:111|O2:80,Ivermectin Plus Doxycycline|Placebo,Improvement ,Improvement,indicator_54,outcome_243,"['improvement', 'Improvement']",Time Frame: Day 6 
254,NCT04523831,Number of Participants With Late Clinical Recovery,O1:183|O2:180,O1:42|O2:67,Ivermectin Plus Doxycycline|Placebo,Recovery,Recovery,indicator_61,outcome_244,['Recovery'],"Time Frame: Day 0 through Day 2, acute phasNumber of Incidents of Epistaxis, Chronic Phase|Time Frame: Day 1 through Day 15, chronic phase "
255,NCT04523831,Number of Patients Having Clinical Deterioration.,O1:183|O2:180,O1:16|O2:32,Ivermectin Plus Doxycycline|Placebo,Deterioration,Deterioration,indicator_107,outcome_245,['Deterioration'],Time Frame: Day 1 
256,NCT04523831,Number of Patients Remain Persistently Positive for RT-PCR of Covid-19,O1:183|O2:180,O1:14|O2:36,Ivermectin Plus Doxycycline|Placebo,RT-PCR,RT-PCR,indicator_85,outcome_246,"['Positive', 'RT-PCR']",Time Frame: Baseline to Day 29 
257,NCT04599959,Number of Participants Testing Positive or Negative for SARS-CoV-2 Virus From Swab and Saliva Samples - Processed in Mexico,O1:151|O2:103,O1:85|O2:13|O1:66|O2:89|O1:0|O2:1,Swab - Processed in Mexico|Saliva - Processed in Mexico,Positive,Positive,indicator_108,outcome_247,['Positive'],NA
258,NCT04599959,Percentage of Participants Testing True Positive or True Negative for SARS-CoV-2 Virus From Swab and Saliva Samples - Processed in Germany,O1:141|O1:69|O1:72,O1:52.2|O1:100.0,Swab+Saliva - Processed in Germany|Swab+Saliva - Processed in Germany|Swab+Saliva - Processed in Germany,Positive,Positive,indicator_108,outcome_248,['Positive'],NA
259,NCT04343092,Number of Cured Patients,O1:16,O1:16,IVM+HCQ+AZT Group,cure,cure,indicator_109,outcome_249,['cure'],"Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 "
260,NCT04343092,Time to Cure of COVID-19 Patients in the IVM +HCQ+AZT Group,O1:16,O1:7.62,IVM+HCQ+AZT Group,cure,cure,indicator_109,outcome_250,['cure'],"Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 "
261,NCT04362137,"Proportion of Patients Who Die, Develop Respiratory Failure [Require Mechanical Ventilation] or Require Intensive Care Unit (ICU) Care",O1:284|O2:144,O1:34|O2:17,Ruxolitinib 5 mg|Placebo,ICU,ICU,indicator_97,outcome_251,"['mechanical Ventilation', 'Mechanical Ventilation', 'Intensive Care', 'ICU']",NA
262,NCT04362137,Clinical Status,O1:287|O2:145|O1:286|O2:145|O1:280|O2:142|O1:278|O2:142,O1:3.7|O2:3.7|O1:1.8|O2:1.8|O1:1.1|O2:1.0,Ruxolitinib 5 mg|Placebo|Ruxolitinib 5 mg|Placebo|Ruxolitinib 5 mg|Placebo|Ruxolitinib 5 mg|Placebo,Clinical Status ,Clinical Status ,indicator_110,outcome_252,['Clinical Status'],Time Frame: Baseline 
263,NCT04362137,Percentage of Patients With at Least Two-point Improvement From Baseline in Clinical Status,O1:286|O2:145,O1:206|O2:108|O1:252|O2:129,Ruxolitinib 5 mg|Placebo,improvement,Improvement,indicator_54,outcome_253,"['improvement', 'Improvement', 'Clinical Status']",Time Frame: Day 14 
264,NCT04362137,Percentage of Patients With at Least One-point Improvement From Baseline in Clinical Status,O1:286|O2:145,O1:250|O2:128|O1:261|O2:136,Ruxolitinib 5 mg|Placebo,improvement,Improvement,indicator_54,outcome_254,"['improvement', 'Improvement', 'Clinical Status']",Time Frame: Day 14 
265,NCT04362137,Percentage of Patients With at Least One-point Deterioration From Baseline in Clinical Status,O1:286|O2:145,O1:16|O2:9|O1:14|O2:5,Ruxolitinib 5 mg|Placebo,Deterioration,Deterioration,indicator_107,outcome_255,"['Deterioration', 'Clinical Status']",Time Frame: Day 3 
266,NCT04362137,Time to Improvement in Clinical Status,O1:286|O2:145,O1:9.0|O2:9.0,Ruxolitinib 5 mg|Placebo,improvement,Improvement,indicator_54,outcome_256,"['improvement', 'Improvement', 'Clinical Status']",Time Frame: Day 14 
267,NCT04362137,Mean Change From Baseline in the Clinical Status,O1:287|O2:145|O1:280|O2:142|O1:278|O2:142,O1:-1.96|O2:-1.93|O1:-2.61|O2:-2.69,Ruxolitinib 5 mg|Placebo|Ruxolitinib 5 mg|Placebo|Ruxolitinib 5 mg|Placebo,Mean Change,Mean Change,indicator_111,outcome_257,"['Clinical Status', 'Mean Change']",Time Frame: Day 1 - Day 29 
268,NCT04362137,Mortality Rate,O1:287|O2:145|O1:286|O2:145|O1:286|O2:145,O1:6|O2:2|O1:9|O2:3,Ruxolitinib 5 mg|Placebo|Ruxolitinib 5 mg|Placebo|Ruxolitinib 5 mg|Placebo,Mortality,Death ,indicator_16,outcome_258,"['Mortality Rate', 'Mortality']",Time Frame: during the survey administration 
269,NCT04362137,Proportion of Patients Requiring Mechanical Ventilation,O1:286|O2:145,O1:22|O2:10,Ruxolitinib 5 mg|Placebo,Mechanical Ventilation,Mechanical Ventilation,indicator_9,outcome_259,"['mechanical Ventilation', 'Mechanical Ventilation']",Time Frame: 29 days 
270,NCT04362137,Duration of Hospitalization,O1:286|O2:145,O1:9.0|O2:9.0,Ruxolitinib 5 mg|Placebo,Hospitalization,Hospitalization,indicator_18,outcome_260,"['Hospitalization', 'hospitalization', 'Hospital']",Time Frame: Day 29 
271,NCT04362137,Time to Hospital Discharge or to a NEWS2 Score of ≤2,O1:286|O2:145,O1:4.0|O2:4.0,Ruxolitinib 5 mg|Placebo,discharge,Discharge,indicator_80,outcome_261,"['NEWS2 Score', 'discharge', 'Discharge', 'Hospital']",Time Frame: Day 29 
272,NCT04362137,Change From Baseline in NEWS2 Score,O1:287|O2:145|O1:264|O2:135|O1:230|O2:120|O1:175|O2:91|O1:113|O2:66|O1:257|O2:132|O1:234|O2:122,O1:-0.7|O2:-0.6|O1:-1.0|O2:-0.8|O1:-1.3|O2:-1.3|O1:-1.1|O2:-1.3|O1:-1.9|O2:-2.2|O1:-2.3|O2:-2.5,Ruxolitinib 5 mg|Placebo|Ruxolitinib 5 mg|Placebo|Ruxolitinib 5 mg|Placebo|Ruxolitinib 5 mg|Placebo|Ruxolitinib 5 mg|Placebo|Ruxolitinib 5 mg|Placebo|Ruxolitinib 5 mg|Placebo,NEWS2 Score,NEWS2 Score,indicator_112,outcome_262,['NEWS2 Score'],Time Frame: At the begining of inhalation (day 1) and on next day of last inhalation (day 11) 
273,NCT04362137,Change From Baseline in SpO2/FiO2 Ratio,O1:287|O2:145|O1:260|O2:132|O1:232|O2:124,O1:90.110|O2:106.766|O1:105.553|O2:109.710,Ruxolitinib 5 mg|Placebo|Ruxolitinib 5 mg|Placebo|Ruxolitinib 5 mg|Placebo,SpO2/FiO2 Ratio ,SpO2/FiO2 Ratio ,indicator_113,outcome_263,"['SpO2', 'SpO2/FiO2 Ratio']",Time Frame: Days 1 - 29. 
274,NCT04362137,Proportion of Patients With no Oxygen Therapy,O1:287|O2:145|O1:274|O2:140|O1:269|O2:139,O1:255|O2:133|O1:262|O2:136,Ruxolitinib 5 mg|Placebo|Ruxolitinib 5 mg|Placebo|Ruxolitinib 5 mg|Placebo,no Oxygen Therapy ,Oxygen,indicator_8,outcome_264,"['Oxygen', 'Oxygen Therapy', 'no Oxygen Therapy']",Time Frame: At the beginning of inhalation (day 1) and on next day of last inhalation (day 11) 
275,NCT04362137,All Collected Deaths,O1:287|O2:145|O1:281|O2:143|O1:287|O2:145,O1:9|O2:3|O1:9|O2:3,Ruxolitinib 5 mg|Placebo|Ruxolitinib 5 mg|Placebo|Ruxolitinib 5 mg|Placebo,Death,Death ,indicator_16,outcome_265,['Death'],NA
276,NCT04724538,Count of White Blood Cells (WBC) After 99mTc-pertechnetate Aerosol Inhalation for Adverse Events Monitoring as Evaluation Safety of This Procedure in Patients With COVID-19 Viral Pneumonia.,O1:11|O2:14,O1:11.2|O2:9.8|O1:9.7|O2:8.7|O1:8.8|O2:9.3,Patient With COVID-19 Pneumonia|Patient With COVID-19 Pneumonia Without Intervention,Adverse,Adverse,indicator_10,outcome_266,"['Adverse Events', 'Adverse', 'Adverse Event']",NA
277,NCT04724538,Count of Red Blood Cells (RBC) After 99mTc-pertechnetate Aerosol Inhalation for Adverse Events Monitoring as Evaluation Safety of This Procedure in Patients With COVID-19 Viral Pneumonia.,O1:11|O2:14,O1:4.5|O2:4.5|O1:4.3|O2:4.4|O1:4.2|O2:4.4,Patient With COVID-19 Pneumonia|Patient With COVID-19 Pneumonia Without Intervention,Adverse,Adverse,indicator_10,outcome_267,"['Adverse Events', 'Adverse', 'Adverse Event']",NA
278,NCT04724538,Hemoglobin Count (Hb) After 99mTc-pertechnetate Aerosol Inhalation for Adverse Events Monitoring as Evaluation Safety of This Procedure in Patients With COVID-19 Viral Pneumonia.,O1:11|O2:14,O1:140.5|O2:132|O1:137.5|O2:130.6|O1:135.3|O2:131,Patient With COVID-19 Pneumonia|Patient With COVID-19 Pneumonia Without Intervention,Adverse,Adverse,indicator_10,outcome_268,"['Adverse Events', 'Adverse', 'Adverse Event', 'Hemoglobin']",NA
279,NCT04724538,Percentage of Neutrophils (N) After 99mTc-pertechnetate Aerosol Inhalation for Adverse Events Monitoring as Evaluation Safety of This Procedure in Patients With COVID-19 Viral Pneumonia.,O1:11|O2:14,O1:76.3|O2:72.2|O1:68.8|O2:72.2|O1:68.4|O2:71.5,Patient With COVID-19 Pneumonia|Patient With COVID-19 Pneumonia Without Intervention,Neutrophils,Neutrophils,indicator_71,outcome_269,"['Adverse Events', 'Adverse', 'Neutrophils', 'Adverse Event']",NA
280,NCT04724538,Absolute Neutrophil Count (ANC) After 99mTc-pertechnetate Aerosol Inhalation for Adverse Events Monitoring as Evaluation Safety of This Procedure in Patients With COVID-19 Viral Pneumonia.,O1:11|O2:14,O1:8.8|O2:7.4|O1:6.8|O2:6.6|O1:6.2|O2:6.9,Patient With COVID-19 Pneumonia|Patient With COVID-19 Pneumonia Without Intervention,Adverse,Adverse,indicator_10,outcome_270,"['Adverse Events', 'Adverse', 'Adverse Event']",NA
281,NCT04724538,Absolute Lymphocyte Count (ALC) After 99mTc-pertechnetate Aerosol Inhalation for Adverse Events Monitoring as Evaluation Safety of This Procedure in Patients With COVID-19 Viral Pneumonia.,O1:11|O2:14,O1:1.6|O2:1.6|O1:2.1|O2:1.4|O1:1.64|O2:1.73,Patient With COVID-19 Pneumonia|Patient With COVID-19 Pneumonia Without Intervention,Adverse,Adverse,indicator_10,outcome_271,"['Adverse Events', 'Adverse', 'Adverse Event', 'Lymphocyte Count']",NA
282,NCT04724538,Level of Lactate in the Blood After 99mTc-pertechnetate Aerosol Inhalation for Adverse Events Monitoring as Evaluation Safety of This Procedure in Patients With COVID-19 Viral Pneumonia.,O1:11|O2:14,O1:5|O2:4.11|O1:4.4|O2:4.6|O1:4.28|O2:4.81,Patient With COVID-19 Pneumonia|Patient With COVID-19 Pneumonia Without Intervention,Adverse,Adverse,indicator_10,outcome_272,"['Adverse Events', 'Adverse', 'Adverse Event']",NA
283,NCT04724538,Level of D-dimer in Blood After 99mTc-pertechnetate Aerosol Inhalation for Adverse Events Monitoring as Evaluation Safety of This Procedure in Patients With COVID-19 Viral Pneumonia.,O1:11|O2:14,O1:1737|O2:1284|O1:843|O2:685|O1:383|O2:859,Patient With COVID-19 Pneumonia|Patient With COVID-19 Pneumonia Without Intervention,D-dimer,D-dimer,indicator_51,outcome_273,"['Adverse Events', 'D-dimer', 'Adverse', 'Adverse Event']",NA
284,NCT04724538,Level of CD4+ T-cells in Blood After 99mTc-pertechnetate Aerosol Inhalation for Evaluation of Cellular Immune Response After This Procedure in Patients With COVID-19 Viral Pneumonia,O1:11|O2:14,O1:761|O2:614|O1:1100|O2:832|O1:845|O2:718,Patient With COVID-19 Pneumonia|Patient With COVID-19 Pneumonia Without Intervention,CD4+,CD4+,indicator_114,outcome_274,['CD4+'],NA
285,NCT04724538,Level of NK-cells in Blood After 99mTc-pertechnetate Aerosol Inhalation for Evaluation of Cellular Immune Response After This Procedure in Patients With COVID-19 Viral Pneumonia,O1:11|O2:14,O1:153|O2:164|O1:188|O2:149|O1:219|O2:181,Patient With COVID-19 Pneumonia|Patient With COVID-19 Pneumonia Without Intervention,NK-cells,NK-cells,indicator_115,outcome_275,[],NA
286,NCT04674644,The Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 Scale,O1:813,O1:18.48,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,Fear,Fear,indicator_116,outcome_276,"['Fear', 'Effect', 'Psychosocial']","Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 "
287,NCT04674644,The Psychosocial Effects of COVID-19 Pandemic Using the Turkish Version of the Coronavirus Anxiety Scale,O1:813,O1:2.17,The Psychosocial Effects of COVID-19 Using the Turkish Version of the Coronavirus Anxiety Scale,Psychosocial ,Psychosocial ,indicator_117,outcome_277,"['Effect', 'Psychosocial']","Time Frame: Day 14, chronic phase "
288,NCT04345653,Recruitment Feasibility,O1:46,O1:46,Study Arm,Recruitment Feasibility ,Recruitment Feasibility ,indicator_118,outcome_278,['Recruitment Feasibility'],Time Frame: Baseline to Day 29 
289,NCT04345653,Resource Utilization,O1:46,O1:46,Study Arm - Hydroxychloroquine Sulfate (HCQ),Resource Utilization ,Resource Utilization ,indicator_119,outcome_279,['Resource Utilization'],Time Frame: Baseline to Day 29 
290,NCT04345653,Safety as Reflected on the Number and Severity of Adverse Events and Serious Adverse Events,O1:46,O1:0|O1:24,Study Arm - Hydroxychloroquine Sulfate (HCQ),Adverse Events,Adverse,indicator_10,outcome_280,"['Adverse Events', 'Adverse', 'Adverse Event']",Time Frame: 22 days after randomization. 
291,NCT04345653,Early Feasibility as Reflected on the Number of Participants Contracting COVID-19 (10% or Less) in Comparison to the Expected 30% as Per CDC.,O1:46,O1:0,Study Arm - Hydroxychloroquine Sulfate (HCQ),Early Feasibility,Early Feasibility,indicator_120,outcome_281,['Early Feasibility'],"Time Frame: Day 1, 3, 5, 8, 11, 15, 22, and 29 "
292,NCT04338009,Hierarchical Composite Endpoint,O1:77|O2:75,O1:81|O2:73,Discontinuation Arm|Continuation Arm,Hierarchical Composite,Hierarchical Composite,indicator_121,outcome_282,['Hierarchical Composite'],Time Frame: Day 1 through Day 29 
293,NCT04338009,All-Cause Death,O1:77|O2:75,O1:10|O2:11,Discontinuation Arm|Continuation Arm,Death ,Death ,indicator_16,outcome_283,['Death'],"Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 "
294,NCT04338009,Length of Hospital Stay,O1:77|O2:75,O1:5|O2:6,Discontinuation Arm|Continuation Arm,Hospital ,Hospitalization,indicator_18,outcome_284,['Hospital'],Time Frame: Day 3 
295,NCT04338009,"Length of ICU Stay, Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation",O1:77|O2:75,O1:15|O2:13,Discontinuation Arm|Continuation Arm,"ICU Stay, Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation ",ICU,indicator_97,outcome_285,"['Oxygen', 'mechanical Ventilation', 'Mechanical Ventilation', 'ICU Stay, Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation', 'Invasive Mechanical Ventilation', 'ICU']","Time Frame: Days 15, 21, 28 "
296,NCT04338009,AUC SOFA,O1:77|O2:75,O1:7|O2:12,Discontinuation Arm|Continuation Arm,AUC SOFA ,AUC SOFA ,indicator_122,outcome_286,['AUC SOFA'],"Time Frame: Through study completion, an average of 3 months "
297,NCT04342663,Number of Participants Who Met Clinical Worsening,O1:80|O2:72,O1:0|O2:6,Fluvoxamine|Placebo,Clinical Worsening,Clinical Worsening,indicator_123,outcome_287,[],NA
298,NCT04342663,Clinical Deterioration on a Likert-type Scale (0-6),O1:80|O2:72,O1:80|O2:66|O1:0|O2:2|O1:0|O2:0|O1:0|O2:3|O1:0|O2:0|O1:0|O2:1|O1:0|O2:0,Fluvoxamine|Placebo,Deterioration,Detection ,indicator_105,outcome_288,['Deterioration'],NA
299,NCT04425850,Number of Infected Subjects,O1:131|O2:98,O1:0|O2:11,IVER+|IVER-,Infect,Infect,indicator_84,outcome_289,['Infect'],Time Frame: Day 0-14 
300,NCT04425850,Adverse Events Other Than Those Resulting From Contagion or Disease Progression,O1:131|O2:98,O1:0|O2:0,IVER+|IVER-,Adverse Events,Adverse,indicator_10,outcome_290,"['Adverse Events', 'Disease Progression', 'Adverse', 'Adverse Event', 'Progression']",Time Frame: From admission to 14 days after being discharge. 
301,NCT04411667,Mechanical Ventilation,O1:16|O2:17,O1:2|O2:7,Group A (Study Drug+SOC)|Group B (SOC),Mechanical Ventilation ,Mechanical Ventilation ,indicator_60,outcome_291,"['mechanical Ventilation', 'Mechanical Ventilation']","Time Frame: from date of patient admission to date of patient discharge or date of death, whichever came first, assessed up to 45 days "
302,NCT04411667,Oxygen Therapy,O1:0|O2:0,NA,Group A (Study Drug+SOC)|Group B (SOC),Oxygen Therapy ,Oxygen,indicator_8,outcome_292,"['Oxygen', 'Oxygen Therapy']",Time Frame: 28 days after randomization 
303,NCT04411667,Length of Stay,O1:16|O2:17,O1:12|O2:17,Group A (Study Drug+SOC)|Group B (SOC),Length of Stay ,Length of Stay ,indicator_124,outcome_293,['Length of Stay'],Require Mechanical Ventilation
304,NCT04698993,Sensitivity,O1:264|O2:0,O1:96.7,Symptomatic|Asymptomatic,Sensitivity,Sensitivity,indicator_125,outcome_294,[],NA
305,NCT04698993,Specificity,O1:264|O2:0,O1:99.5,Symptomatic|Asymptomatic,Specificity,Specificity,indicator_126,outcome_295,[],NA
306,NCT04698993,Sensitivity in Relation to the Cycle Threshold Value of the Reference RT-PCR (in the Symptomatic Group),O1:69|O2:0,O1:97.8,Symptomatic|Asymptomatic,Symptom,Symptom,indicator_99,outcome_296,"['Symptom', 'RT-PCR']",NA
307,NCT04698993,Sensitivity in Relation to the Time Since Symptom Onset (in the Symptomatic Group),O1:69|O2:0,O1:90.9,Symptomatic|Asymptomatic,Symptom,Symptom,indicator_99,outcome_297,['Symptom'],NA
308,NCT04698993,Specificity in Asymptomatic Participants,O1:0|O2:105,O2:100,Symptomatic|Asymptomatic,Symptom,Symptom,indicator_99,outcome_298,['Symptom'],NA
309,NCT04698993,Frequency of Nosebleed or Unbearable Pain During or Immediately After Specimen Collection,O1:275|O2:113,O1:0|O2:0,Symptomatic|Asymptomatic,Pain,Pain,indicator_127,outcome_299,[],NA
310,NCT04502056,Incidence Rate for Knowledge Gaps: Control vs. Any Intervention,O1:14999|O2:3763,O1:0.214|O2:0.241,Intervention|Control,Incidence Rate,Incidence Rate,indicator_128,outcome_300,[],NA
311,NCT04502056,Incidence Rate for Knowledge Gaps: Control vs. Any Intervention - Follow up,O1:4819|O2:1211,O1:0.241|O2:0.250,Intervention|Control,Incidence Rate,Incidence Rate,indicator_128,outcome_301,[],NA
312,NCT04502056,Incidence Rate for Information-seeking Behavior: Control vs. Any Intervention,O1:14569|O2:3654,O1:0.338|O2:0.320,Intervention|Control,Incidence Rate,Incidence Rate,indicator_128,outcome_302,[],NA
313,NCT04502056,Incidence Rate - Safety Gap Score: Control vs. Any Intervention,O1:4823|O2:1212,O1:0.450|O2:0.465,Intervention|Control,Incidence Rate,Incidence Rate,indicator_128,outcome_303,[],NA
314,NCT04502056,Willingness to Pay (WTP) for Masks: Control vs. Any Intervention,O1:13399|O2:3360,O1:14.580|O2:14.072,Intervention|Control,Willingness to Pay (WTP) for Masks,WTP,indicator_129,outcome_304,[],NA
315,NCT04502056,Incidence Rate Ratio (IRR) - Knowledge Gap,O1:18762|O2:18762|O3:18762|O4:18762|O5:18762|O6:18762,O1:1.01|O2:0.99|O3:1.01|O4:0.99|O5:0.99|O6:0.89,Within Intervention Group: Black Physician (Arm A) vs. White Physician (Arm B)|Within Intervention Group: AMA Anti-racism (Arm A) vs. Either/Neither (Arm B)|Within Intervention Group: Doctor Racial Disparity (Arm A) vs. Either/Neither (Arm B)|Within Control Group: Black Physician (Arm A) vs. White Physician (Arm B)|Within Control Group: AMA Anti-racism vs. Either/Neither|Intervention Group vs. Control Group,Incidence Rate Ratio (IRR),IRR,indicator_130,outcome_305,[],NA
316,NCT04502056,Incidence Rate Ratio (IRR) - Knowledge Gap - Follow up,O1:6030|O2:6030|O3:6030|O4:6030|O5:6030|O6:6030,O1:0.98|O2:0.98|O3:1.01|O4:1.01|O5:0.98|O6:0.97,Within Intervention Group: Black Physician (Arm A) vs. White Physician (Arm B)|Within Intervention Group: AMA Anti-racism (Arm A) vs. Either/Neither (Arm B)|Within Intervention Group: Doctor Racial Disparity (Arm A) vs. Either/Neither (Arm B)|Within Control Group: Black Physician (Arm A) vs. White Physician (Arm B)|Within Control Group: AMA Anti-racism vs. Either/Neither|Intervention Group vs. Control Group,Incidence Rate Ratio (IRR),IRR,indicator_130,outcome_306,[],NA
317,NCT04502056,Incidence Rate Ratio (IRR) - Information-seeking Behavior,O1:18223|O2:18223|O3:18223|O4:18223|O5:18223|O6:18223,O1:1.04|O2:1.03|O3:1.02|O4:0.96|O5:0.97|O6:1.01,Within Intervention Group: Black Physician (Arm A) vs. White Physician (Arm B)|Within Intervention Group: AMA Anti-racism (Arm A) vs. Either/Neither (Arm B)|Within Intervention Group: Doctor Racial Disparity (Arm A) vs. Either/Neither (Arm B)|Within Control Group: Black Physician (Arm A) vs. White Physician (Arm B)|Within Control Group: AMA Anti-racism vs. Either/Neither|Intervention Group vs. Control Group,Incidence Rate Ratio (IRR),IRR,indicator_130,outcome_307,[],NA
318,NCT04502056,Incidence Rate Ratio (IRR) - Safety Gap Score,O1:6035|O2:6035|O3:6035|O4:6035|O5:6035|O6:6035,O1:1.04|O2:1.03|O3:1.01|O4:0.97|O5:0.95|O6:0.93,Within Intervention Group: Black Physician (Arm A) vs. White Physician (Arm B)|Within Intervention Group: AMA Anti-racism (Arm A) vs. Either/Neither (Arm B)|Within Intervention Group: Doctor Racial Disparity (Arm A) vs. Either/Neither (Arm B)|Within Control Group: Black Physician (Arm A) vs. White Physician (Arm B)|Within Control Group: AMA Anti-racism vs. Either/Neither|Intervention Group vs. Control Group,Incidence Rate Ratio (IRR),IRR,indicator_130,outcome_308,[],NA
319,NCT04502056,OLS Regression Coefficients - Willingness to Pay (WTP) for Masks,O1:16759|O2:16759|O3:16759|O4:16759|O5:16759|O6:16759,O1:-0.21|O2:-0.29|O3:0.07|O4:0.17|O5:0.32|O6:0.71,Within Intervention Group: Black Physician (Arm A) vs. White Physician (Arm B)|Within Intervention Group: AMA Anti-racism (Arm A) vs. Either/Neither (Arm B)|Within Intervention Group: Doctor Racial Disparity (Arm A) vs. Either/Neither (Arm B)|Within Control Group: Black Physician (Arm A) vs. White Physician (Arm B)|Within Control Group: AMA Anti-racism vs. Either/Neither|Intervention Group vs. Control Group,Willingness to Pay (WTP) for Masks,WTP,indicator_129,outcome_309,[],NA
320,NCT04491994,Number of Participants With Progression,O1:151|O2:349,O1:5|O2:11,Standard of Care (SOC)|Intervention Group,Progression ,Progression ,indicator_131,outcome_310,['Progression'],Time Frame: 14 days 
321,NCT04491994,Viral Clearance,NA,NA,NA,Viral Clearance ,Viral Clearance,indicator_55,outcome_311,['Viral Clearance'],Time Frame: Pre-SSI 
322,NCT04728802,14 Day Recovery Rate,O1:317|O2:328,O1:258|O2:117,Proxalutamide + Usual Care|Placebo + Usual Care,Recovery,Recovery,indicator_61,outcome_312,['Recovery'],Time Frame: Baseline to Day 29 
323,NCT04728802,28 Day Recovery Rate,O1:317|O2:328,O1:271|O2:155,Proxalutamide + Usual Care|Placebo + Usual Care,Recovery,Recovery,indicator_61,outcome_313,['Recovery'],Time Frame: Day 29 
324,NCT04728802,28 Day Mortality Rate,O1:317|O2:328,O1:35|O2:162,Proxalutamide + Usual Care|Placebo + Usual Care,Mortality,Death ,indicator_16,outcome_314,"['Mortality Rate', 'Mortality']",Time Frame: during the survey administration 
325,NCT04728802,Post-Randomization Time to Recover (Alive Hospital Discharge),O1:317|O2:328,O1:5|O2:10,Proxalutamide + Usual Care|Placebo + Usual Care,discharge,Discharge,indicator_80,outcome_315,"['discharge', 'Discharge', 'Alive', 'Hospital']",Time Frame: Day 1 through Day 29 
326,NCT04422561,"Development of Symptoms ( Fever ,Cough, Sore Throat, Myalgia,Diarrhea, Shortness of Breath)",O1:203|O2:101,O1:15|O2:59,Ivermectin Group|Control Group,Fever ,Fever ,indicator_56,outcome_316,"['Development', 'Symptom', 'Fever']","Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 "
327,NCT04422561,Development of COVID,NA,NA,NA,Development,Development,indicator_132,outcome_317,['Development'],Time Frame: Day 5 
328,NCT04356937,Mechanical Ventilation or Death,O1:161|O2:81,O1:9.9|O2:10.0|O1:10.6|O2:12.5,Tocilizumab|Placebo,Death,Death ,indicator_16,outcome_318,"['mechanical Ventilation', 'Mechanical Ventilation', 'Death']",NA
329,NCT04356937,Clinical Worsening on Ordinal Scale,O1:161|O2:81,O1:18.0|O2:14.9|O1:19.3|O2:17.4,Tocilizumab|Placebo,Ordinal Scale,Ordinal Scale,indicator_79,outcome_319,"['Ordinal Scale', 'ordinal scale']",NA
330,NCT04356937,Discontinuation of Supplemental Oxygen Among Patients Receiving it at Baseline,O1:138|O2:66,O1:75.4|O2:78.8|O1:82.6|O2:84.9,Tocilizumab|Placebo,Oxygen,Oxygen,indicator_8,outcome_320,['Oxygen'],NA
331,NCT04407507,Participants With a Disease Control Status Defined as no Disease Progression to Severe.,O1:30|O2:26,O1:30|O2:26,Ivermectin|Placebo,Disease Progression,Progression,indicator_133,outcome_321,"['Disease Progression', 'Progression']",Time Frame: Day 1 through Day 29 
332,NCT04407507,"SARS-CoV-2 Viral Load, at 5 and 14 Days",O1:30|O2:26|O1:30|O2:26|O1:26|O2:24|O1:21|O2:20,O1:26.17|O2:23.3|O1:30.52|O2:28.5|O1:33.74|O2:32.94,Ivermectin|Placebo|Ivermectin|Placebo|Ivermectin|Placebo|Ivermectin|Placebo,Viral Load ,Viral Load,indicator_95,outcome_322,['Viral Load'],Time Frame: Immediately Post-SSI only 
333,NCT04407507,Presence and Frequency of Symptoms Associated With the COVID-19 Disease,O1:30|O2:26,O1:7.67|O2:5.44|O1:51.7|O2:34.1|O1:29.5|O2:24.6|O1:45.4|O2:38.1|O1:16.7|O2:14.9|O1:32.3|O2:26.9|O1:13|O2:9.74|O1:25.7|O2:17.5|O1:13|O2:7.16|O1:18.9|O2:8.31|O1:19.4|O2:10.9|O1:1.79|O2:0.57|O1:28.6|O2:14.3,Ivermectin|Placebo,Symptom,Symptom,indicator_99,outcome_323,['Symptom'],Time Frame: Approximately 30 days 
334,NCT04390022,Proportion of Patients With a Positive SARS-CoV-2 PCR,O1:12|O2:12,O1:12|O2:12|O1:11|O2:12,Ivermectin|Placebo,Positive,Positive,indicator_108,outcome_324,['Positive'],Time Frame: 14 days 
335,NCT04390022,Median Viral Load,O1:12|O2:12,O1:16850000|O2:26700000|O1:161000|O2:493500|O1:1018|O2:23550|O1:7|O2:30|O1:1|O2:0|O1:367000000|O2:327500000|O1:269000|O2:2194500|O1:2255|O2:36800|O1:86|O2:75|O1:0|O2:107,Ivermectin|Placebo,Viral Load ,Viral Load,indicator_95,outcome_325,['Viral Load'],Time Frame: Pre-SSI only 
336,NCT04390022,Fever and Cough Progression,O1:12|O2:12,O1:0|O2:0|O1:1|O2:0|O1:0|O2:0|O1:0|O2:0|O1:5|O2:6|O1:5|O2:5|O1:1|O2:3|O1:1|O2:3,Ivermectin|Placebo,Fever ,Fever ,indicator_56,outcome_326,"['Fever', 'Progression']","Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 "
337,NCT04390022,Seroconversion at Day 21,O1:12|O2:12,O1:12|O2:12,Ivermectin|Placebo,Seroconversion at Day 21 ,Seroconversion,indicator_134,outcome_327,['Seroconversion at Day 21'],Time Frame: Baseline up to 60 days 
338,NCT04390022,Proportion of Drug-related Adverse Events,O1:12|O2:12,O1:0|O2:0,Ivermectin|Placebo,Adverse Events,Adverse,indicator_10,outcome_328,"['Adverse Events', 'Adverse', 'Adverse Event']",Time Frame: Admission to discharge dates (approximately 4-14 days after admission). Discharge variables considered as the last available data before their death for the expired patients. 
339,NCT04390022,"Levels of IgG, IgM and IgA",NA,NA,NA,IgG,IgG,indicator_135,outcome_329,['IgG'],Time Frame: 28 Days 
340,NCT04390022,Frequency of Innate Immune Cells,NA,NA,NA,Innate Immune Cells ,Innate Immune Cells ,indicator_136,outcome_330,['Innate Immune Cells'],"Time Frame: Baseline, Minutes 5, 10, 15, 30 (15 minutes after treatment ends) "
341,NCT04390022,Frequency SARS-CoV-2-specific CD4+ T and and CD8+ T Cells,NA,NA,NA,CD4+,CD4+,indicator_114,outcome_331,['CD4+'],Time Frame: Baseline 
342,NCT04390022,Results From Cytokine Human Magnetic 30-Plex Panel,NA,NA,NA,Cytokine Human Magnetic 30-Plex Panel ,Cytokine Human Magnetic 30-Plex Panel ,indicator_137,outcome_332,['Cytokine Human Magnetic 30-Plex Panel'],"Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 "
343,NCT04409886,Oxygenation Index,O1:0,NA,HBOT (Hyperbaric Oxygen Therapy),Oxygen,Oxygen,indicator_8,outcome_333,['Oxygen'],NA
344,NCT04399980,Subjects Alive and Off of Oxygen at Day 14,O1:21|O2:19,O1:12|O2:9,Intervention|Control,Off of Oxygen at Day 14 ,Oxygen,indicator_8,outcome_334,"['Oxygen', 'Alive', 'Off of Oxygen at Day 14']",Time Frame: Day 30 
345,NCT04399980,Number of Subjects Alive and Without Respiratory Failure at Day 28,O1:21|O2:19,O1:20|O2:15,Intervention|Control,Without Respiratory Failure at Day 28,Without Respiratory Failure,indicator_138,outcome_335,"['Without Respiratory Failure at Day 28', 'Alive']",Time Frame: 0 to 24 hours post dose 
346,NCT04399980,Mortality at Day 28,O1:21|O2:19,O1:1|O2:3,Intervention|Control,Mortality,Death ,indicator_16,outcome_336,['Mortality'],Time Frame: 7 days post-treatment 
347,NCT04365153,Number of Participants With Clinical Improvement at Day 14,O1:15|O2:14|O3:16,O1:9|O2:7|O3:9,High Dose Intervention|Low Dose Intervention|Control,Improvement,Improvement,indicator_54,outcome_337,"['improvement', 'Improvement']",Time Frame: Day 14 
348,NCT04365153,All-cause Mortality,O1:15|O2:14|O3:16,O1:1|O2:3|O3:3,High Dose Intervention|Low Dose Intervention|Control,Mortality,Death ,indicator_16,outcome_338,['Mortality'],Time Frame: Up to and including day 21 
349,NCT04365153,NA,NA,NA,NA,nan,nan,indicator_104,outcome_339,['nan'],NA
350,NCT04491240,Number of Participants With Non-serious and Serious Adverse Events During Trial,O1:10|O2:10|O3:10,O1:0|O2:0|O3:0|O1:0|O2:0|O3:0,EXO-1|EXO-2|Placebo,Adverse Events,Adverse,indicator_10,outcome_340,"['Adverse Events', 'Adverse', 'Adverse Event']",Time Frame: Admission to discharge dates (approximately 4-14 days after admission). Discharge variables considered as the last available data before their death for the expired patients. 
351,NCT04491240,Number of Participants With Non-serious and Serious Adverse During Inhalation Procedure,O1:10|O2:10|O3:10,O1:0|O2:0|O3:0|O1:0|O2:0|O3:0|O1:0|O2:0|O3:0|O1:0|O2:0|O3:0,EXO-1|EXO-2|Placebo,Adverse,Adverse,indicator_10,outcome_341,['Adverse'],Time Frame: Day 1 to end-of-trial (Visit 9) 
352,NCT04491240,Time to Clinical Recovery (TTCR),O1:10|O2:10|O3:10,O1:13.8|O2:14.8|O3:14.1,EXO-1|EXO-2|Placebo,Recovery,Recovery,indicator_61,outcome_342,['Recovery'],"Time Frame: Baseline, Days 4, 7, 15, 21, and 29 "
353,NCT04491240,C-reactive Protein,O1:10|O2:10|O3:10,O1:78.3|O2:75.4|O3:61.5|O1:5.04|O2:5.83|O3:8.29,EXO-1|EXO-2|Placebo,C-reactive Protein ,CRP,indicator_1,outcome_343,['C-reactive Protein'],Time Frame: 14 days 
354,NCT04491240,C-reactive Protein,NA,NA,NA,C-reactive Protein ,CRP,indicator_1,outcome_344,['C-reactive Protein'],Time Frame: 14 days 
355,NCT04491240,C-reactive Protein,NA,NA,NA,C-reactive Protein ,CRP,indicator_1,outcome_345,['C-reactive Protein'],Time Frame: 14 days 
356,NCT04491240,Lactic Acid Dehydrogenase (LDH),O1:10|O2:10|O3:10,O1:773|O2:732|O3:669|O1:441|O2:365|O3:430,EXO-1|EXO-2|Placebo,Lactic Acid Dehydrogenase (LDH) ,LDH,indicator_89,outcome_346,"['LDH', 'Lactic Acid Dehydrogenase (LDH)']",Time Frame: First dose date up to last dose date (maximum: 10 days) plus 30 days 
357,NCT04491240,Lactic Acid Dehydrogenase (LDH),NA,NA,NA,Lactic Acid Dehydrogenase (LDH) ,LDH,indicator_89,outcome_347,"['LDH', 'Lactic Acid Dehydrogenase (LDH)']",Time Frame: First dose date up to last dose date (maximum: 10 days) plus 30 days 
358,NCT04491240,Lactic Acid Dehydrogenase (LDH),NA,NA,NA,Lactic Acid Dehydrogenase (LDH) ,LDH,indicator_89,outcome_348,"['LDH', 'Lactic Acid Dehydrogenase (LDH)']",Time Frame: First dose date up to last dose date (maximum: 10 days) plus 30 days 
359,NCT04335552,World Health Organization (WHO) Ordinal Scale Measured at 14 Days After Enrollment,O1:1|O2:4|O3:3|O4:2,O1:1|O2:2.5|O3:5.3|O4:4.5,Standard of Care|Standard of Care Plus Hydroxychloroquine|Standard of Care Plus Azithromycin|Standard of Care Plus Hydroxychloroquine Plus Azithromycin,Ordinal Scale,Ordinal Scale,indicator_79,outcome_349,"['Ordinal Scale', 'ordinal scale']",NA
360,NCT04335552,Number of Participants Who Died During the Index Hospitalization,O1:1|O2:4|O3:3|O4:2,O1:0|O2:1|O3:2|O4:1,Standard of Care|Standard of Care Plus Hydroxychloroquine|Standard of Care Plus Azithromycin|Standard of Care Plus Hydroxychloroquine Plus Azithromycin,Died,Death ,indicator_16,outcome_350,"['Hospitalization', 'hospitalization', 'Hospital']",NA
361,NCT04335552,Number of Days on Mechanical Ventilation,O1:1|O2:4|O3:3|O4:2,O1:0|O2:5.5|O3:8.67|O4:0,Standard of Care|Standard of Care Plus Hydroxychloroquine|Standard of Care Plus Azithromycin|Standard of Care Plus Hydroxychloroquine Plus Azithromycin,Mechanical Ventilation,Mechanical Ventilation,indicator_9,outcome_351,"['mechanical Ventilation', 'Mechanical Ventilation']",NA
362,NCT04335552,Number of Patients Not Receiving Mechanical Ventilation at Baseline Who Progress to Requiring Mechanical Ventilation During the Index Hospitalization,O1:1|O2:4|O3:3|O4:2,O1:0|O2:1|O3:1|O4:0,Standard of Care|Standard of Care Plus Hydroxychloroquine|Standard of Care Plus Azithromycin|Standard of Care Plus Hydroxychloroquine Plus Azithromycin,Mechanical Ventilation,Mechanical Ventilation,indicator_9,outcome_352,"['Hospitalization', 'mechanical Ventilation', 'Mechanical Ventilation', 'hospitalization', 'Hospital']",NA
363,NCT04335552,WHO Ordinal Scale Measured at 28 Days After Enrollment,O1:1|O2:4|O3:3|O4:2,O1:1|O2:2.8|O3:5.3|O4:4.5,Standard of Care|Standard of Care Plus Hydroxychloroquine|Standard of Care Plus Azithromycin|Standard of Care Plus Hydroxychloroquine Plus Azithromycin,Ordinal Scale,Ordinal Scale,indicator_79,outcome_353,"['Ordinal Scale', 'ordinal scale']",NA
364,NCT04335552,Hospital Length of Stay in Days for the Index Hospitalization,O1:1|O2:4|O3:3|O4:2,O1:6|O2:9|O3:14.7|O4:2.5,Standard of Care|Standard of Care Plus Hydroxychloroquine|Standard of Care Plus Azithromycin|Standard of Care Plus Hydroxychloroquine Plus Azithromycin,Hospitalization,Hospitalization,indicator_18,outcome_354,"['Length of Stay', 'Hospitalization', 'hospitalization', 'Hospital']",NA
365,NCT04335552,Number of Participants With All-cause Study Medication Discontinuation,O1:1|O2:4|O3:3|O4:2,O1:0|O2:0|O3:0|O4:0,Standard of Care|Standard of Care Plus Hydroxychloroquine|Standard of Care Plus Azithromycin|Standard of Care Plus Hydroxychloroquine Plus Azithromycin,Number,Number,indicator_139,outcome_355,[],NA
366,NCT04335552,Number of Participants With Severe Adverse Events,O1:1|O2:4|O3:3|O4:2,O1:0|O2:1|O3:1|O4:0,Standard of Care|Standard of Care Plus Hydroxychloroquine|Standard of Care Plus Azithromycin|Standard of Care Plus Hydroxychloroquine Plus Azithromycin,Adverse,Adverse,indicator_10,outcome_356,"['Adverse Events', 'Adverse', 'Adverse Event']",NA
367,NCT04898166,Androgenetic Alopecia Frequency in Participants.,O1:220|O2:80,O1:209|O2:37|O1:11|O2:43,220 Hospitalized Participants Diagnosed Case of COVID-19.|80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19,Androgenetic Alopecia,Androgenetic Alopecia,indicator_140,outcome_357,[],NA
368,NCT04898166,Severity of Androgenetic Alopecia in Patients,O1:220|O2:37,O1:43|O2:9|O1:177|O2:28,220 Hospitalised Male Participants Diagnosed Case of COVID-19.|80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19.,Androgenetic Alopecia,Androgenetic Alopecia,indicator_140,outcome_358,[],NA
369,NCT04898166,300 Participants Mean Age,O1:300,O1:53.06,300 Participants Diagnosed Case of Hospitalized COVID-19. Mean Age be Noted,Age,Age,indicator_141,outcome_359,[],NA
370,NCT04898166,Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group.,O1:220|O2:80,O1:15|O2:10|O1:13|O2:18|O1:13|O2:0|O1:15|O2:4|O1:37|O2:12|O1:20|O2:0|O1:4|O2:11|O1:16|O2:15|O1:10|O2:0|O1:7|O2:4|O1:33|O2:6|O1:37|O2:0,220 Hospitalised Male Participants Diagnosed Case of COVID-19.|80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19.,Androgenetic Alopecia,Androgenetic Alopecia,indicator_140,outcome_360,[],NA
371,NCT04898166,Disease Outcome as Assessed by Severity of Androgeneic Alopecia in Males,O1:220,O1:20|O1:52|O1:14|O1:27|O1:5|O1:25|O1:4|O1:73,220 Hospitalised Male Subjects. Their Disease Outcomes in Relation to Severity of AGA,Androgenetic Alopecia,Androgenetic Alopecia,indicator_140,outcome_361,[],NA
372,NCT04898166,Disease Outcome be Assessed by Severity of Androgenetic Alopecia in Females,O1:80,O1:9|O1:3|O1:4|O1:17|O1:3|O1:8|O1:14|O1:3|O1:9|O1:3|O1:0|O1:7,80 Hospitalised Female Participants. Their Disease Outcomes in Relation to Severity of AGA,Androgenetic Alopecia,Androgenetic Alopecia,indicator_140,outcome_362,[],NA
373,NCT04898166,Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females.,O1:37|O2:43,O1:0|O2:4|O1:7|O2:5|O1:00|O2:00|O1:3|O2:7|O1:8|O2:10|O1:00|O2:00|O1:6|O2:5|O1:6|O2:9|O1:00|O2:00|O1:3|O2:1|O1:4|O2:2|O1:00|O2:00,37 Hospitalised Female Participants of COVID-19 With Androgenetic Alopecia|43 Hospitalised Female Participants of COVID-19 Without Androgenetic Alopecia With Respect to Age,Androgenetic Alopecia,Androgenetic Alopecia,indicator_140,outcome_363,[],NA
374,NCT04898166,Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males,O1:43|O2:177,O1:4|O2:11|O1:10|O2:27|O1:6|O2:14|O1:6|O2:9|O1:5|O2:8|O1:3|O2:10|O1:1|O2:3|O1:2|O2:14|O1:2|O2:8|O1:0|O2:7|O1:1|O2:32|O1:3|O2:34,43 Hospitalised Male Participants Diagnosed Case of COVID-19 With HNS <3.|177 Hospitalised Male Participants Diagnosed Case of COVID-19 With HNS >3-7,Androgenetic Alopecia,Androgenetic Alopecia,indicator_140,outcome_364,[],NA
375,NCT04898166,Hospital Disease Outcome in 300 Subjects. Having 220 Males and 80 Females,O1:220|O2:80,O1:41|O2:28|O1:72|O2:16|O1:30|O2:26|O1:77|O2:10,220 Hospitalized Participants Diagnosed Case of COVID-19.|80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19,Hospitalization,Hospitalization,indicator_18,outcome_365,['Hospital'],NA
376,NCT04898166,"Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants",O1:300,O1:29|O1:6|O1:4|O1:12|O1:15|O1:8|O1:5|O1:9|O1:20|O1:6|O1:1|O1:15|O1:8|O1:6|O1:4|O1:9|O1:17|O1:1|O1:2|O1:7|O1:10|O1:6|O1:1|O1:12|O1:26|O1:1|O1:9|O1:18|O1:18|O1:1|O1:5|O1:9,300 Participants Diagnosed Case of Hospitalized COVID-19 Outcome in Relation to Comorbidities,Comorbidities,Comorbidities,indicator_142,outcome_366,[],NA
377,NCT04898166,Disease Duration of COVID-19,O1:300,O1:11.79,300 Participants Diagnosed Case of Hospitalized COVID-19 Disease Duration,Disease Duration,Disease Duration,indicator_143,outcome_367,[],NA
378,NCT04475588,One-month Mortality Rate Between the Two Arms,O1:20|O2:10,O1:0|O2:3,Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC),Mortality,Death ,indicator_16,outcome_368,"['Mortality Rate', 'Mortality']","Time Frame: Days 4, 7, 14 and 21 "
379,NCT04475588,Lung Function Assessment - Proportion of the Patients With Stable or Improved SpO2 Without Increasing FiO2,O1:20|O2:10,O1:17|O2:5|O1:19|O2:7|O1:20|O2:7|O1:20|O2:7,Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC),SpO2,SpO2,indicator_17,outcome_369,"['SpO2', 'Improved', 'Lung Function Assessment - Proportion']",Time Frame: Days 1 - 29 
380,NCT04475588,Endo-tracheal Intubation/Invasive Mechanical Ventilation (IMV),O1:20|O2:10,O1:0|O2:2,Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC),Endo-tracheal Intubation/Invasive Mechanical Ventilation (IMV) ,IMV,indicator_144,outcome_370,"['mechanical Ventilation', 'Mechanical Ventilation', 'Invasive Mechanical Ventilation', 'Endo-tracheal Intubation/Invasive Mechanical Ventilation (IMV)']",Time Frame: Day 1 through Day 29 
381,NCT04475588,Reduction in Proportion of Patients on Non-invasive Ventilation,O1:20|O2:10,O1:5|O2:4|O1:0|O2:0|O1:5|O2:1|O1:5|O2:1|O1:5|O2:1,Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC),Reduction in Proportion of Patients on Non-invasive Ventilation ,Reduction in Proportion of Patients on Non-invasive Ventilation ,indicator_145,outcome_371,['Reduction in Proportion of Patients on Non-invasive Ventilation'],Time Frame: Baseline to Day 29 
382,NCT04475588,Lung Function Assessment - Proportion of Patients With Stable PaO2 Without Increasing FiO2,O1:20|O2:10,O1:18|O2:6|O1:19|O2:7|O1:20|O2:7|O1:20|O2:7,Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC),Lung Function Assessment - Proportion,Lung Function Assessment - Proportion,indicator_146,outcome_372,['Lung Function Assessment - Proportion'],"Time Frame: Baseline, Day 15, Day 29 "
383,NCT04475588,Reduction in Proportion of Patients- Invasive Mechanical Ventilation,O1:0|O2:0,NA,Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC),Invasive Mechanical Ventilation ,Mechanical Ventilation,indicator_9,outcome_373,"['mechanical Ventilation', 'Mechanical Ventilation', 'Invasive Mechanical Ventilation']",Time Frame: Up to 28 days 
384,NCT04475588,Reduction in Proportion of Patients-High Flow Nasal Oxygen,O1:0|O2:0,NA,Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC),High Flow Nasal Oxygen ,High Flow Nasal Oxygen ,indicator_147,outcome_374,"['Oxygen', 'High Flow Nasal Oxygen']",Time Frame: Day 1 through Day 29 
385,NCT04475588,Mean Change From Baseline in Ferritin,O1:20|O2:10|O1:18|O2:7|O1:15|O2:5|O1:11|O2:3|O1:3|O2:2,O1:-117.8|O2:-87.05|O1:-713.9|O2:-209.6|O1:-780.9|O2:4238|O1:-479.3|O2:-234.4,Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC),Ferritin,Ferritin,indicator_50,outcome_375,"['Mean Change', 'Ferritin']","Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 "
386,NCT04475588,Mean Change From Baseline in LDH,O1:20|O2:10|O1:18|O2:7|O1:15|O2:5|O1:11|O2:3|O1:3|O2:2,O1:-134|O2:-44.29|O1:-195.8|O2:-195.2|O1:-308.1|O2:155.3|O1:-212.7|O2:-97,Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC),LDH,LDH,indicator_89,outcome_376,"['LDH', 'Mean Change']",Time Frame: Day 11 
387,NCT04475588,Mean Change From Baseline in CRP (C-reactive Protein),O1:20|O2:10|O1:18|O2:8|O1:16|O2:5|O1:11|O2:3|O1:3|O2:2,O1:-61.69|O2:-103.6|O1:-81.65|O2:-107.2|O1:-90.99|O2:-127.5|O1:-103.2|O2:-127.6,Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC),CRP (C-reactive Protein),CRP,indicator_1,outcome_377,"['C-reactive Protein', 'CRP (C-reactive Protein)', 'Mean Change']","Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 "
388,NCT04475588,Mean Change From Baseline D-Dimer,O1:20|O2:10|O1:18|O2:7|O1:12|O2:4|O1:11|O2:2|O1:3|O2:2,O1:-1.43|O2:2.30|O1:-0.45|O2:-0.68|O1:-4.35|O2:8.54|O1:-2.63|O2:-0.35,Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC),D-dimer,D-dimer,indicator_51,outcome_378,"['D-dimer', 'Mean Change']","Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 "
389,NCT04475588,Mean Change From Baseline of Absolute Lymphocyte Count,O1:20|O2:10|O1:20|O2:8|O1:16|O2:5|O1:11|O2:3|O1:4|O2:2,O1:119.95|O2:45.88|O1:421.25|O2:142.60|O1:701.55|O2:10.00|O1:719.75|O2:85.00,Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC),Lymphocyte Count,Lymphocyte Count,indicator_19,outcome_379,"['Mean Change', 'Lymphocyte Count']","Time Frame: Baseline, Day 15, Day 29 "
390,NCT04475588,"Biomarkers (IL-6, TNF-a)",O1:18|O2:10|O1:18|O2:10|O1:18|O2:10|O1:13|O2:4|O1:13|O2:4|O1:18|O2:10|O1:18|O2:10|O1:13|O2:4|O1:13|O2:4,O1:159.09|O2:162.16|O1:42.98|O2:211.52|O1:311.3|O2:310.4|O1:91.0|O2:316.8|O1:43.64|O2:11.26|O1:8.87|O2:39.19|O1:68.0|O2:107.8|O1:50.1|O2:185.0,Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC),TNF,TNF,indicator_5,outcome_380,"['TNF', 'IL-6']",Time Frame: Pre-SSI to 3-month follow-up 
391,NCT04475588,"Mean PaO2 (Partial Pressure of Oxygen) / FiO2 (Fraction of Inspired Oxygen, FiO2) Ratio (or P/F Ratio)",O1:20|O2:10|O1:20|O2:10|O1:16|O2:6|O1:14|O2:5|O1:8|O2:3|O1:3|O2:0,O1:126.57|O2:114.05|O1:203.50|O2:184.53|O1:283.43|O2:338.40|O1:350.25|O2:398.33|O1:397.67,Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC),P/F Ratio,P/F Ratio,indicator_47,outcome_381,"['Oxygen', 'P/F Ratio']",Time Frame: 28 days after randomization 
392,NCT04475588,Number and Percentage of Patients With Radiological Response,O1:20|O2:10,O1:9|O2:1,Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC),Radiological Response ,Radiological Response ,indicator_148,outcome_382,['Radiological Response'],Time Frame: 24 hours after the last 2000 U dose of the chronic phase 
393,NCT04343261,Mortality,O1:41,O1:19,COVID-19 Patients Treated With Convalescent Plasma,Mortality,Death ,indicator_16,outcome_383,['Mortality'],"Time Frame: Baseline and on days 4, 7, 14 and 21 "
394,NCT04343261,Viral Load,O1:35|O1:13|O1:9|O1:7|O1:4,O1:3524|O1:2033|O1:315|O1:494,COVID-19 Patients Treated With Convalescent Plasma|COVID-19 Patients Treated With Convalescent Plasma|COVID-19 Patients Treated With Convalescent Plasma|COVID-19 Patients Treated With Convalescent Plasma|COVID-19 Patients Treated With Convalescent Plasma,Viral Load ,Viral Load,indicator_95,outcome_384,['Viral Load'],Time Frame: Pre-SSI only 
395,NCT04343261,Serum Antibody Titers,O1:39|O1:39|O1:36|O1:30|O1:24,O1:18.5|O1:37.2|O1:47.4|O1:55.2,COVID-19 Patients Treated With Convalescent Plasma|COVID-19 Patients Treated With Convalescent Plasma|COVID-19 Patients Treated With Convalescent Plasma|COVID-19 Patients Treated With Convalescent Plasma|COVID-19 Patients Treated With Convalescent Plasma,Serum Antibody Titers ,Antibody Titers,indicator_149,outcome_385,['Serum Antibody Titers'],Time Frame: Baseline up to 60 days 
396,NCT04446429,COVID-19 Hospitalization,O1:134|O2:134,O1:35|O2:3,Usual Care|Proxalutamide + Usual Care,Hospitalization,Hospitalization,indicator_18,outcome_386,"['Hospitalization', 'hospitalization', 'Hospital']",Time Frame: Day 1 through Day 15 
397,NCT04446429,NA,NA,NA,NA,nan,nan,indicator_104,outcome_387,['nan'],NA
398,NCT04332991,COVID Outcomes Scale Score on Study Day 15 (14 Days After Randomization),O1:242|O2:237,O1:6|O2:6,Hydroxychloroquine|Placebo,scale score,scale score,indicator_150,outcome_388,"['outcomes scale', 'scale score']",Time Frame: Baseline to Day 29 
399,NCT04332991,COVID Ordinal Outcomes Scale on Study Day 3 (2 Days After Randomization),O1:242|O2:237,O1:4|O2:4,Hydroxychloroquine|Placebo,outcomes scale,outcomes scale,indicator_151,outcome_389,['outcomes scale'],Time Frame: assessed on study day 29 
400,NCT04332991,COVID Ordinal Outcomes Scale on Study Day 8 (7 Days After Randomization),O1:242|O2:237,O1:5|O2:6,Hydroxychloroquine|Placebo,outcomes scale,outcomes scale,indicator_151,outcome_390,['outcomes scale'],Time Frame: assessed on study day 15 
401,NCT04332991,COVID Ordinal Outcomes Scale on Study Day 29 (28 Days After Randomization),O1:242|O2:237,O1:6|O2:6,Hydroxychloroquine|Placebo,outcomes scale,outcomes scale,indicator_151,outcome_391,['outcomes scale'],Time Frame: assessed on study day 29 
402,NCT04332991,"All-location, All-cause Mortality Assessed on Study Day 15 (14 Days After Randomization)",O1:241|O2:236,O1:18|O2:14,Hydroxychloroquine|Placebo,Mortality,Death ,indicator_16,outcome_392,['Mortality'],Time Frame: 7 days post treatment 
403,NCT04332991,"All-location, All-cause Mortality Assessed on Study Day 29 (28 Days After Randomization)",O1:241|O2:236,O1:25|O2:25,Hydroxychloroquine|Placebo,Mortality,Death ,indicator_16,outcome_393,['Mortality'],Time Frame: Up to and including day 28 
404,NCT04332991,Number of Patients Dead or With Receipt of ECMO Between Enrollment and Day 28,O1:241|O2:236,O1:29|O2:28,Hydroxychloroquine|Placebo,ECMO,ECMO,indicator_77,outcome_394,['ECMO'],Time Frame: Day 1 through Day 15 
405,NCT04332991,Oxygen-free Days Through Day 28,O1:242|O2:237,O1:21|O2:20,Hydroxychloroquine|Placebo,Oxygen-free,Oxygen,indicator_8,outcome_395,"['Oxygen', 'Oxygen-free']",Time Frame: 28 days after randomization 
406,NCT04332991,Ventilator-free Days Through Day 28,O1:242|O2:237,O1:28|O2:28,Hydroxychloroquine|Placebo,Ventilator-free,Ventilator-free,indicator_90,outcome_396,['Ventilator-free'],Time Frame: Pre-SSI only 
407,NCT04332991,Vasopressor-free Days Through Day 28,O1:242|O2:237,O1:28|O2:28,Hydroxychloroquine|Placebo,Vasopressor-free,Vasopressor-free,indicator_152,outcome_397,['Vasopressor-free'],Time Frame: Pre-SSI only 
408,NCT04332991,ICU-free Days to Day 28,O1:242|O2:237,O1:28|O2:28,Hydroxychloroquine|Placebo,ICU-free,ICU,indicator_97,outcome_398,"['ICU-free', 'ICU']",Time Frame: 28 Days 
409,NCT04332991,Hospital-free Days to Day 28,O1:242|O2:237,O1:21|O2:20,Hydroxychloroquine|Placebo,Hospital-free,Hospitalization,indicator_18,outcome_399,"['Hospital', 'Hospital-free']",Time Frame: Day 5 
410,NCT04385238,Number of Participants With Symptoms of Post-traumatic Stress Disorder,O1:5712|O2:1182,O1:1028|O2:532,Pregnant Women|Post-partum Women,Post-traumatic Stress Disorder ,PTSD,indicator_153,outcome_400,"['Symptom', 'Post-traumatic Stress Disorder']",Time Frame: 30 days 
411,NCT04385238,Number of Participants With Symptoms of Anxiety and Depression,O1:5712|O2:1182,O1:1200|O2:438,Pregnant Women|Post-partum Women,"Anxiety, Depression ","Anxiety, Depression ",indicator_154,outcome_401,['Symptom'],Time Frame: From starting to the end of ivermectin therapy (0 to the end of 5th day) 
412,NCT04370834,Number of Participants With at Least 1 Point Reduction in Score on 7-category Clinical Status Ordinal Scale,O1:1|O2:0|O3:0|O4:0,O1:1,Cohort A1|Cohort A2|Cohort B1|Cohort B2,Ordinal Scale,Ordinal Scale,indicator_79,outcome_402,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']",NA
413,NCT04323592,"Composite Primary End-point: Admission to ICU, Need for Invasive Mechanical Ventilation (MV), or All-cause Death by Day 28",O1:83|O2:90,O1:19|O2:40,Exposed to Methylprednisolone|Non-exposed to Methylprednisolone,Invasive Mechanical Ventilation ,Mechanical Ventilation,indicator_9,outcome_403,"['mechanical Ventilation', 'Mechanical Ventilation', 'Invasive Mechanical Ventilation', 'Death', 'ICU']",Time Frame: 28 days 
414,NCT04323592,In-hospital Death Within 28 Days,O1:83|O2:90,O1:6|O2:21,Exposed to Methylprednisolone|Non-exposed to Methylprednisolone,Hospital,Hospitalization,indicator_18,outcome_404,"['Death', 'Hospital']","Time Frame: Day 1, 3, 5, 8, 11, 15, 22, and 29 "
415,NCT04323592,Admission to Intensive Care Unit (ICU),O1:83|O2:90,O1:15|O2:27,Exposed to Methylprednisolone|Non-exposed to Methylprednisolone,Intensive Care,Intensive Care,indicator_58,outcome_405,"['Intensive Care', 'ICU']","Time Frame: baseline, day 14 "
416,NCT04323592,Endotracheal Intubation (Invasive Mechanical Ventilation),O1:83|O2:90,O1:15|O2:26,Exposed to Methylprednisolone|Non-exposed to Methylprednisolone,Invasive Mechanical Ventilation ,Mechanical Ventilation,indicator_9,outcome_406,"['mechanical Ventilation', 'Mechanical Ventilation', 'Invasive Mechanical Ventilation']",Time Frame: Day 14 
417,NCT04323592,Change in C-reactive Protein (CRP),O1:83|O2:90,O1:-82.08|O2:-34.34,Exposed to Methylprednisolone|Non-exposed to Methylprednisolone,C-reactive Protein (CRP),CRP,indicator_1,outcome_407,"['C-reactive Protein (CRP)', 'C-reactive Protein']","Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 "
418,NCT04323592,Number of Days Free From Mechanical Ventilation,O1:83|O2:90,O1:19.11|O2:14.34,Exposed to Methylprednisolone|Non-exposed to Methylprednisolone,mechanical Ventilation,Mechanical Ventilation,indicator_9,outcome_408,"['mechanical Ventilation', 'Mechanical Ventilation']","Time Frame: Baseline, Day 15, Day 29 "
419,NCT04371419,Incidence Rate for Knowledge Gaps: Control vs. Any Intervention,O1:1525|O2:10711,O1:0.085|O2:0.065,Study Participants - Control|Study Participants - Any Intervention,Incidence Rate,Incidence Rate,indicator_128,outcome_409,[],NA
420,NCT04371419,Incidence Rate for Information-seeking Behavior: Control vs. Any Intervention,O1:1450|O2:10244,O1:0.335|O2:0.344,Study Participants - Control|Study Participants - Any Intervention,Incidence Rate,Incidence Rate,indicator_128,outcome_410,[],NA
421,NCT04371419,Incidence Rate for Knowledge Gaps by Intervention,O1:5395|O2:5316|O3:8041|O4:2670|O5:8010|O6:2701|O7:8058|O8:2653|O9:5366|O10:5345,O1:0.066|O2:0.065|O3:0.065|O4:0.068|O5:0.066|O6:0.063|O7:0.066|O8:0.063|O9:0.066|O10:0.065,Intervention 1: Racial Discordance/Concordance Between Physician and Participant-Discordant (Arm A)|Intervention 1: Racial Discordance/Concordance Between Physician and Participant-Concordant (Arm B)|Intervention 2: Video 2 Recorded by MGH Physician/Dr. Birx of the CDC - MGH Physician (Arm A)|Intervention 2: Video 2 Recorded by MGH Physician/Dr. Birx of the CDC - Dr. Birx of the CDC (Arm B)|Intervention 3: Received Acknowledgment of Discrimination - No (Arm A)|Intervention 3: Received Acknowledgment of Discrimination - Yes (Arm B)|Intervention 4: Received Acknowledgment of Economic Inequalities - No (Arm A)|Intervention 4: Received Acknowledgment of Economic Inequalities - Yes (Arm B)|Intervention 5: Received Information About Social Perception - No (Arm A)|Intervention 5: Received Information About Social Perception - Yes (Arm B),Incidence Rate,Incidence Rate,indicator_128,outcome_411,[],NA
422,NCT04371419,Incidence Rate for Information-seeking Behavior by Intervention,O1:5147|O2:5097|O3:7697|O4:2547|O5:7653|O6:2591|O7:7696|O8:2548|O9:5142|O10:5102,O1:0.336|O2:0.353|O3:0.343|O4:0.348|O5:0.346|O6:0.341|O7:0.344|O8:0.345|O9:0.345|O10:0.344,Intervention 1: Racial Discordance/Concordance Between Physician and Participant-Discordant (Arm A)|Intervention 1: Racial Discordance/Concordance Between Physician and Participant-Concordant (Arm B)|Intervention 2: Video 2 Recorded by MGH Physician/Dr. Birx of the CDC - MGH Physician (Arm A)|Intervention 2: Video 2 Recorded by MGH Physician/Dr. Birx of the CDC - Dr. Birx of the CDC (Arm B)|Intervention 3: Received Acknowledgment of Discrimination - No (Arm A)|Intervention 3: Received Acknowledgment of Discrimination - Yes (Arm B)|Intervention 4: Received Acknowledgment of Economic Inequalities - No (Arm A)|Intervention 4: Received Acknowledgment of Economic Inequalities - Yes (Arm B)|Intervention 5: Received Information About Social Perception - No (Arm A)|Intervention 5: Received Information About Social Perception - Yes (Arm B),Incidence Rate,Incidence Rate,indicator_128,outcome_412,[],NA
423,NCT04402970,Change in Arterial Blood Oxygen Content to Fraction of Inspired Oxygen Ratio (PaO2/FiO2),O1:10|O2:20|O1:10|O2:20|O1:10|O2:20|O1:10|O2:20|O1:10|O2:20|O1:8|O2:20|O1:5|O2:11,O1:10.7|O2:21.4|O1:61.1|O2:11.8|O1:23.5|O2:12.5|O1:24.1|O2:3.5|O1:37.6|O2:5|O1:55|O2:-11.2,Inhaled/Nebulized Dornase Alfa|Standard of Care|Inhaled/Nebulized Dornase Alfa|Standard of Care|Inhaled/Nebulized Dornase Alfa|Standard of Care|Inhaled/Nebulized Dornase Alfa|Standard of Care|Inhaled/Nebulized Dornase Alfa|Standard of Care|Inhaled/Nebulized Dornase Alfa|Standard of Care|Inhaled/Nebulized Dornase Alfa|Standard of Care,PaO2/FiO2,P/F Ratio,indicator_47,outcome_413,"['Oxygen', 'PaO2/FiO2']",Time Frame: 28 days after randomization 
424,NCT04402970,Change in Static Lung Compliance,O1:10|O2:20|O1:10|O2:16|O1:10|O2:15|O1:8|O2:16|O1:8|O2:15|O1:5|O2:12|O1:4|O2:6,O1:3.1|O2:-0.1|O1:4|O2:-0.4|O1:6.3|O2:-5.7|O1:4|O2:-5.6|O1:7.4|O2:-4.8|O1:0.8|O2:-10.2,Inhaled/Nebulized Dornase Alfa|Standard of Care|Inhaled/Nebulized Dornase Alfa|Standard of Care|Inhaled/Nebulized Dornase Alfa|Standard of Care|Inhaled/Nebulized Dornase Alfa|Standard of Care|Inhaled/Nebulized Dornase Alfa|Standard of Care|Inhaled/Nebulized Dornase Alfa|Standard of Care|Inhaled/Nebulized Dornase Alfa|Standard of Care,Static Lung Compliance,Lung Compliance,indicator_155,outcome_414,['Static Lung Compliance'],Time Frame: Days 1 - 29. 
425,NCT04402970,Duration of Mechanical Ventilation,O1:10|O2:20,O1:15.2|O2:18.2,Inhaled/Nebulized Dornase Alfa|Standard of Care,Mechanical Ventilation,Mechanical Ventilation,indicator_9,outcome_415,"['mechanical Ventilation', 'Mechanical Ventilation']",Time Frame: 29 days 
426,NCT04402970,Length of ICU Stay,O1:10|O2:20,O1:16.5|O2:22.1,Inhaled/Nebulized Dornase Alfa|Standard of Care,ICU,ICU,indicator_97,outcome_416,['ICU'],Time Frame: 28 days 
427,NCT04402970,Length of Hospitalization,O1:10|O2:20,O1:22.5|O2:28.7,Inhaled/Nebulized Dornase Alfa|Standard of Care,Hospitalization,Hospitalization,indicator_18,outcome_417,"['Hospitalization', 'hospitalization', 'Hospital']",Time Frame: Day 1 through Day 29 
428,NCT04402970,Secondary Bacterial Infections,O1:10|O2:20,O1:30|O2:25,Inhaled/Nebulized Dornase Alfa|Standard of Care,Infect,Infect,indicator_84,outcome_418,['Infect'],Time Frame: Day 0-14 
429,NCT04402970,Mortality,O1:10|O2:20,O1:40|O2:45|O1:40|O2:55,Inhaled/Nebulized Dornase Alfa|Standard of Care,Mortality,Death ,indicator_16,outcome_419,['Mortality'],Time Frame: Up to and including day 28 
430,NCT04328467,COVID-19-free Survival,O1:494|O2:495|O3:494,O1:464|O2:468|O3:454,Intervention Once Weekly|Intervention Twice Weekly|Control Group,Survival,Survival,indicator_156,outcome_420,[],NA
431,NCT04328467,Number of Confirmed SARS-CoV-2 Detection,O1:494|O2:495|O3:494,O1:29|O2:29|O3:39,Intervention Once Weekly|Intervention Twice Weekly|Control Group,Detection,Detection ,indicator_105,outcome_421,['Detection'],NA
432,NCT04328467,Incidence of Possible COVID-19 Symptoms,O1:494|O2:495|O3:494,O1:29|O2:28|O3:38,Intervention Once Weekly|Intervention Twice Weekly|Control Group,Symptom,Symptom,indicator_99,outcome_422,['Symptom'],NA
433,NCT04328467,Incidence of All-cause Study Medicine Discontinuation,O1:494|O2:495|O3:494,O1:119|O2:158|O3:133,Intervention Once Weekly|Intervention Twice Weekly|Control Group,Medicine Discontinuation,Medicine Discontinuation,indicator_157,outcome_423,['Medicine Discontinuation'],NA
434,NCT04328467,Ordinal Scale of COVID-19 Disease Maximum Severity if COVID-19 Diagnosed at Study End,O1:0|O2:1|O3:1,O2:1|O3:1,Intervention Once Weekly|Intervention Twice Weekly|Control Group,Ordinal Scale,Ordinal Scale,indicator_79,outcome_424,"['Ordinal Scale', 'ordinal scale']",NA
435,NCT04328467,Incidence of Hospitalization for COVID-19 or Death,O1:494|O2:495|O3:494,O1:3|O2:8|O3:9,Intervention Once Weekly|Intervention Twice Weekly|Control Group,Hospitalization/Death,Hospitalization/Death,indicator_158,outcome_425,"['Hospitalization', 'Death', 'hospitalization', 'Hospital']",NA
436,NCT04328467,Incidence of Possible Study Medication-related Side Effects,O1:494|O2:495|O3:494,O1:148|O2:168|O3:100,Intervention Once Weekly|Intervention Twice Weekly|Control Group,Effect,Effect,indicator_100,outcome_426,['Effect'],NA
437,NCT04728594,Number of Employees Who Scheduled Vaccination Appointments After 3 Days,O1:3178|O2:3198|O3:3190,O1:101|O2:207|O3:220,Delayed Contact|Social Proof|Reframing Side Effects and Adverse Reactions,Employees,Employees,indicator_159,outcome_427,[],NA
438,NCT04728594,Number of Employees Who Scheduled Vaccination Appointments After 3 Days,O1:3198|O2:3190,O1:1481|O2:1398,Social Proof|Reframing Side Effects and Adverse Reactions,Employees,Employees,indicator_159,outcome_428,[],NA
439,NCT04728594,Number of Employees Who Scheduled Vaccination Appointments After 3 Days,O1:3198|O2:3190,O1:562|O2:382,Social Proof|Reframing Side Effects and Adverse Reactions,Employees,Employees,indicator_159,outcome_429,[],NA
440,NCT04728594,Number of Employees Who Opened Emails After 3 Days,NA,NA,NA,Employees,Employees,indicator_159,outcome_430,[],NA
441,NCT04728594,Number of Employees Who Clicked Scheduling Links After 3 Days,NA,NA,NA,Employees,Employees,indicator_159,outcome_431,[],NA
442,NCT04425863,Patients Who Improved Their Condition or Did Not Worsen it,O1:135|O2:12|O3:20,O1:135|O2:12|O3:19,Mild Cases|Moderate Cases|Severe Cases,Improved,Improvement,indicator_54,outcome_432,['Improved'],Time Frame: 28 day post enrollment 
443,NCT04425863,ICU-treated Patients After 2-week Treatment,O1:135|O2:12|O3:20,O1:0|O2:0|O3:2,Mild Cases|Moderate Cases|Severe Cases,ICU,ICU,indicator_97,outcome_433,['ICU'],Time Frame: 10 days 
444,NCT04425863,Mortality,O1:135|O2:12|O3:20,O1:0|O2:0|O3:1,Mild Cases|Moderate Cases|Severe Cases,Mortality,Death ,indicator_16,outcome_434,['Mortality'],Time Frame: Up to and including day 28 
445,NCT04425863,Mortality,NA,NA,NA,Mortality,Death ,indicator_16,outcome_435,['Mortality'],Time Frame: Up to and including day 28 
446,NCT04425863,Mortality,NA,NA,NA,Mortality,Death ,indicator_16,outcome_436,['Mortality'],Time Frame: Up to and including day 28 
447,NCT04425863,Patients Needing Drug Dose Adjustment,O1:135|O2:12|O3:20,O1:0|O2:0|O3:0,Mild Cases|Moderate Cases|Severe Cases,Drug Dose Adjustment ,Drug Dose Adjustment ,indicator_160,outcome_437,['Drug Dose Adjustment'],Time Frame: Day 1 through Day 29 
448,NCT04425863,Adverse Events,O1:135|O2:12|O3:20,O1:0|O2:0|O3:1,Mild Cases|Moderate Cases|Severe Cases,Adverse Events,Adverse,indicator_10,outcome_438,"['Adverse Events', 'Adverse', 'Adverse Event']",Time Frame: At the first day of the study 
449,NCT04542226,Clinical Status of the Patient (According to 7-point Ordinal Scale),O1:81,O1:0|O1:0|O1:22|O1:24|O1:24|O1:11|O1:0|O1:3|O1:27|O1:37|O1:9|O1:3|O1:2|O1:0,Adult Patients Hospitalized With COVID-19,ordinal scale,Ordinal Scale,indicator_79,outcome_439,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']",Time Frame: Assessed on study day 15 
450,NCT04542226,Time to Improvement in Clinical Status of the Patient (According to Ordinal Scale) by 1 Point for Each OS Score,O1:80,O1:13.77,Adult Patients Hospitalized With COVID-19,"ordinal scale, Improvement",Ordinal Scale,indicator_79,outcome_440,"['Ordinal Scale', 'improvement', 'Improvement', 'Clinical Status', 'ordinal scale']",Time Frame: assessed on study day 8 
451,NCT04542226,Clinical Status of the Patient (According to National Early Warning Score (NEWS Scale)),O1:80,O1:8.85,Adult Patients Hospitalized With COVID-19,Clinical Status ,Clinical Status ,indicator_110,outcome_441,['Clinical Status'],Time Frame: Baseline 
452,NCT04542226,Number of Patients Requiring Supplementary Oxygen,O1:81,O1:59|O1:22|O1:58|O1:23|O1:56|O1:25|O1:47|O1:34|O1:31|O1:50|O1:14|O1:67|O1:1|O1:80,Adult Patients Hospitalized With COVID-19,Oxygen,Oxygen,indicator_8,outcome_442,['Oxygen'],Time Frame: 28 days after randomization 
453,NCT04542226,Hospitalisation Duration,O1:80,O1:19.13,Adult Patients Hospitalized With COVID-19,Hospital,Hospitalization,indicator_18,outcome_443,['Hospital'],Time Frame: Day 15 
454,NCT04542226,Mortality,O1:81,O1:81|O1:0,Adult Patients Hospitalized With COVID-19,Mortality,Death ,indicator_16,outcome_444,['Mortality'],Time Frame: Up to and including day 7 
455,NCT04542226,The Number of Participants With Serious Adverse Events,O1:81,O1:1,Adult Patients Hospitalized With COVID-19,Adverse Events,Adverse,indicator_10,outcome_445,"['Adverse Events', 'Adverse', 'Adverse Event']",Time Frame: At the first day of the study 
456,NCT04542226,The Number of Participants With Adverse Events,O1:81,O1:7,Adult Patients Hospitalized With COVID-19,Adverse Events,Adverse,indicator_10,outcome_446,"['Adverse Events', 'Adverse', 'Adverse Event']",Time Frame: At the first day of the study 
457,NCT04542226,Number of Participants With Discontinuation of Drug Administration,O1:81,O1:1|O1:2,Adult Patients Hospitalized With COVID-19,Discontinuation of Drug Administration ,Discontinued,indicator_78,outcome_447,['Discontinuation of Drug Administration'],Time Frame: Day 1 through Day 10 
458,NCT04490239,"Number of Participants With Normal or Abnormal Activated Partial Thromboplastin Time (aPTT), Acute Phase Day 1",O1:6,O1:6|O1:0,Experimental Arm,Activated Partial Thromboplastin Time (aPTT),aPTT,indicator_161,outcome_448,['Activated Partial Thromboplastin Time (aPTT)'],Time Frame: Treatment period of 7 days (Day 1 to Day 8) 
459,NCT04490239,"Number of Participants With Normal or Abnormal Activated Partial Thromboplastin Time (aPTT), Acute Phase Day 2",O1:6,O1:6|O1:0,Experimental Arm,Activated Partial Thromboplastin Time (aPTT),aPTT,indicator_161,outcome_449,['Activated Partial Thromboplastin Time (aPTT)'],Time Frame: Treatment period of 7 days (Day 1 to Day 8) 
460,NCT04490239,"Number of Participants With Normal or Abnormal Activated Partial Thromboplastin Time (aPTT), Chronic Phase Day 14",O1:6,O1:6|O1:0,Experimental Arm,Activated Partial Thromboplastin Time (aPTT),aPTT,indicator_161,outcome_450,['Activated Partial Thromboplastin Time (aPTT)'],Time Frame: Treatment period of 7 days (Day 1 to Day 8) 
461,NCT04490239,"Number of Participants With Normal or Abnormal Activated Partial Thromboplastin Time (aPTT), Chronic Phase Day 15",O1:6,O1:6|O1:0,Experimental Arm,Activated Partial Thromboplastin Time (aPTT),aPTT,indicator_161,outcome_451,['Activated Partial Thromboplastin Time (aPTT)'],"Time Frame: End-of treatment, Day 7 or 8 "
462,NCT04490239,Percent Change in Platelet Count From Pre-dose Baseline,O1:6,O1:2.2,Experimental Arm,Platelet,Platelet,indicator_67,outcome_452,['Platelet'],"Time Frame: From date of first admission to intensive care unit until discharge/transfer out of the ICU or date of death from any cause, whichever came first, assessed up to 6 months "
463,NCT04490239,"Number of Incidents of Epistaxis, Acute Phase",O1:6,O1:0,Experimental Arm,Incidents of Epistaxis,Incidents of Epistaxis,indicator_162,outcome_453,['Incidents of Epistaxis'],Time Frame: Day 12 
464,NCT04490239,"Number of Incidents of Epistaxis, Chronic Phase",O1:6,O1:1,Experimental Arm,Incidents of Epistaxis,Incidents of Epistaxis,indicator_162,outcome_454,['Incidents of Epistaxis'],NA
465,NCT04490239,"Number of Participants With Normal or Abnormal Platelet Counts, Chronic Phase Day 14",O1:6,O1:6|O1:0,Experimental Arm,Platelet,Platelet,indicator_67,outcome_455,['Platelet'],"Time Frame: From date of hospital admission until discharge from acute care hospital or date of death from any cause, whichever came first, assessed up to 6 months "
466,NCT04490239,"Other Adverse Effects, Acute Phase",O1:6,O1:2,Experimental Arm,Effect,Effect,indicator_100,outcome_456,"['Effect', 'Adverse']",Time Frame: Day 1 through Day 29 
467,NCT04490239,"Other Adverse Effects, Chronic Phase",O1:6,O1:5,Experimental Arm,Effect,Effect,indicator_100,outcome_457,"['Effect', 'Adverse']",Time Frame: Day 1 through Day 29 
468,NCT04327388,Time to Improvement in Clinical Status of Participants (Using 7-point Ordinal Scale Score) by at Least 2 Points,O1:159|O2:173|O3:84,O1:10.0|O2:10.0|O3:12.0,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,improvement,Improvement,indicator_54,outcome_458,"['Ordinal Scale', 'improvement', 'Improvement', 'Clinical Status', 'scale score', 'ordinal scale']",Time Frame: Day 14 
469,NCT04327388,Percentage of Participants Who Were Alive at Day 29,O1:159|O2:173|O3:84,O1:89.9|O2:91.9|O3:91.7,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Alive,Alive,indicator_163,outcome_459,['Alive'],Time Frame: From starting to the end of ivermectin therapy (0 to the end of 5th day) 
470,NCT04327388,"Percentage of Participants With Improvement in Clinical Status (According to 7-point Ordinal Scale Score) by at Least 1 Point From Baseline at Days 4, 7, 15, 21, and 29",O1:159|O2:173|O3:84,O1:25.2|O2:25.4|O3:23.8|O1:51.6|O2:48.6|O3:42.9|O1:74.8|O2:76.9|O3:71.4|O1:80.5|O2:81.5|O3:85.7|O1:84.9|O2:84.4|O3:88.1,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,improvement,Improvement,indicator_54,outcome_460,"['Ordinal Scale', 'improvement', 'Improvement', 'Clinical Status', 'scale score', 'ordinal scale']",Time Frame: 4 weeks 
471,NCT04327388,"Change From Baseline at Days 4, 7, 15, 21, 29 in 7-point Ordinal Scale Score",O1:159|O2:173|O3:84|O1:159|O2:173|O3:84|O1:159|O2:173|O3:84|O1:158|O2:171|O3:83|O1:155|O2:169|O3:83|O1:156|O2:170|O3:83,O1:0.1|O2:0.1|O3:0.2|O1:0.7|O2:0.7|O3:0.7|O1:1.9|O2:2.0|O3:1.7|O1:2.3|O2:2.3|O3:2.5|O1:2.5|O2:2.5|O3:2.7,Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo,ordinal scale,Ordinal Scale,indicator_79,outcome_461,"['Ordinal Scale', 'scale score', 'ordinal scale']",Time Frame: 30 days 
472,NCT04327388,Time to Resolution of Fever,O1:159|O2:173|O3:84,O1:8.0|O2:9.0|O3:7.0,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Fever ,Fever ,indicator_56,outcome_462,['Fever'],"Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 "
473,NCT04327388,Time to Resolution of Fever and Improvement in Oxygenation,O1:159|O2:173|O3:84,O1:9.0|O2:10.0|O3:8.0,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Fever ,Fever ,indicator_56,outcome_463,"['Oxygen', 'improvement', 'Improvement', 'Fever']","Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 "
474,NCT04327388,Number of Days With Fever,O1:143|O2:159|O3:77,O1:1.2|O2:1.3|O3:1.8,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Fever ,Fever ,indicator_56,outcome_464,['Fever'],"Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 "
475,NCT04327388,"Percentage of Participants in Each National Early Warning Score 2 (NEWS2) Clinical Risk Category at Baseline and at Days 4, 7, 15, 21, and 29",O1:159|O2:169|O3:84|O1:146|O2:163|O3:79|O1:146|O2:163|O3:79|O1:146|O2:163|O3:79|O1:146|O2:163|O3:79|O1:159|O2:169|O3:84|O1:159|O2:169|O3:84|O1:159|O2:169|O3:84|O1:159|O2:169|O3:84|O1:135|O2:143|O3:74|O1:135|O2:143|O3:74|O1:135|O2:143|O3:74|O1:135|O2:143|O3:74|O1:61|O2:67|O3:36|O1:61|O2:67|O3:36|O1:61|O2:67|O3:36|O1:61|O2:67|O3:36|O1:29|O2:38|O3:12|O1:29|O2:38|O3:12|O1:29|O2:38|O3:12|O1:29|O2:38|O3:12|O1:14|O2:18|O3:5|O1:14|O2:18|O3:5|O1:14|O2:18|O3:5|O1:14|O2:18|O3:5,O1:28.8|O2:22.1|O3:34.2|O1:0|O2:0|O3:0|O1:34.2|O2:37.4|O3:27.8|O1:37.0|O2:40.5|O3:38.0|O1:52.8|O2:56.2|O3:40.5|O1:0.6|O2:1.2|O3:0|O1:19.5|O2:16.6|O3:28.6|O1:27.0|O2:26.0|O3:31.0|O1:57.0|O2:60.8|O3:51.4|O1:0|O2:2.1|O3:0|O1:20.0|O2:10.5|O3:20.3|O1:23.0|O2:26.6|O3:28.4|O1:52.5|O2:52.2|O3:61.1|O1:0|O2:1.5|O3:2.8|O1:21.3|O2:19.4|O3:13.9|O1:26.2|O2:26.9|O3:22.2|O1:44.8|O2:50.0|O3:66.7|O1:13.8|O2:0|O3:0|O1:24.1|O2:21.1|O3:8.3|O1:17.2|O2:28.9|O3:25.0|O1:57.1|O2:27.8|O3:60.0|O1:0|O2:0|O3:0|O1:14.3|O2:27.8|O3:20.0|O1:28.6|O2:44.4|O3:20.0,Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Clinical Risk,Clinical Risk,indicator_164,outcome_465,"['Clinical Risk', 'National Early Warning Score 2']",Time Frame: Baseline 
476,NCT04327388,Time to National Early Warning Score of Less Than (<) 2 and Maintained for 24 Hours,O1:159|O2:173|O3:84,O1:9.0|O2:9.0|O3:11.0,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Time to National Early Warning Score,Time to National Early Warning Score,indicator_165,outcome_466,['Time to National Early Warning Score'],Time Frame: 14 days 
477,NCT04327388,"Change From Baseline at Days 4, 7, 15, 21, and 29 in National Early Warning Score 2",O1:146|O2:159|O3:79|O1:146|O2:159|O3:79|O1:122|O2:133|O3:69|O1:55|O2:62|O3:33|O1:26|O2:34|O3:12|O1:13|O2:17|O3:5,O1:-1.07|O2:-1.25|O3:-0.36|O1:-1.63|O2:-1.47|O3:-0.83|O1:-2.10|O2:-1.83|O3:-2.36|O1:-3.02|O2:-2.24|O3:-2.96|O1:-2.57|O2:-1.27|O3:-3.64,Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo,National Early Warning Score 2 ,National Early Warning Score 2 ,indicator_166,outcome_467,['National Early Warning Score 2'],Time Frame: Up to 28 days 
478,NCT04327388,Time-to-improvement in Oxygenation,O1:159|O2:173|O3:84,O1:6.0|O2:6.0|O3:7.0,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,improvement,Improvement,indicator_54,outcome_468,"['Oxygen', 'improvement', 'Improvement']",Time Frame: 4 week 
479,NCT04327388,Percentage of Participants Alive Off Supplemental Oxygen at Day 29,O1:159|O2:173|O3:84,O1:84.9|O2:83.8|O3:86.9,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Oxygen,Oxygen,indicator_8,outcome_469,"['Oxygen', 'Alive']",Time Frame: 28 days after randomization 
480,NCT04327388,Percentage of Days With Hypoxemia,O1:159|O2:173|O3:84,O1:73.01|O2:75.10|O3:76.32,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Hypoxemia ,Hypoxemia ,indicator_167,outcome_470,['Hypoxemia'],"Time Frame: By Visit 3, approximately 10 days "
481,NCT04327388,Percentage of Days With Supplemental Oxygen Use,O1:159|O2:173|O3:84,O1:70.57|O2:73.30|O3:73.23,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Oxygen Use,Oxygen,indicator_8,outcome_471,"['Oxygen', 'Oxygen Use']",Time Frame: 28 days after randomization 
482,NCT04327388,Percentage of Days With Resting Respiratory Rate > 24 Breaths Per Minute,O1:150|O2:164|O3:78,O1:14.74|O2:14.58|O3:15.74,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Respiratory Rate,Respiratory Rate,indicator_44,outcome_472,['Respiratory Rate'],Time Frame: Baseline to Day 29 
483,NCT04327388,Time to Oxygen Saturation >= 94% on Room Air,O1:159|O2:173|O3:84,O1:8.0|O2:8.0|O3:8.0,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Oxygen,Oxygen,indicator_8,outcome_473,"['Oxygen', 'Oxygen Saturation']",Time Frame: 28 days after randomization 
484,NCT04327388,Mean Number of Ventilator Free Days,O1:159|O2:173|O3:84,O1:23.8|O2:24.0|O3:24.9,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Ventilator Free,Ventilator Free,indicator_168,outcome_474,['Ventilator Free'],Time Frame: Pre-SSI only 
485,NCT04327388,"Percentage of Participants With Initiation of Mechanical Ventilation, Non-invasive Ventilation, or Use of High Flow Nasal Cannula",O1:127|O2:141|O3:68,O1:20.5|O2:23.4|O3:19.1,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Mechanical Ventilation,Mechanical Ventilation,indicator_9,outcome_475,"['mechanical Ventilation', 'Mechanical Ventilation']","Time Frame: Baseline, Days 3, 5, 8, 11, 15, and 29 "
486,NCT04327388,Percentage of Participants Who Required Rescue Medication,O1:159|O2:173|O3:84,O1:13.8|O2:15.0|O3:22.6,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Rescue Medication ,Rescue Medication ,indicator_169,outcome_476,['Rescue Medication'],Time Frame: Baseline to Day 29 
487,NCT04327388,Percentage of Participants Who Needed Intensive Care Unit (ICU) Care During Study,O1:98|O2:114|O3:56,O1:11.2|O2:14.9|O3:12.5,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Intensive Care,Intensive Care,indicator_58,outcome_477,"['Intensive Care', 'ICU']",Time Frame: Assessed for up to 28 days 
488,NCT04327388,Number of Days of Hospitalization Among Survivors (Alive Participants),O1:142|O2:155|O3:75,O1:15.6|O2:16.1|O3:15.9,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Hospitalization,Hospitalization,indicator_18,outcome_478,"['Hospitalization', 'Alive', 'hospitalization', 'Hospital']",Time Frame: Day 1 through Day 29 
489,NCT04327388,Number of Participants With Treatment-emergent Serious Adverse Events (SAEs),O1:159|O2:173|O3:84,O1:42|O2:51|O3:20,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Adverse Events,Adverse,indicator_10,outcome_479,"['Adverse Events', 'Adverse', 'Adverse Event']",Time Frame: At the first day of the study 
490,NCT04327388,Number of Participants With Major or Opportunistic Bacterial or Fungal Infections,O1:159|O2:173|O3:84,O1:8|O2:15|O3:3,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Infect,Infect,indicator_84,outcome_480,['Infect'],"Time Frame: Baseline, Minutes 5, 10, 15, 30 (15 minutes after treatment ends) "
491,NCT04327388,Number of Participants With Grade 4 Neutropenia and Grade 4 Neutropenia With Concurrent Invasive Infection,O1:159|O2:173|O3:84|O1:159|O2:173|O3:84|O1:3|O2:6|O3:0,O1:3|O2:6|O3:0|O1:0|O2:0,Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Infect,Infect,indicator_84,outcome_481,['Infect'],"Time Frame: Baseline, Minutes 5, 10, 15, 30 (15 minutes after treatment ends) "
492,NCT04327388,"Number of Participants With Grade >=2 Infusion Reactions, Grade >=2 Hypersensitivity Reactions and Gastrointestinal Perforation",O1:159|O2:173|O3:84,O1:1|O2:6|O3:0|O1:1|O2:7|O3:0|O1:1|O2:0|O3:0,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Gastrointestinal Perforation ,Gastrointestinal Perforation ,indicator_170,outcome_482,['Gastrointestinal Perforation'],"Time Frame: Baseline, Minutes 5, 10, 15, 30 (15 minutes after treatment ends) "
493,NCT04327388,"Number of Participants With Potentially Clinically Significant Laboratory Abnormalities (PCSA): Hematological Parameter - Hemoglobin, Leukocytes and Platelets",O1:156|O2:170|O3:84,O1:29|O2:34|O3:15|O1:0|O2:0|O3:0|O1:32|O2:30|O3:15|O1:19|O2:31|O3:1|O1:13|O2:21|O3:6|O1:2|O2:7|O3:3|O1:3|O2:2|O3:2,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Hemoglobin,Hemoglobin,indicator_66,outcome_483,"['Platelets', 'Platelet', 'Hemoglobin']",Time Frame: Day 1 through Day 14 
494,NCT04327388,Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Renal Function Parameters,O1:156|O2:170|O3:84,O1:15|O2:15|O3:5|O1:31|O2:30|O3:10|O1:6|O2:7|O3:3,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Renal Function Parameters ,Renal Function Parameters ,indicator_171,outcome_484,['Renal Function Parameters'],Time Frame: Baseline to Day 29 
495,NCT04327388,Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Liver Function Parameters,O1:156|O2:169|O3:84|O1:156|O2:168|O3:83|O1:156|O2:168|O3:83|O1:156|O2:168|O3:83|O1:156|O2:168|O3:83|O1:156|O2:169|O3:84|O1:156|O2:169|O3:84,O1:60|O2:63|O3:24|O1:28|O2:25|O3:12|O1:6|O2:5|O3:3|O1:1|O2:0|O3:0|O1:5|O2:4|O3:4|O1:4|O2:2|O3:2,Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Liver Function Parameters,Liver Function Parameters,indicator_172,outcome_485,['Liver Function Parameters'],Require Mechanical Ventilation
496,NCT04322396,Number of Days Alive and Discharged From Hospital Within 14 Days,O1:56|O2:61,O1:9|O2:9,Control|Intervention,discharge,Discharge,indicator_80,outcome_486,"['discharge', 'Discharge', 'Alive', 'Hospital']",NA
497,NCT04322396,Categorization of Hospitalization Status,O1:56|O2:61,O1:2|O2:1|O1:1|O2:3|O1:0|O2:1|O1:2|O2:2|O1:2|O2:1|O1:0|O2:1|O1:27|O2:26|O1:22|O2:26,Control|Intervention,Hospitalization,Hospitalization,indicator_18,outcome_487,"['Hospitalization', 'hospitalization', 'Hospital']",NA
498,NCT04322396,Length of Stay in ICU,O1:56|O2:61,O1:11|O2:14,Control|Intervention,ICU,ICU,indicator_97,outcome_488,"['Length of Stay', 'ICU']",NA
499,NCT04322396,Number of Participants on Non-invasive Ventilation (NIV) During Hospitalization,O1:56|O2:61,O1:1|O2:3,Control|Intervention,Non-invasive Ventilation (NIV) ,NIV,indicator_173,outcome_489,"['Hospitalization', 'hospitalization', 'Hospital']",NA
500,NCT04322396,Mortality,O1:56|O2:61,O1:2|O2:1,Control|Intervention,Mortality,Death ,indicator_16,outcome_490,['Mortality'],NA
501,NCT04322396,Length of Hospitalization,O1:56|O2:61,O1:4|O2:4,Control|Intervention,Hospitalization,Hospitalization,indicator_18,outcome_491,"['Hospitalization', 'hospitalization', 'Hospital']",NA
502,NCT04322396,Days Alive and Discharged From Hospital,O1:56|O2:61,O1:26|O2:26,Control|Intervention,discharge,Discharge,indicator_80,outcome_492,"['discharge', 'Discharge', 'Alive', 'Hospital']",NA
503,NCT04322396,Number of Readmissions (All Causes),O1:56|O2:61,O1:6|O2:9,Control|Intervention,Readmissions,Readmissions,indicator_174,outcome_493,[],NA
504,NCT04322396,Number of Days Using Non-invasive Ventilation (NIV),O1:1|O2:3,O1:9.0|O2:6.7,Control|Intervention,Non-invasive Ventilation (NIV),NIV,indicator_173,outcome_494,[],NA
505,NCT04322396,Change in Patient's Oxygen Partial Pressure,O1:56|O2:61,O1:-0.2|O2:-3.0,Control|Intervention,Oxygen,Oxygen,indicator_8,outcome_495,['Oxygen'],NA
506,NCT04322396,Change in Patient's Carbondioxide Partial Pressure,O1:56|O2:61,O1:1.4|O2:-3.0,Control|Intervention,Pressure,Pressure,indicator_175,outcome_496,[],NA
507,NCT04322396,Change of pH in Blood,O1:56|O2:61,O1:0.0|O2:0.0,Control|Intervention,PH,PH,indicator_176,outcome_497,[],NA
508,NCT04322396,"Time for no Oxygen Supplement (or Regular Oxygen Supplement ""LTOT"")",O1:27|O2:25,O1:72|O2:72,Control|Intervention,Oxygen,Oxygen,indicator_8,outcome_498,['Oxygen'],NA
509,NCT04308668,Number of Participants With Active COVID-19 Disease at Day 14 Among Those Who Were Asymptomatic at Baseline,O1:414|O2:407,O1:49|O2:58,Treatment|Placebo,Active COVID-19 Disease at Day 14,Active COVID-19 Disease at Day 15,indicator_177,outcome_499,"['Active COVID-19 Disease at Day 14', 'Symptom']",Time Frame: Treatment period of 7 days (Day 1 to Day 8) 
510,NCT04308668,Change in Disease Severity Over 14 Days Among Those Who Are Symptomatic at Baseline,O1:212|O2:211,O1:-2.6|O2:-2.33,Treatment|Placebo,Disease Severity,Disease Severity,indicator_178,outcome_500,"['Symptom', 'Disease Severity']",Time Frame: Day 1 through Day 29 
511,NCT04308668,Rate of Hospitalization,O1:645|O2:641,O1:5|O2:9,Treatment|Placebo,Hospitalization,Hospitalization,indicator_18,outcome_501,"['Hospitalization', 'hospitalization', 'Hospital']",Time Frame: Day 1 through Day 29 
512,NCT04308668,Rate of Death,O1:645|O2:641,O1:1|O2:1,Treatment|Placebo,Death ,Death ,indicator_16,outcome_502,['Death'],"Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 "
513,NCT04308668,Rate of Confirmed SARS-CoV-2 Detection,O1:414|O2:407,O1:11|O2:9,Treatment|Placebo,Detection ,Detection ,indicator_105,outcome_503,['Detection'],"Time Frame: Days 1, 3, 5, 8, 11, 15, 22, and 29 "
514,NCT04308668,Occurrence of Symptoms Compatible With COVID-19 (Possible Disease),O1:414|O2:407,O1:48|O2:55,Treatment|Placebo,Occurrence of Symptoms,Symptoms,indicator_41,outcome_504,"['Symptom', 'Occurrence of Symptoms']","Time Frame: Day 7, Day 14, Day 21 & Day 30 "
515,NCT04308668,Rate of All-Cause Study Medicine Discontinuation or Withdrawal,O1:645|O2:641,O1:97|O2:63,Treatment|Placebo,Medicine Discontinuation,Medicine Discontinuation,indicator_157,outcome_505,['Medicine Discontinuation'],"Time Frame: from date of patient admission to date of patient discharge or date of death, whichever came first, assessed up to 60 days "
516,NCT04308668,Overall Symptom Severity at 5 and 14 Days,O1:212|O2:211,O1:-2.22|O2:-2.05|O1:-3.36|O2:-3.08,Treatment|Placebo,Symptom Severity,Symptom,indicator_99,outcome_506,"['Symptom Severity', 'Symptom']",Time Frame: 14 days 
517,NCT04308668,Number of Participants With Severe COVID-19 Disease at 14 Days Among Those Who Are Symptomatic at Trial Entry,O1:231|O2:234,O1:5|O2:8,Treatment|Placebo,Severe COVID-19 Disease at 14 Days,COVID-19,indicator_179,outcome_507,"['Symptom', 'Severe COVID-19 Disease at 14 Days']",Time Frame: 7 days 
518,NCT04340557,Mechanical Ventilation,O1:16|O2:15,O1:1|O2:1,Group A (Study Drug+SOC)|Group B (SOC),Mechanical Ventilation,Mechanical Ventilation,indicator_9,outcome_508,"['mechanical Ventilation', 'Mechanical Ventilation']","Time Frame: Day 15, Day 29 "
519,NCT04340557,ICU Transfer,O1:16|O2:15,O1:1|O2:2,Group A (Study Drug+SOC)|Group B (SOC),ICU,ICU,indicator_97,outcome_509,['ICU'],Time Frame: 28 days 
520,NCT04340557,Oxygen Therapy,O1:16|O2:15,"O1:10,469|O2:82,734",Group A (Study Drug+SOC)|Group B (SOC),Oxygen,Oxygen,indicator_8,outcome_510,"['Oxygen', 'Oxygen Therapy']",Time Frame: 28 days after randomization 
521,NCT04392219,Part 1: Number of Participants With Treatment Emergent Adverse Events and Severity of Treatment Emergent Adverse Events,O1:16|O2:6|O3:6|O4:6|O5:6|O6:6|O7:6|O8:6|O9:6,O1:7|O2:2|O3:0|O4:3|O5:3|O6:4|O7:2|O8:1|O9:2|O1:7|O2:2|O3:0|O4:3|O5:3|O6:4|O7:2|O8:1|O9:2|O1:1|O2:0|O3:0|O4:0|O5:1|O6:0|O7:0|O8:0|O9:0|O1:0|O2:0|O3:0|O4:0|O5:0|O6:0|O7:0|O8:0|O9:0,Part 1 - Placebo|Part 1 - 50 mg EIDD-2801|Part 1 - 100 mg EIDD-2801|Part 1 - 200 mg EIDD-2801|Part 1 - 400 mg EIDD-2801|Part 1 - 600 mg EIDD-2801|Part 1 - 800 mg EIDD-2801|Part 1 - 1200 mg EIDD-2801|Part 1 - 1600 mg EIDD-2801,Adverse,Adverse,indicator_10,outcome_511,"['Adverse Events', 'Adverse', 'Adverse Event']",NA
522,NCT04392219,Part 3: Number of Participants With Treatment Emergent Adverse Events and Severity of Treatment Emergent Adverse Events,O1:14|O2:6|O3:6|O4:6|O5:6|O6:6|O7:6|O8:6,O1:7|O2:2|O3:3|O4:3|O5:2|O6:3|O7:2|O8:3|O1:7|O2:2|O3:3|O4:3|O5:2|O6:3|O7:2|O8:3|O1:0|O2:0|O3:0|O4:1|O5:0|O6:0|O7:0|O8:0|O1:0|O2:0|O3:0|O4:0|O5:0|O6:0|O7:0|O8:0,Part 3 - Placebo|Part 3 - 50 mg EIDD-2801|Part 3 - 100 mg EIDD-2801|Part 3 - 200 mg EIDD-2801|Part 3 - 300 mg EIDD-2801|Part 3 - 400 mg EIDD-2801|Part 3 - 600 mg EIDD-2801|Part 3 - 800 mg EIDD-2801,Adverse,Adverse,indicator_10,outcome_512,"['Adverse Events', 'Adverse', 'Adverse Event']",NA
523,NCT04634903,Change in Adolescent Depressive Symptom Severity,O1:818|O2:821|O3:813,O1:14.31|O2:14.15|O3:14.22|O1:12.57|O2:11.47|O3:11.58,Supportive Therapy SSI (ST-SSI)|Behavioral Activation SSI (BA-SSI)|Growth Mindset SSI (GM-SSI),Depressive,Depressive,indicator_180,outcome_513,"['Symptom Severity', 'Depressive', 'Symptom']","Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 "
524,NCT04634903,Change in State Hope Scale - Pathways Subscale,O1:818|O2:821|O3:813,O1:3.88|O2:3.93|O3:3.96|O1:5.26|O2:5.68|O3:5.50|O1:4.89|O2:5.06|O3:5.17,Supportive Therapy SSI (ST-SSI)|Behavioral Activation SSI (BA-SSI)|Growth Mindset SSI (GM-SSI),State Hope Scale - Pathways Subscale ,Scale,indicator_181,outcome_514,['State Hope Scale - Pathways Subscale'],Time Frame: Days 1 - 29. 
525,NCT04634903,Change in Beck Hopelessness Scale - 4 Item Version,O1:818|O2:821|O3:813,O1:1.71|O2:1.72|O3:1.72|O1:1.36|O2:1.22|O3:1.21|O1:1.51|O2:1.37|O3:1.39,Supportive Therapy SSI (ST-SSI)|Behavioral Activation SSI (BA-SSI)|Growth Mindset SSI (GM-SSI),Beck Hopelessness Scale - 4 Item Version ,Beck Hopelessness Scale - 5 Item Version,indicator_182,outcome_515,['Beck Hopelessness Scale - 4 Item Version'],Time Frame: At the end of 10th day 
526,NCT04634903,Program Feedback Scale,O1:630|O2:729|O3:653,O1:3.80|O2:3.93|O3:3.83|O1:4.54|O2:4.46|O3:4.48|O1:4.46|O2:4.42|O3:4.48|O1:4.45|O2:4.42|O3:4.45|O1:3.97|O2:4.12|O3:3.93|O1:4.24|O2:4.30|O3:4.20|O1:4.50|O2:4.54|O3:4.47,Supportive Therapy SSI (ST-SSI)|Behavioral Activation SSI (BA-SSI)|Growth Mindset SSI (GM-SSI),Program Feedback Scale ,Scale,indicator_181,outcome_516,['Program Feedback Scale'],Time Frame: 14 days 
527,NCT04160975,Rating of Sender,O1:832|O2:430|O3:827|O4:845,O1:.1828917|O2:-.0750636|O3:.0997998|O4:-.5397662,Concordant (Arm A) vs. Discordant Expert Sender (Arm B) - Black Participants|Concordant (Arm A) vs. Discordant Expert Sender (Arm B) - White Participants|Acknowledgement (Arm A) vs. Standard Signal (Arm B) - Black Participants|Layperson Sender (Arm A) vs. Expert Sender (Arm B) - Black Participants,Sender,Sender,indicator_183,outcome_517,[],NA
528,NCT04160975,Rating of Signal,O1:832|O2:1221|O3:827|O4:845,O1:.1387205|O2:-.0088105|O3:.1423725|O4:-.0806321,Concordant (Arm A) vs. Discordant Expert Sender (Arm B) - Black Participants|Concordant (Arm A) vs. Discordant Expert Sender (Arm B) - White Participants|Acknowledgement (Arm A) vs. Standard Signal (Arm B) - Black Participants|Layperson Sender (Arm A) vs. Expert Sender (Arm B) - Black Participants,Signal,Signal,indicator_184,outcome_518,[],NA
529,NCT04160975,Signal Content Recall,O1:832|O2:1221|O3:827|O4:845,O1:-.0062555|O2:.0193832|O3:.0041984|O4:.1166304,Concordant (Arm A) vs. Discordant Expert Sender (Arm B) - Black Participants|Concordant (Arm A) vs. Discordant Expert Sender (Arm B) - White Participants|Acknowledgement (Arm A) vs. Standard Signal (Arm B) - Black Participants|Layperson Sender (Arm A) vs. Expert Sender (Arm B) - Black Participants,Signal,Signal,indicator_184,outcome_519,[],NA
530,NCT04160975,Safety Beliefs,O1:832|O2:1221|O3:827|O4:845,O1:-.0979564|O2:-.027714|O3:-.1065867|O4:-.0242752,Concordant (Arm A) vs. Discordant Expert Sender (Arm B) - Black Participants|Concordant (Arm A) vs. Discordant Expert Sender (Arm B) - White Participants|Acknowledgement (Arm A) vs. Standard Signal (Arm B) - Black Participants|Layperson Sender (Arm A) vs. Expert Sender (Arm B) - Black Participants,Safety,Safety,indicator_185,outcome_520,[],NA
531,NCT04160975,Coupon Interest,O1:832|O2:1221|O3:827|O4:845,O1:-.0078177|O2:-.0827849|O3:.0280955|O4:-.0162865,Concordant (Arm A) vs. Discordant Expert Sender (Arm B) - Black Participants|Concordant (Arm A) vs. Discordant Expert Sender (Arm B) - White Participants|Acknowledgement (Arm A) vs. Standard Signal (Arm B) - Black Participants|Layperson Sender (Arm A) vs. Expert Sender (Arm B) - Black Participants,Coupon Interest,Coupon Interest,indicator_186,outcome_521,[],NA
532,NCT04160975,(Posterior) Flu Vaccine Intent,O1:832|O2:1221|O3:827|O4:845,O1:.0263281|O2:.0034755|O3:.0268659|O4:.0187403,Concordant (Arm A) vs. Discordant Expert Sender (Arm B) - Black Participants|Concordant (Arm A) vs. Discordant Expert Sender (Arm B) - White Participants|Acknowledgement (Arm A) vs. Standard Signal (Arm B) - Black Participants|Layperson Sender (Arm A) vs. Expert Sender (Arm B) - Black Participants,Vaccine,Vaccine,indicator_187,outcome_522,[],NA
533,NCT04160975,COVID-19 Vaccine Intent,O1:587|O2:866|O3:581|O4:592,O1:.0350147|O2:.009072|O3:.0544277|O4:.0881949,Concordant (Arm A) vs. Discordant Expert Sender (Arm B) - Black Participants|Concordant (Arm A) vs. Discordant Expert Sender (Arm B) - White Participants|Acknowledgement (Arm A) vs. Standard Signal (Arm B) - Black Participants|Layperson Sender (Arm A) vs. Expert Sender (Arm B) - Black Participants,Vaccine,Vaccine,indicator_187,outcome_523,[],NA
534,NCT04160975,Flu Vaccine Take-up,O1:139|O2:377|O3:137|O4:151,O1:-7.70997|O2:-01.39307|O3:-12.00413|O4:14.96955,Concordant (Arm A) vs. Discordant Expert Sender (Arm B) - Black Participants|Concordant (Arm A) vs. Discordant Expert Sender (Arm B) - White Participants|Acknowledgement (Arm A) vs. Standard Signal (Arm B) - Black Participants|Layperson Sender (Arm A) vs. Expert Sender (Arm B) - Black Participants,Vaccine,Vaccine,indicator_187,outcome_524,[],NA
535,NCT04406194,AUC0-tlast of Favipiravir,O1:29|O2:29,O1:9641.989|O2:9907.170,Favicovir 200 mg FT|Avigan 200 mg FT,AUC0-tlast of Favipiravir ,AUC1-tlast of Favipiravir,indicator_188,outcome_525,"['AUC0-tlast', 'AUC0-tlast of Favipiravir']",Time Frame: From 6th to the end of 10th day 
536,NCT04406194,Cmax of Favipiravir,O1:29|O2:29,O1:5411.624|O2:5002.171,Favicovir 200 mg FT|Avigan 200 mg FT,Cmax of Favipiravir ,Favipiravir Cmax ,indicator_189,outcome_526,['Cmax of Favipiravir'],Time Frame: Baseline 
537,NCT04406194,AUC0-inf of Favipiravir,O1:29|O2:29,O1:9910.494|O2:10152.115,Favicovir 200 mg FT|Avigan 200 mg FT,AUC0-inf of Favipiravir ,AUC0-inf of Favipiravir ,indicator_190,outcome_527,['AUC0-inf of Favipiravir'],Time Frame: From 6th to the end of 10th day 
538,NCT04406194,Tmax of Favipiravir,O1:29|O2:29,O1:0.609|O2:0.733,Favicovir 200 mg FT|Avigan 200 mg FT,Tmax of Favipiravir ,Favipiravir Cmax ,indicator_189,outcome_528,['Tmax of Favipiravir'],"Time Frame: from date of patient admission to date of patient discharge or date of death, whichever came first, assessed up to 45 days "
539,NCT04400682,AUC0-tlast,O1:25|O2:25,O1:10400.038|O2:9907.948,FAVIRA (Novelfarma-Turkey)|AVIGAN (Toyama-Japan),AUC0-tlast ,AUC1-tlast,indicator_191,outcome_529,['AUC0-tlast'],Time Frame: From 6th to the end of 10th day 
540,NCT04400682,Favipiravir Cmax,O1:25|O2:25,O1:5242.459|O2:4969.881,FAVIRA (Novelfarma-Turkey)|AVIGAN (Toyama-Japan),Favipiravir Cmax ,Favipiravir Cmax ,indicator_189,outcome_530,['Favipiravir Cmax'],"Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 "
541,NCT04400682,AUC0-inf of Favipiravir,O1:25|O2:25,O1:10400.038|O2:10186.389,FAVIRA (Novelfarma-Turkey)|AVIGAN (Toyama-Japan),AUC0-inf of Favipiravir ,AUC0-inf of Favipiravir ,indicator_190,outcome_531,['AUC0-inf of Favipiravir'],Time Frame: From 6th to the end of 10th day 
542,NCT04400682,Tmax of Favipiravir,O1:25|O2:25,O1:0.766|O2:0.770,FAVIRA (Novelfarma-Turkey)|AVIGAN (Toyama-Japan),Tmax of Favipiravir ,Favipiravir Cmax ,indicator_189,outcome_532,['Tmax of Favipiravir'],"Time Frame: from date of patient admission to date of patient discharge or date of death, whichever came first, assessed up to 45 days "
